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Cyclophilin A (CypA) is an ubiquitous intracellular protein that binds the 
immunosuppressant drug, cyclosporin A (C5A). CypA also plays important roles in 
protein folding and HIV-1 virus replication, whilst other cyclophilin isoforms have 
been implicated in nematode parasitic development. CsA inhibits these processes 
but is disadvantaged by its large molecular weight and immunosuppressive effects. 
Hence, there is a strong therapeutic driving force to design small, tight binding 
inhibitors, with which to probe cyclophilin functions. 
In light of this, an in-house in silico database mining programme (LIDAEUS) was 
used to screen a library of small molecules for binding to CypA. This approach 
identified dimedone 33 as a lead which mimics two of the key interactions of CsA 
and was found to possess a Kd = 22 mM (cf. 30 nM for CsA). Several rounds of 
chemical derivatisation led to the synthesis of conformationally constrained ligands, 
the best of which 123 was found to bind CypA with a Kd = 16 tM, a greater than 
1000-fold improvement on the original lead. 
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Inhibitor 123 was tested in vivo against the nematode C. elegans to screen for 
antiparasitic effects. High concentrations (>500 gM) of 123 were lethal resulting in 
rapid death of the worms. At lower concentrations the worms suffered growth 
defects and displayed cuticle shedding and severe gut development disorders, similar 
in phenotype to those observed in organisms treated with CsA. 
Fluorescent tags were incorporated to investigate the uptake and localisation of the 
ligand within C. elegans. Sulfonamide 169a displayed similar effects to 123 and 
CsA in vivo and its fluorescence was detected throughout the worms' gut lumen in 
areas where cyclophilins are thought to be involved in structural formation of the gut 
lining. These results demonstrate the potential of such ligands to act as chemical 
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probes to elucidate the role of cyclophilins at different stages of C. elegans 
development. Such a forward chemical genetics approach could in future provide 
valuable information concerning the biological mode of action of cyclophilins in 
nematode parasites and help to identify new targets for antiparasitic drugs. 
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Chapter] 	 Introduction 
1 	Introduction 
This thesis describes the design and synthesis of high affinity ligands for 
cyclophilins, in particular human cyclophilin A (CypA). By way of introduction, a 
general review of drug discovery is given, with specific emphasis on new 
developments applicable to this project such as chemical genetics. The nature and 
functions of CypA are then described, followed by a review of the literature on CypA 
inhibitors. The chapter ends with an account of the ligand design approach that 
resulted in the discovery of the lead compound, dimedone. 
1.1 Drug Discovery 
1.1.1 Historical 
The beginning of drug research as a discipline in its own right can be traced back to 
the early nineteenth century when researchers began to propose that the observed 
medicinal benefit of some plant extracts could be attributed to a single active 
ingredient. Support for this view grew when Frederick Serttirner successfully 
isolated the first active compound, morphine, from opium extract in 1815.1  It was 
not until the beginning of the twentieth century, however, that the next crucial 
breakthrough was made with the concept of 'receptors' as described by Paul 
Ehrlich. 2  Ehrlich argued that certain chemoreceptors, as he classed them, would be 
different between species and could therefore be exploited therapeutically. This idea 
stemmed from observations that dyes (e.g. methylene blue), derived from coal-tar, 
showed affinity for biological tissues (e.g. nerve cells). Coal-tar, itself a by-product 
of the burgeoning chemical industries of the time, contained many organic 
derivatives, which would form the basis of early medicines and lead to the discovery 
of drugs such as aspirin 1 (Figure 1.1). The need to research, characterise, and 
develop these new substances led to the birth of the pharmaceutical industry. 
The early pursuit of new drugs relied upon natural products isolated from plants, 
fungi, and bacteria. Often new discoveries were made in a serendipitous fashion, 
such as the discovery of penicillin 2 (Figure 1.1) by Fleming 3 that led to the 
1 
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development of antibiotics to treat bacterial infections. Once new lead compounds 
had been identified, their structures would be systematically altered using synthetic 
techniques with the hope of finding compounds with improved pharmacological 
profiles. Notable successes include the derivatives of the antibiotic, sulfanilamide 3 
(Figure 1. 1), which have given rise to effective diuretics and antihypertension drugs. 3 
However, much of this approach was still based on trial and error and the molecular 
basis of the observed effect was often poorly understood. This situation began to 
change with the characterisation of receptors and enzymes allowing chemists to 
design molecules for specific targets. Some of the early successes included the 
discovery of n-blockers, 3-agonists and benzodiazepines. 4 










Despite the increase in the number of new classes of drugs reaching the market, 
traditional drug discovery was still heavily reliant on screening compound 
collections from pharmaceutical companies against newly discovered biological 
targets. These collections often suffered from a lack of chemical diversity; a result of 
being populated by analogues of a relatively small number of diverse lead 
compounds. Whilst natural products increased the number of structurally diverse 
compounds available, they routinely suffered from difficulties associated with their 
isolation and synthetic modification. Further challenges arose from advancements in 
biology, which gave rise to improved methods for protein production that enabled 
key proteins to be routinely produced in sufficient yield and purity for use in 
biological assays and structure determination. Similar progress in gene technology 
and DNA sequencing resulted in. a huge increase in the number of hypothetical 
targets available to chemists; and finding ways to design and synthesise ligands for 
them all provided a unique challenge. To meet this challenge, the pharmaceutical 
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industries developed new technologies such as high-throughput screening and 
combinatorial chemistry. 5 
1.1.2 High-Throughput Screening and Combinatorial Chemistry 
The increasing availability of drug targets that could form the basis of in vitro assays, 
combined with advances in robotic technology, allowed pharmaceutical companies 
to automatically assess the activity of samples in their collections by screening them 
in multi-well microtitre plates. This process was referred to as high-throughput 
screening (HTS) and today it is capable of screening hundreds of thousands of 
compounds in a 24 hour period. 6 To keep pace with HTS, new methods were 
developed to increase the number of compounds available for testing. Combinatorial 
chemistry involves the synthesis of compound libraries as opposed to single 
products. It has its origins in solid phase chemistry, as pioneered by Merrifield, 7 
since the immobilisation of molecules on resin allows for simple purification 
protocols and large excesses of reagents to drive the reactions to completion. 5 Since 
much of the early work on solid phase was concerned with the synthesis of peptides, 
early uses of combinatorial chemistry involved the generation of peptide libraries. 
However, the full impact of combinatorial chemistry in this area was not fully 
realised until the publication of the split-pool technique (Figure 1 .2).58 
Figure 1.2 The split-pool synthetic scheme for the synthesis of a 27-member library 
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Split-pool synthesis involves dividing the solid support into portions and reacting 
each portion with a single reagent (building block). The portions are pooled to 
provide a single batch of solid support containing a mixture of components. 
Repeating this divide-couple-recombine approach gives rise to a library where each 
resin bead contains one library member. An example of the power of this technique 
was given by Houghten and co-workers who synthesised over 34 million N-
acetylated hexapeptides from 18 different amino acids. 9 
Despite solid-phase techniques being tailor-made for peptide synthesis, such 
compounds are not ideal drug candidates due to their poor bioavailability. The 
combinatorial synthesis of "drug-like" (low molecular weight, organic molecules) 
compound libraries has received much attention. Although hampered by difficulties 
associated with transferring solution phase reactions to resin support, the area has 
given rise to some notable successes. For example, Eliman developed a solid phase 
route to benzodiazepines 9 and used it to synthesis a 192-member library (Scheme 
1. 1).b0  This seminal piece of work came to represent the potential of combinatorial 
synthesis to the pharmaceutical industry. The extent of the progress made since 
Eliman's work was demonstrated by Schreiber and co-workers through their 
stereoselective synthesis of over two million natural-product like compounds using 
split-pool technology. 1 ' 
Combinatorial chemistry coupled with HTS has enabled vast numbers of compounds 
to be synthesised for testing against a range of biological targets. New technologies, 
such as analytical constructs to aid quantitation and isotope encoding strategies to 
allow mass spectrometry to identify hits, have led to further advances. 12  However, 
doubts remain as to whether simply synthesising many more compounds will lead to 
a commensurate rise in the number, of leads? It is true to say that whilst 
combinatorial chemistry and HTS have generated more hits than previous methods of 
drug discovery, turning these hits into viable drug candidates has proven to be much 
more difficult than was anticipated. 13  Part of the reason for this may lie in figures 
that have estimated the total number of small organic molecules in the universe to be 





realistically be synthesised and screened, thus an element of rational drug design 
must be considered when planning combinatorial libraries. This need is increasingly 
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1.1.3 Structure-Based Design 
The growth of structural biology has seen an increasing number of protein structures 
solved by X-ray crystallography, NMR spectroscopy, or homology modelling. 
Knowledge of the 3D structure of proteins allows computer programmes to calculate 
the most favourable points of interaction between the protein and a ligand. The 
software achieves this by assessing the various binding points involving hydrogen 
bonding, electrostatic contacts, or Van der Waals interactions. This information can 
then be used to identify ligands with the required functional groups to interact at 
5 
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these key sites. 15  This process is helped if an X-ray crystal structure of the protein-
ligand complex is known, as is the case with CypA.' 6 
The challenge is to build virtual molecules into the protein binding site which are 
novel (de novo design) yet chemically tractable. Docking algorithms are used to 
screen compound databases in order to predict which molecules will possess the best 
binding affinities for a particular target. The advantage of docking is that the process 
is fast and entire compound collections can be virtually screened. In addition, 
algorithms can now take into account key properties such as adsorption, distribution, 
metabolism and excretion (ADME), which can have a serious impact on the viability 
of a lead. 17  Common criticisms of docking studies are that the suggested ligands 
show poor activity experimentally, or that they are synthetically challenging to make 
or modify. 18  Whilst it is impossible for docking to guarantee the activity of all hits, 
ever more sophisticated algorithms should continue to minimise the number of false 
positives. The screening of databases of available compounds has helped to ensure 
that hits from virtual screening can be easily derivatised. In terms of our studies, we 
have exploited structure-based design to identify novel ligands for CypA, using an 
in-house molecular docking programme, LIDEAUS, to screen the Maybridge Fine 
Chemicals database for hits. This approach will be discussed in more detail in 
Section 1.5. 
Computational studies play an increasingly important role in lead discovery and 
enable combinatorial chemistry to be tailored towards the synthesis of more focused 
libraries which stand a better chance of delivering compounds with optimised drug-
like properties. ' 9  For this approach to be successful, a detailed knowledge of the 
therapeutic target is necessary. Furthermore, an understanding of how a ligand 
interacts with its target on a molecular level is crucial for understanding its effect and 
designing analogues with improved pharmacological characteristics. The need to 
identify new drugable targets and understand their biological pathways is 
increasingly being met through the use of small molecules as probes for exploring 
protein functions. This field has been termed chemical genetics 20  and is discussed 
below. 
71 
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1.1.4 Chemical Genetics 
Classical genetic screens in model organisms have proved incredibly useful in 
elucidating the genes that control important biological processes. 21 ' 22 Two 
complementary approaches are commonly employed: the first, termed forward 
genetics involves introducing random mutations into cells, screening the mutants for 
a phenotype (physiological effect) of interest, and then identifying the gene 
responsible; reverse genetics, on the other hand, entails introducing a mutation in a 
specific gene of interest and observing the phenotypic effect of this mutation in a 
cellular context. Despite the success of these methods, they do suffer from a number 
of limitations: (1) they are not suitable for investigations in mammals, whose size 
and slow rate of reproduction are prohibitive; (2) gene mutations cannot usually be 
turned on or off, restricting a thorough analysis of their effects; (3) mutations in 
important proteins are often lethal, preventing a study of their function. 
Chemical genetics offers distinct advantages over the classical method due to the 
unique properties of small molecules: (1) their effect is often rapid and reversible 
(due to metabolism/clearing) enabling them to act as conditional alleles; (2) they can 
activate or deactivate their protein targets providing better information into the cause 
of phenotype changes. Chemical genetics should, however, be seen as a complement 
to the traditional approach, rather than a replacement, since the specificity of genetic 
mutations is unmatched by exogenous ligands at present. 23 There is also the 
challenge of synthesising each small molecule, although this has become less of a 
problem with the development of combinatorial chemistry. 
The power of chemical genetics lies in the ability of small molecules to perturb 
complex biological systems by binding to specific protein targets. With access to 
large numbers of compounds via combinatorial libraries, chemical genetic screens 
analogous to those of classical genetics can be used to identify protein targets 
(forward chemical genetics), or investigate the effect of ligands on a specific protein 
of interest (reverse chemical genetics). In, the former, a library of diverse compounds 
is screened against an organism of interest, and those that cause a phenotypic 
7 
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response selected and used to identify the protein target. In the latter, the library is 
screened against a specific purified protein to identify high affinity ligands, whose 
abilities to induce a phenotypic effect are then investigated. A classic example of 
forward chemical genetics is the discovery of the immunosuppressant molecule 
FK506 10 (Figure 1.3 ).24  The natural inhibitor of CypA, cyclosporin A (CsA) 11 
(Figure 1.3), had until then been the sole treatment for preventing organ-transplant 
rejection. Kino et al.24 tested fermentation broth extracts from Streptomyces for their 
ability to mimic CsA's ability to block the production of interluekin-2. This 
phenotype-based screen identified FK506 10, which was found to be structurally 
unrelated to CsA 11. FK506 subsequently helped to elucidate the biological pathway 
that governs immunosuppression, thus providing a powerful endorsement of the 
forward chemical genetics approach. 
Figure 1.3 Structures of FK506 10 and CsA 11. 
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The scientific literature also contains examples of reverse chemical genetics that 
have yielded novel ligands for specific protein targets. For example, Komarov and 
co-workers 25  identified a small molecule inhibitor of p53, whose effect was to reduce 
the damage to healthy tissues from anticancer treatments such as chemotherapy. In 
our work, we plan to explore the role of cyclophilins in the nematode parasite, 
Caenorhabditis elegans, by the use of novel small molecule inhibitors. It is hoped 
that inhibitors of CypA will have antiparasitic properties, but this relies on 
developing a clear understanding of the function cyclophilins perform in the 
organisms. 
8 
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Chemical genetics, therefore, offers the potential to gain a greater understanding of 
biological pathways and uncover novel protein targets. In addition, since it relies on 
the use of small molecules, these can form the starting point for drug discovery 
programmes. In general, to be successful chemical genetics requires: (1) access to a 
diverse range of small molecules; (2) an appropriate HTS method; (3) accurate target 
identification and validation. These points are discussed below: 
The first requirement can be satisfied through the synthesis of focused 
combinatorial libraries. To ensure the structures are diverse it is often advantageous 
to employ structure-based design and virtual screening technologies as discussed 
previously. How the compounds are synthesised is decided through a retrosynthetic 
analysis of the suggested lead. In contrast, some groups have pursued a diversity-
oriented synthesis (DOS) approach as a way to increase diversity into their library. 26 
DOS generally involves a combination of complexity forming reactions and split-
pool technology to synthesise a vast array of structurally diverse small molecules for 
use as probes in biological systems. 27 
An efficient HTS method is essential to test the effects of library members on 
proteins of interest. In industry this is almost completely robotised, with assay 
volumes now decreased to the nanolitre level, enabling more compounds per hour to 
be screened at less cost. 6 For the purposes of our research we have developed a 
novel in vitro screen that uses electrospray mass spectrometry to provide a rapid 
indication of binding. The method can also be used to obtain a rank order for our 
synthetic ligands, which enables those of highest affinity to be selected for in vivo 
testing. This technique and the results obtained will be discussed in depth in Chapter 
4. 
Target identification and validation; traditionally a drawback of the chemical 
genetics process, have been greatly aided by the advent of new technologies such as 
DNA microarrays28 and expression profiling. 29  The former involves monitoring the 
changes in gene expression of a cell, which has been modulated by a small molecule, 
to identify the effected gene and the subsequent target protein it encodes for. In the 
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latter, the pattern of gene expression changes that occurs when a ligand binds is used 
to produce an expression profile for the cell. Specific genes can be deleted and 
phenotype effects and expression profiles compared to identify whether the ligands 
bind specifically or promiscuously. 
1.1.5 Conclusions 
Drug discovery has made significant advances since the time when products derived 
from coal-tar or the natural world provided the only source of new medicines. 
Developments in molecular biology removed the traditional bottleneck of target 
identification and shifted the onus onto synthetic chemists involved in lead 
discovery. Their response was to invent new methodologies such as HTS and 
combinatorial chemistry. However, initially these techniques failed to live up to 
their promise of identifying many new lead compounds. This was largely due to a 
failed approach, where greater emphasis was place on quantity as opposed to quality. 
The need for a rational approach to drug design soon became apparent and molecular 
docking and virtual screening technologies played an important role in the planning 
of focused combinatorial libraries containing members with a high probability of 
interacting with protein targets. Computational methods rely heavily on pre-
determined structural characteristics of the protein targets, but such information is 
not always readily available. In fact, it is often the case that the target itself has not 
been identified and/or its function remains unclear. The field of chemical genetics 
aims to solve these problems through the use of small molecules that can act as 
probes in biological systems. This approach has helped to elucidate complex 
biological pathways and identify previously unknown targets, with the added 
advantage that the structures of the small molecule modulators provide leads for drug 
discovery. With the sequencing of the human genome now complete, the number of 
potential drug targets looks set to rise exponentially. Chemical genetics (or 
genomics as it should now be referred) will play a valuable role in identifying the 





1.2 The Immunophilins 
Cyclophilin A (CypA) and FK506 Binding Protein (FKBP) are ubiquitous 
intracellular proteins that have been given the generic name inmiunophilins on 
account of their ability to bind the immunosuppressive drugs, cyclosporin A (CsA) 
11 and FK506 10 respectively. 30  CsA 11 is specific for CypA, whereas FK506 10 
only binds to FKBP. Despite possessing no sequence homology or apparent 
structural similarities both immunophilin/drug complexes target and inhibit the 
calciumlcalmodulin dependent phosphatase calcineurin (CaN). 3 ' Since CaN is a key 
regulatory species in the T-cell activation pathway, inhibition of this leads to 
immunosuppression. Another drug, rapamycin (RAPA) 12 (Figure 1.4) was also 
found to complex FKBP and inhibit T-cell activation, however, unlike CsA 11 or 
FK506 10, its mechanism of immunosuppression does not involve the blocking of 
CaN. 32 
Figure 1.4 Structure of rapamycin 12. 
Me 
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The immunophilins are also enzymes which catalyse the cis-trans isomerisation of 
prolyl amide bonds in peptide and protein substrates. 33,34 This peptidyl-prolyl 
isomerase (PPIase) activity has important biological implications as it leads to 
protein folding, which in turn determines protein function. CsA 11 or FK506 10, 
when bound to their respective immunophilins, inhibit their PPIase activity and this 
was put forward as an early mechanism for immunosuppression. 35 However, it was 
later shown that PPIase activity was not required for T-cell activation. 36  A third type 
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of PPIase, parvulin, was isolated from E. coli in 1994 and is structurally unrelated to 
CypA or FKBP. 37 
1.2.1 Cyclophilin A 
In 1984, Fischer isolated an 18 kDa protein from porcine kidney that was found to 
possess PPIase activity and, hence, became known as PPIase. 38 In that same year, 
Handschumacher and fellow researchers purified a CsA 11 binding protein from 
bovine spleen which they termed cyclophilin. 39 At the time its amino acid sequence 
was thought unrelated to any known protein and it was not until 1989 that it was 
proved that PPIase and cyclophilin were identical. 33 Over the past 18 years over 30 
immunophilins belonging to the cyclophilin family have been discovered, with CypA 
the archetypal member. 
Figure 1.5 X-ray crystal structure of CypA bound to CsA 11. 
W121 
The structure of CypA has been determined using NMR4° and X-ray 
crystallography. 16  It consists of a /3-barrel formed by eight antiparallel /3-strands 
closed by two a-helices at the top and bottom (Figure 1.5). Inside the barrel, six 
phenylalanines and a tyrosine residue orientate their side-chains together to create a 
very hydrophobic core. The binding site for CsA 11 is formed by two loops, which 
protrude out from the globular protein core, on top of two /3-strands (Figure 1.5). It 
has also been confirmed as the PPIase active site. 41 
12 
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1.2.2 Cyclosporin A 
CsA 11 (Figure 1.3) is a cyclic undecapeptide of fungal origin that was discovered in 
1973 and later shown to be a potent immunosuppressant (Sadimmune®, Neoral®). 42 
CsA 11 binds to CypA with a dissociation constant (Kd) of 46 nMU  and is currently 
administered to organ transplant patients to prevent graft rejection. Aside from its 
clinical use, CsA 11 has allowed researchers investigating its mechanism of action to 
gain a much greater understanding of T-lymphocyte function and cellular signalling 
pathways. 
Unlike CypA, whose structure in its free and bound states is essentially the same, the 
conformation of CsA 11 in solution and in the CypA/CsA 11 complex is very 
different. 44  In chloroform, CsA 11 consists of an antiparallel fl-sheet with four 
intramolecular hydrogen bonds involving the four non-methylated NH groups. The 
amide bond between MeLeu-9 and MeLeu- 10 is in the cis conformation. However, 
in the bound form all four hydrogen bonds are disrupted and each amide bond is 
trans. 45  A new intramolecular hydrogen bond between the hydroxyl group of the 
MeBmt-1 side-chain and the carbonyl oxygen of MeLeu-4 is also present. These 
unexpected discoveries gave fresh impetus to researchers' attempts to design 
conformationally constrained analogues of CsA 11, in order to discover compounds 
with higher affinities. 
1.2.3 Cyclophilin A - Cyclosporin A complex 
Only CsA residues 9, 10, 11, 1, 2 and 3 make contact with CypA. 4 ' Thirteen key, 
highly conserved residues of CypA (Arg-55, Phe-60, Met-61, Gln-63, Gly-72, Ala-. 
101, Asn-102, Ala-103, Gin-111, Phe-113, Trp-121, Leu-122 and His-126) are 
located within 4 A of the bound ligand and define the active site of the protein. Of 
these, Phe-60, Met-61, Phe-1 13, Leu-122 and His-126 make up a deep hydrophobic 
pocket into which the MeVal- 11 residue of CsA 11 is located. This pocket is also the 
binding site of the proline ring in peptide substrates. The six residues that interact 
with CypA are referred to as the binding domain of CsA 11. The remaining residues 
protrude out from the binding site and are involved in complexing to CaN. 46 These 
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residues make up the effector domain of CsA 11. There are five direct hydrogen 
bonds between CypA and CsA 11 and five water molecules involved in mediating 
intermolecular interactions. 
1.2.4 Mechanism of Immunosuppression 
The mechanism by which CsA 11 elicits its immunosuppressive effects has been 
extensively studied and reviewed. 36'47 The CypAICsA 11 complex has a high affinity 
for the calmodulin-dependent serine/phosphatase calcineurin (CaN), exhibiting a 
dissociation constant of 33 nM. 48  None of the individual components favour 
complexation with CaN indicating that it is the immunophilinldrug combination that 
is important. 
Figure 1.6 Schematic representing events in the immunosuppressive pathway. 54 
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T-cell activation begins with the stimulation of T-cell receptors, present on the 
membrane of a cell, by foreign antigens. This leads to an influx of calcium into the 
cell which results in calmodulin (CaM) binding to CaN (Figure 1.6). The CaM/CaN 
complex effects the dephosphorylation of nuclear factor of activated T-cells (NF -
AT), a transcription factor that regulates the production of T-cell activation genes, 
such as interleukin-2 (1L2). Only the dephosphorylated form of NF-AT is capable of 
14 
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passing into the nucleus and causing the transcription of the 1L2 gene. Hence, 
inhibition of CaN by the immunophilin/drug complexes prevents NF-AT 
translocation and subsequent production of 1L2. 
Proof that inhibition of CypA's PPIase activity was not responsible for 
immunosuppression came from studies on a modified CsA 11 derivative termed SDZ 
NIM 81113 (Figure 1.7) . 49  The replacement of MeLeu-4 with Me-lie resulted in 
improved binding to CypA and inhibition of its PPIase activity. The compound, 
however, was unable to interact with CaN and therefore did not give rise to 
immunosuppression. 
Figure 1.7 Structure of SDZ NIM 811 13. 
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1.2.5 PPIase Mechanism 
The majority of peptide bonds adopt the trans conformation due to unfavourable 
steric interactions between side chains when in the cis form. However, prolyl 
peptide bonds are an exception, with at least 10 % found in the cis conformation at 
equilibrium.50 This is a consequence of the unique dialkyalted nature of proline, 
which reduces the energy difference between the two forms. The conformation 
prolylamides adopt is important in determining the structure and function of proteins. 
However, the rate of cis-trans isomerisation of prolylamides is slow on a 'biological' 
time scale and in some cases has been found to be rate determining. 51  Nature 
overcomes this problem by using PPlases such as CypA to catalyse the cis-trans 
isomerisation of Xaa-Pro bonds (where Xaa = any amino acid). CypA is a highly 
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efficient enzyme and has broad substrate specificity. 52  Structural studies have found 
that CypA prefers to bind substrates in the cis conformation despite the trans form 
dominating at equilibrium. 53  It is thought that only cis-prolines can be 
accommodated into the hydrophobic pocket of CypA. 54 
There have been many mechanisms proposed to explain the immunophilins' PPIase 
activity. However, the one now generally accepted involves catalysis by distortion 
(Figure 1 In this mechanism, the immunophilins bind the peptide substrate in 
a twisted amide conformation which results in a lower barrier to rotation due to a loss 
of amide resonance. It is thought that distortion of the amide bond is facilitated by 
hydrogen bonding of the prolyl nitrogen by the active site residue Arg-55 in CypA. 
Evidence in support of this mechanism came from the structure of CsA 11, where the 
MeBmt- 1 side chain that is required for binding to CypA is located in approximately 
the same position in the active site as the amide carbonyl of a peptide substrate 
(Figure 1 •9)•30  Therefore, it has been suggested that the side-chain hydroxyl group 
may mimic the carbonyl of the peptide bond that undergoes isomerisation. In this 
way, CsA 11 could be binding as a transition state analogue. 56  This view was 
strengthened by a similar study on FK506 10, where it was found that allylic [A" 3 ] 
strain results in the ketone carbonyl lying in a plane orthogonal to the adjacent 
homoprolyl amide bond (Figure 1 9)57 
Figure 1.8 Proposed mechanism of cis/trans isomerisation of prolyl peptides by CypA. 












Figure 1.9 (A) Model of the transition state structure of the twisted peptidyl-prolyl 
amide bond. (B) Substructure of FK506 and (C) CsA that is proposed to mimic the 
twisted amide bond of a peptide substrate. 30 
I 
1.3 Other Functions of Cyclophilins 
Due to their high abundance in a variety of cell types it is not surprising that 
cyclophilins, in particular CypA, have been implicated in a range of cellular 
processes besides immunosuppression. Some of the most important are discussed 
below. 
1.3.1 Role in HIV-1 
The Gag polyprotein of human immunodeficiency virus type 1 (HIV-1) is 
responsible for the assembly and packaging of new HIV-1 virions. 58 Late in the 
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infectious cycle, Gag accumulates at the cell membrane and forms new virions that 
bud from the host cell. During the budding process Gag is cleaved by the viral 
protease to produce several proteins, including the matrix, capsid (CA) and 
nucleocapsid in a process called maturation. The matrix lines the viral membrane, 
whereas the CA protein forms a conical core structure which contains the viral 
RNAlnucleocapsid complex. On infecting a new host, the virion must disassemble 
to allow reverse transcription of the RNA genome. CA, therefore, plays a crucial 
role in HIV- 1 replication and infectivity. 
CypA has been reported to bind to Gag and become incorporated into the new virion, 
where it is thought to be important for maintaining the infectious nature of the 
disease. 59 ' 60  CypA from the host cell cytoplasm binds to the CA domain of Gag and 
subsequently becomes packaged into the budding virion. CsA 11 inhibits this 
process, which leads to virions devoid of CypA. Whilst this does not affect virion 
assembly or production, it has a drastic effect on viral infectivity. Although the 
function of CypA in viral replication is still poorly understood, it has been reported 
to act at an early stage of the retroviral life cycle, following receptor binding and 
membrane fusion but preceding reverse transcription. 61 These findings suggest that 
CypA may play a role in viral CA core disassembly. 
X-ray crystal structures of CypA in complex with portions of CA have been obtained 
and reveal a proline rich fragment of CA to bind to CypA. 62 ' 63 The Pro-90 residue of 
CA was found to bind in the hydrophobic pocket of CypA analogous to the proline of 
the tetrapeptide Suc-Ala-Ala-Pro-Phe-p-nitroanilide (AAPF), a commonly studied 
substrate for CypA. In addition, CA binds with a N- to C-terminal peptide chain 
direction, opposite to CsA 11, but the same as AAPF. These findings suggested a 
role for PPIase activity in HIV-1 infectivity. However, despite the similarities 
between the structures of bound CA and AAPF, significant differences remain. The 
most notable of these concerns the conformation of the prolyl amide bond: in CA it is 
trans, whereas in AAPF and all other known peptide substrates it is cis. Normally, 
unfavourable steric interactions involving the side chains of amino acids immediately 
preceding the proline prevent the peptides binding in the trans conformation. 
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However, glycine occupies this position in CA and its compact nature allows it to 
bind deeply in CypA's hydrophobic pocket provided the trans conformation is 
adopted. The Gly-89-Pro-90 segment is highly conserved in all reported HIV-1 
sequences suggesting it forms a critical recognition site for CypA. Mutation of either 
residue to Ala inhibits CypA packaging and blocks viral infectivity. In light of these 
findings it was thought unlikely that CypA's PPIase activity was responsible for its 
role in HIV-1. Instead it was proposed that CypA probably acts as a molecular 
chaperone. 62  However, Bosco et al. recently used NIfvlIR exchange spectroscopy to 
show that CypA is capable of catalysing the cis/trans isomerisation of the Gly-89-
Pro-90 peptide bond, suggesting that PPIase activity may play a role after all. 64 
There is, therefore, a need for further research in this area to ascertain the exact 
function of CypA in HIV- 1 replication and infectivity. 
Despite CsA 11 inhibiting the effects of CypA it has been of little benefit as an anti-
HIV drug. The main reason for this is that the dose required for inhibition of the 
CypA/CA complex is 10-100 fold higher than that required for 
immunosuppression. 59 At such levels, CsA 11 is toxic in vivo. There is, therefore, a 
strong therapeutic driving force to design inhibitors of CypA that might possess anti-
HIV properties. The finding that non-immunosuppressive analogues such as SDZ 
NIM 81113 displayed potent anti-HIV activity against a number of cell lines helped 
to confirm that CsA's antiviral activity was not related to its immunosuppressive 
action. 65  Hence, new anti-HIV drugs do not have to be designed to interact with 
CaN. However, the HIV-1 virus is constantly evolving and studies have suggested 
that it may become insensitive to CsA 11, similar to other primate immunodeficiency 
viruses which do not require CypA for replication. 66  There may be, therefore, a 
limited window of opportunity to maximise the benefits of small molecule CypA 
inhibitors acting as anti-HIV drugs. 
1.3.2 Antiparasitic Activity 
Due to its potent immunosuppressive properties CsA 11 is an important tool for 
investigating hosts' immune response to parasitic infections. However, studies in 
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this area in the early eighties found CsA 11 to possess antiparasitic properties in 
schistosome and malaria; 67  These unexpected findings prompted researchers to 
examine the nature of this effect and attempt to elucidate its mechanism of action. 
The antiparasitic activity of CsA 11 was later found to be widespread in both 
protozoa and helminth infections, although not all classes of parasite were 
susceptible and the observed effect was often unpredictable. For example, 
Schistosoma mansomi was found to be CsA 11 sensitive, whereas the filarial 
nematode, Brugia malayi, proved much less susceptible to CsA 11 mediated 
treatment. 68  In addition, the immunosuppressive properties of CsA 11 can often 
complicate attempts to understand the host-parasite interaction. In the case of the 
protozoan Trypanosoma.cruz, CsA 11 actually exacerbated the infection, most likely 
as a result of suppressing the host's immune response. 67 
How CsA 11 exerts its antiparasitic effects, and the reason behind the observed 
species specificity, has yet to be determined. However, its mechanism of action 
appears distinct from its immunosuppressive properties. 69  Evidence in support of 
this view includes: 1) the doses required for antiparasitic effects are well below those 
needed to induce significant immunosuppression; 2) non-immunosuppressive 
analogues of CsA 11 have shown similar activity against organisms such as S. 
mansomi; 3) CsA 11 also shows antiparasitic action in vitro, suggesting that activity 
in vivo is not reliant on interactions with the host's immune system. Attention, 
therefore, turned to the intracellular targets of CsA 11, with parasitic cyclophilins the 
obvious candidates. 
Cyclophilins have been described from a number of parasites including Toxoplasma 
gondi,7° plasmodium falciparum, 7 ' S. mansomi 72 and B. malayi. 73 Cyclophilins of 
parasites that display sensitivity to CsA 11 (the first three listed) show strong 
similarities to human cyclophilins. and possess a highly conserved region, capable of 
binding CsA 11. Furthermore, cyclophilins from CsA 11-sensitive parasites 
generally display PPIase activity, which is thought to be required for the correct 
folding of collagen, 74  a crucial component of nematode cuticles. CsA li's ability to 
block the PPIase activity of parasitic cyclophilins may, therefore, explain its 
,i1 
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antiparasitic effects. 	CsA 11-insensitive parasites, like B. malayi, possess 
cyclophilins with significant structural differences compared to those isolated from 
CsA 11-sensitive species. 75  Most notable are an eight amino acid divergent loop and 
a histidine residue in place of the Trp-121 in the active site. Since Trp-121 is a key 
recognition factor for CsA 11, its replacement may help explain B. malayi 'S 
resistance to CsA 11. 
The fact that multiple isoforms of cyclophilin exist in parasites suggests that they 
may have a range of different functions, some of which may be species specific. 
Understanding the role of such cyclophilins is important if new antiparasitic 
treatments are to be discovered. Caenorhabdtis elegans is a free-living nematode 
that is genetically tractable, easily cultured and has a relatively fast reproductive 
cycle. It has also been found to contain no less than 11 cyclophilin isoforms, all of 
which possess PPIase activity. 76  C. elegans, therefore, provides an ideal model for 
studying the function of the various cyclophilins and determining the action of CsA 
11. This information will not only be of biological interest but will aid the design of 
new families of antiparasitic drugs. 
1.4 Cyclophilin A Inhibitors 
CsA 11 suffers from a number of serious side effects: it is toxic if administered in 
high doses; displays poor bioavailability due to its high molecular weight; and 
studying its effects are complicated by the presence of inhibitory and 
immunosuppressive functions. Hence, a great deal of research has been devoted over 
the last decade to the design of novel CsA 11 analogues which have improved 
binding and better pharmacological profiles. 
1.4.1 Modifications of CsA 
Much of the work carried out into the design of CypA inhibitors has centred on the 
modification of CsA 11 residues, particularly those that comprise the drug's binding 
domain. Kallen et al. investigated the structure-activity relationships (SAR) of 
eleven cyclosporin derivatives (Table 1 In general, they found that derivatives 
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at residues 1 or 2 exhibited diminished binding to CypA, whereas modifications of 
residue 4 did not significantly affect CypA binding but drastically decreased the 
complex's inirnunosuppressive ability. These findings are in agreement with the 
observation that residues 1 and 2 belong to CsA's binding domain, whereas residue 4 
is associated with the drug's effector region. In most cases, the conformation of 
CypA was conserved on binding to the ligand. Only in the case of Val substitution at 
position 2 was any change in the structure of the protein observed. This change was 
explained by increased bulk in the Abu-binding pocket pushing main-chain protein 
atoms closer together. One surprising finding in the study was the improved CypA 
binding observed for derivatives 209650, 209217, and 209825 respectively. The 
presence of a Val at position 2 had been shown to be detrimental to binding (33804), 
whilst the modifications at residue 3 were not shown to make any significant contacts 
with the protein. It was highlighted earlier that CypA is selective for the trans 
isomer of CsA 11, hence it may be the case that modification of certain residues 
results in a higher proportion of the preferred isomer being present at equilibrium. 
Further evidence that this may be a significant factor came from research carried out 
by Papageorgiou et al. which found that replacing the MeLeu-4 residue of CsA 11 
with a sec-butyl group resulted in a four-fold increase in binding to CypA. 78 X-ray 
analysis showed that the 3D structure of the ligand bound to CypA matches that of 
the CypAICsA 11 complex, with the new side-chain not in contact with the protein 
but protruding out from the binding site into the solvent. Hence, the improved 
binding cannot be explained by structural differences. 
Derivatives of residue 4 have been of interest to researchers as they offer a means of 
probing the interactions of the immunophilin/drug complex with CaN. The series of 
modifications of MeLeu-4 shown in Table 1.2 reveal that position 4 is very sensitive 
to structural changes, with branched fl-carbon atoms 14 particularly disfavoured with 
respect to immunosuppression. 79  These findings suggest that CaN has a very tight-
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144 modification CypA a) 1L2 b) 
CsA 11 CH2CH(CH3)2 1 1 
14 CH(CH3)2 0.5 2500 
15 CH2CH3 1.2 163 
16 CH2Cyclopropyl 2.8 5.3 
17 CH2C(CH2)(CH3) 1.8 4.0 
18 CH2CH2CH(CH3)2 1.9 9.0 
19 CH2CF(CH3)2 2.1 7.0 
20 CH2C(OH)(CH3)2 0.9 110 
IC50 (derivative) / IC50 CsA 11 
Measure of effect of suppression 
of 1L2 production relative to CsA 11 
Since the free and bound structures of CsA 11 differ significantly, Alberg and 
Schreiber used a structure-based design approach to design a tricyclic analogue 21 of 
CsA (Figure 1.10) that would more closely mimic the bound conformation. 80  They 
achieved this by incorporating a bicyclic heterocycle between residues 6 and 9 of 
CsA 11. The tricyclic CsA derivative 21 showed a three-fold increase in affinity for 
CypA and was twice as effective at T-cell inhibition. The latter finding was most 
likely due to the conformational restraints of the derivative helping to minimise the 
entropy lost on binding CaN. 
Figure 1.10 Structure of tricyclic CsA 21. 
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1.4.2 Novel Synthetic Inhibitors of CypA 
Rather than attempt to modify the existing CsA 11 structure, a number of groups 
have turned their attention to the design of small molecules which mimic the 
important binding sites of peptide substrates. For example, Boros et al. used 
fluoroolefins 22, 23 (Figure 1.11) as mimics for the prolyl amide bond in the 
tetrapeptide substrate Suc-Ala-Gly-Pro-Phe-pNA. 8 ' 
Figure 1.11 Fluoroolefins act as prolyl peptide mimics. 














The conformation of the Gly-Pro peptide bond was fixed by the fluoroolefin, with 
the (2)-isomer equivalent to the trans configuration and the (E)-isomer 
corresponding to the cis configuration. CypA predominantly binds tetrapeptides in 
the cis form, hence, it was hoped that by conformationally constraining the ligands, 
improved binding to CypA would be observed. Preliminary results showed that the 
two (E)-isomers and one of the (2)-isomers inhibited the PPIase activity of CypA. 
Hart et al. have reported the synthesis of a (Z)-alkene cis-proline mimic by the route 
shown in Scheme 1.2.82  Analogous to the approach described above, the researchers 
conformationally locked the Suc-Ala-Ala-Pro-Phe-pNA peptide by introducing a (2)-
alkene to mimic the cis-prolyl amide bond favoured by CypA. Subsequent 
experiments showed that ligand 27 inhibited the PPIase activity of CypA with an 
IC50 value of 6.5 ± 0.5 j.xM. 
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Wang et al. described the SAR of a number of bicyclic lactam molecules 28 (Table 
1.3) that had been found to mimic the CypA bound conformation of cis-Gly-Pro. 83 
The study found that bicyclic lactams with hydrophobic groups adjacent to the 
lactam carbonyl 28e bound with highest affinity, whereas those with large N-
alkylamide substituents 28a displayed the lowest affinity. In addition, the 
researchers attempted to design a transition state analogue that would mimic the 
twisted amide transition state of the natural substrate (Figure 1.12). It was envisaged 
that reducing the lactam carbonyl group to an amine functionality would afford a 
conformationally constrained ligand with a prolyl-like nitrogen atom that could 
interact with the Arg-55 residue in the active site of the protein. However, it was 
found that the transition state analogue 29b displayed lower affinity than its ground 
state equivalent 28b (Table 1.3). This disappointing result was probably due to the 
structure of the bound ligand failing to coincide with that of the natural substrate, 
preventing favourable interactions with active site residues such as Arg-55. 
Nevertheless, the results showed that it was possible to design small ligands with the 
ability to bind CypA and inhibit its PPIase activity. 
26 
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Table 1.3 
Derivative R1 R2 Kd (PM) 
28a H ButO >200 
28b 2-CH2C 10H7 ButO 17 ±8 
28c CH2Ph BnO 124 ±30 
28d 2-CH2C 10H7 BnO 4.7 ±2 
28e 2-CH2C 10H7 Me 1.5 ± 0.05 
28f CH2Ph ButO 140 ± 32 





Derivative R1 Kd (MM) 
29a H >200 
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Wu and co-workers employed a virtual screening approach to identify novel non-
peptide inhibitors of CypA. 84 They discovered the lead compound 30 (Figure 1.13), 
which was found to inhibit PPIase activity with an IC 50 value of 6 .iM. Various 
modifications of the aryl groups, central core and urea linkers were made in order to 
develop SAR data. Such studies uncovered a compound 31, with an IC 50 value ten-
fold better than the original lead, which displayed neuroprotective/neurotrophic 
effects as a result of its interaction with cyclophilins in the brain. 
Figure 1.13 Novel non-peptidic inhibitors of CypA. 
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1.4.3 Peptide Ligands 
There have been numerous studies of CypA in complex with small proline 
containing peptides. 85  These arose from researchers' desire to gain a greater 
understanding of CypA's PPIase mechanism. The CypA/peptide ligand structures 
have a number of common features: 
They bind with an N- to C- chain direction, opposite to bound CsA 11. 
The proline binds in a deep hydrophobic pocket in CypA's active site. 
Hydrogen bonds exist between Asn-102 and the prolyl amide carbonyl and NH 
from the preceding amino acid. These interactions are key recognition factors. 
A hydrogen bond exists between Arg-55 and the carbonyl oxygen on proline's C-
terminal side. Arg-55 has also been postulated to form a hydrogen bond to the 
proline nitrogen during isomerisation. 






Sanglier and co-workers screened microbial broth extracts for metabolites with 
affinities for CypA. 86  They discovered an actinomycetes strain Streptomyces A92-
308110 that produced novel macrolides, which they termed sanglifehrins. 
Sanglifebrin A (SFA) 32 (Figure 1.14), the archetypal member, was found to exhibit 
a higher affinity for CypA than CsA 11 but had no effect on the phosphatase activity 
of CaN. Nevertheless, SFA was found to block T-cell proliferation suggesting it has 
a different mode of action to CsA 11.87 
Figure 1.14 Structure of sanglifehrin A 32. 
HO 	 - - 	- - OH 
NH OH 	 0 N, 00" OH 
HO 
32 
1.5 Ligand Design 
The previous sections have highlighted the significant role CypA and its analogues 
play in a number of important areas such as immunosuppression, protein folding, 
HIV-1 infectivity and parasitic development. Despite extensive research, however, 
the exact mode of action of cyclophilins in a number of processes remains to be 
elucidated. This field of research would benefit from the design and synthesis of 
novel ligands for CypA that could be used to probe its biological function and give 
insight into its mechanism of action. Most of the ligands designed to date, however, 
have been modified CsA 11 derivatives, peptides, or complex natural products. 
These are not ideal candidates for in vivo studies due to their poor bioavailability and 





addition, they are often challenging to synthesise. There is, therefore, a strong case 
for the use of small, non-immunosuppressive inhibitors of CypA that, in addition to 
acting as biological probes, could form the basis for the design of novel drugs to 
combat important diseases such as HIV-1 and parasitic infections. 
Using the X-ray crystal structure of CypA, we have employed a structure-based 
design approach to identify novel ligands that can form strong interactions with 
CypA. To achieve this, an in-house in silico database mining programme LIDAEUS 
was used to select lead compounds, which were then modified synthetically to 
optimise protein-ligand interactions. The ligands were then screened using in vitro 
assays to determine their binding and the best inhibitors carried forward for in vivo 
testing. An overview of the entire process is given in Figure 1.15. 
Figure 1.15 Overview of structure-based approach to ligand design. 
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1.5.1 Discovery of Lead Compound Dimedone 
The programme LIDAEUS was used to select compounds from the Maybridge Fine 
Chemicals database. 88  Using the X-ray crystal structure of CypA's active site as a 
template, the programme docks ligands of appropriate type into the defined binding 
region. The generated fits are evaluated with scoring functions that account for Van 
der Waals, hydrophobic and H-bonding interactions. The ligand is then screened in a 
number of conformations to optimise favourable interactions and minimise any steric 
clashes. A least-squares energy minimisation is then carried out for each hit ligand 
in order to obtain a final ranked list of hits. 
This process led to the identification of 5,5-dimethylcyclohexane-1,3-dione 
(dimedone) 33 (Figure 1.16) as a potential lead structure for CypA. Confirmation of 
dimedone 33's viability as a lead was achieved by obtaining an X-ray crystal 
structure of it bound in the active site of CypA (Figure 1.1 7B). This revealed 
dimedone 33's geminal dimethyl group binds in the hydrophobic pocket of the active 
site, mimicking the interactions of MeVal-1 1 in CsA 11 or the proline ring in peptide 
substrates. One of the carbonyl groups of dimedone 33 is close enough to form a H-
bond with the Arg-55 residue of CypA, analogous to the MeLeu-10 residue of CsA 
11 (Figure 1.17A). The dissociation constant (Kd) for dimedone 33 was 22 MM as 
determined by fluorescence binding assay (see Chapter 4). For comparison, the Kd 
for CsA 11 was measured to be 36.8 nM by the same assay. 89 

















Figure 1.17 (A) Dimedone 33 mimics two key residues of CsA 11 responsible for 
binding CypA; (B) X-ray crystal structure of dimedone 33 (green) and CsA 11 
(highlighted) in complex with CypA. 
32 
Chapter 2 	 Results and Discussion I 
2 	Results and Discussion I 
2.1 Aim 
The overall aim of this project was to design and synthesise a new class of small 
molecule inhibitors for CypA that could be used to probe protein function and 
investigate protein-ligand interactions. The plan was to build upon the previous 
work that had identified dimedone 33 as a partial mimic of CsA, 90 but attempt to 
overcome some of the drawbacks associated with the parent compound and its 
derivatives. Hence, conformationally constrained ligands 34 and 35 were proposed, 
based on the dimedone template (Figure 2.1). It was hoped that, compared to linear 
analogues, these would display greater affinities for CypA as a result of losing less 
entropy during binding. In addition, preliminary modelling studies indicated that 
incorporating an amide bond in the position shown would allow it to act as a mimic 
for the twisted-peptide bond of a bound peptide substrate. Thus, these molecules 
may bind as transition state analogues, which should improve their affinities. 
Figure 2.1 Proposed lead compounds incorporating dimedone functionality within a 
conformationally rigid structure. 
corresponds to Xaa-Pro 	
Hydrophobic 
pocket amide bond 	
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34 	 35 
Since dimedone 33 is commercially available, inexpensive and easily functionalised 
at a number of positions it was decided to use this as the starting point for our 
synthetic approach. Using chiral a-amino acids as the basis for the construction of 
the second ring would allow for a diverse family of compounds to be synthesised. 
Two complementary synthetic routes were proposed. The first involved the 
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36 derived from protected a-amino acids (Scheme 2.1). Deprotection of the amine 
followed by condensation with the carbonyl of dimedone 33 would provide the 
molecules of interest 39. This route was attractive for a number of reasons: the 
regioselective alkylation of dimedone is known in the literature; 9 ' there are well-
established methods for converting amino acids into their bromomethylketone 
derivatives; 92  and the final condensation step should result in a favourable increase in 
rotational entropy. 
Scheme 2.1 
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The second approach (Scheme 2.2) involves condensation of dimedone 33 with an 
amino acid 40 (protected as its ester) to generate an enaminone derivative 41. The 
ester is then hydrolysed and reacted with diazomethane to generate a diazoketone 43. 
43 can form a carbene species in the presence of a dirhodium catalyst, which can 
then insert into one of the adjacent C-H bonds on dimedone, thereby furnishing the 
final compound 39. Although this route is an elegant four-step synthesis to the target 
ligands, the uncertainty over the viability of the final step, given the other 
functionality present in the molecule, resulted in the first method taking precedence. 
2.2 Alkylation of Dimedone 
Berry et al. reported a procedure for the regioselective alkylation of dimedone 33 
using a range of electrophiles (Scheme 2.3).' This method involved the initial 
formation of a dianionic species 44 by treating dimedone 33 with two equivalents of 
LDA in the presence of an excess of hexamethyiphosphoric triamide (HMPA). 
Subsequent treatment with various bromo-electrophiles led to alkylation exclusively 
at the 4-position. Such regioselectivity was a result of the differing reactivities of the 
two enolates: the enolate between the dicarbonyl being more stable, and hence less 
reactive, than the enolate generated by deprotonation at the 4-position. 
Scheme 2.3 





44 	 45a-d 
Table 2.1 
Entry" R Product Yield/% 
1 PhCOCH2- 45a - 
2 Me02CCH2- 45b 26 
3 CH2CHCH2- 45c 37 
4 But02CCH2- 45d 52 
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Unfortunately, attempts to alkylate dimedone 33 with a range of electrophiles using 
Berry's conditions proved problematic. Initial attempts (Entries 1-3, Table 2.1) were 
poor to moderate yielding as a large number of by-products were obtained, which 
proved difficult to separate. These may have arisen from reaction at the 2-position or 
through O-acylation. In addition, the failure of the reaction with bromoacetophenone 
(Entry 1, Table 2.1) did not augur well for the use of other bromomethylketones as 
electrophiles. Berry had noted that the use of an excess of HMPA (3 eq) was critical 
to the reaction proceeding well. However, it was found that increasing the amount of 
HIvIPA employed in the alkylations had negligible effect on the yields obtained. In a 
further attempt to improve the reaction conditions, sodium iodide was added together 
with the electrophile in order to effect halogen exchange, thus generating a more 
reactive iodo-electrophile in situ. The addition of sodium iodide did not result in a 
significant improvement in the reaction, suggesting the reagents themselves might 
not be stable under the strongly basic conditions. This view was supported by the 
reaction involving the relatively base-stable tert-butyl bromoacetate, which afforded 
the desired alkylated derivative 45d in 52 % yield (Entry 4, Table 2.1). This yield 
was the best obtained to date and the reaction was free of many of the by-products 
that had complicated previous attempts. In fact, the only other compounds isolated 
after chromatography were unreacted starting materials. The relative success of this 
reaction leant credence to the argument that the forceful reaction conditions 
involving strong bases and hard dianion enolates may not be favoured by certain 
electrophiles with reactive functional groups. Hence, it was envisaged that using a 
softer enolate equivalent and less harsh conditions would allow for a greater variety 
of electrophiles to be used. 
2.3 Silylation of Dimedone 
2.3.1 Bis-Silyl Enol Ether of Dimedone 
By synthesising the bis-silyl enol ether of dimedone 46 and carrying out alkylations 
using Mulcaiyama-type chemistry it was felt that a greater degree of control could be 
exerted over the process. Direct conversion of dimedone 33 to the bis-silyl enol 
ether derivative 46 was attempted using a literature procedure which involved adding 
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dimedone 33 to a mixture of zinc chloride and triethylamine, followed by 
chlorotrimethylsilane (TMSC1), at 0 °C (Scheme However, this failed to give 
any of the desired compound 46 and a majority of the starting material 33 was 
recovered. Changing the silylating reagent to trimethylsilyl 







Et3N 	- 	TMSO 	OTMS 
TMSOTf 
33 	 46 
Torkelson and Ainsworth reported problems associated with self-condensation when 
trying to synthesise the bis-silyl enol ether 46 directly. 96  Their solution was to 
proceed via the mono-silyl enol ether 47. This approach was followed and 47 was 
successfully synthesised in 95 % yield by reacting dimedone 33 with 
hexamethyldisilazane as shown in Scheme 2.5 .97  The mono-silyl enol ether 47 was 
carried forward to the next step without delay to guard against hydrolysis. 47 was 
dissolved in anhydrous THF and added to a solution of LDA at -78 °C via a 
cannula. 98  The reaction was then quenched with TMSCI and worked-up. Distillation 
of the crude oil afforded the desired bis-silyl enol ether 46 in moderate yield (45 %), 
which was stored at —20 °C under argon until required to prevent it hydrolysing back 
to the starting materials. 
Scheme 2.5 
(Me3Si)2NH 	
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2.3.2 Reactions of the Bis-Silyl Enol Ether of Dimedone 
A series of test reactions were devised to investigate the applicability of the bis-silyl 
enol ether 46 towards regioselective alkylations and hence, whether it could form the 
basis of the synthetic route to the target molecules (Scheme 2.6). The first 
electrophile chosen was benzaldehyde, as regioselective aldol reactions involving 
silyl enol ethers are very well known and studied since their development by 
Mukaiyama and co-workers in the seventies. 99 The reaction proceeded in the 
presence of a titanium tetrachloride catalyst (TiC1 4) to afford the aldol product 48 in 
17 % yield. The TMS-groups were thought to have been hydrolysed during the 
work-up. From the NMR spectra it appeared that the reaction had occurred 
regioselectively, although the yield was disappointing. 
Scheme 2.6 
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Attempts at forming the corresponding acylated product through the reaction with 
benzoyl chloride were unsuccessful. An examination of the NMR spectra of the 
major product revealed it to be the O-acylated derivative 49. There was no evidence 
that the 4-alkylated species had also formed. The lack of the expected product may 
have been a result of the bis-silyl enol ether 46 hydrolysing back to dimedone 33 
during the course of the reaction. Acid chlorides are hard electrophilic centres and 
are likely to react preferentially with a hard nucleophilic centre, such as oxygen. A 
significant proportion of dimedone 33 exists in the enol form at equilibrium, thereby 
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increasing the likelihood of reaction occurring at oxygen. However, alkylated 
derivatives such as 48 or 45d were found to be predominantly in the keto form, 
suggesting the ratios were very ligand sensitive. Changing the Lewis acid used 
(from TMSOTf to TiCL) had no impact on the course of the reaction. 
The third and final reaction involved treating the TMS-protected dimedone 46 with 
methyl vinyl ketone. Silyl enol ethers are stable, neutral enolate equivalents and 
therefore favour conjugate addition. It was hoped that this reaction would provide a 
carbonyl containing alkyl chain at the 4-position that could undergo further 
derivatisation. However, the reaction did not proceed smoothly with a number of by-
products detected by TLC. ESI-MS found the correct mass of the product 50, 
however a pure sample could not be isolated due to the number of other species 
present. In addition, the crude yield was low (14 %). 
In summary, while the reactions on the bis-silyl enol ether 46 showed some promise, 
the yields were poor and isolating pure products proved problematic. One of the 
main reasons for this is likely to be the lability of the TMS groups, which may 
undergo hydrolysis during the course of the reaction. To overcome this problem, 
more stable silyl-protecting groups could be used, such as triethylsilyl (TES) or tert-
butyldimethylsilyl (TBS). However, the drawback of these would be the increase in 
steric bulk around the dimedone ring, which could hinder attack by electrophiles. In 
reality, alternative protecting groups were not investigated as the focus of the 
synthetic strategy changed due to progress made towards regioselective alkylations 
on dimedone analogues. 
2.4 Alkylation of 3-Methoxy-5,5-dimethyl-cyclohex-2-enone 
Whilst the regioselective alkylation of dimedone 33 proved difficult and low 
yielding, much greater success was achieved by alkylating a methoxy-enol ether 
analogue 51. 51 can be easily prepared by dissolving dimedone 33 in MeOH and 
treating with DIPEA and TMSC1 (Scheme 2.7). The product was afforded in almost 
quantitative yield after work-up, without the need for further purification. 
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33 	 (99%) 	 51 
The methoxy-dimedone derivative 51 was first reacted with tert-butyl bromoacetate 
in a repeat of the most successful alkylation involving dimedone 33 (Scheme 2.8) 
(Entry 1, Table 2.2). Only one equivalent of LDA was now required due to the 
presence of the enol ether. The reaction proved successful (70 %) and higher 
yielding than the analogous one involving dimedone 33 (52 %). Optimisation of the 
conditions improved the yield to an excellent 90 % after column chromatography. 
The improved conditions involved: ensuring the reaction was carried out under 
scrupulously anhydrous conditions; replacing the toxic HMPA with N,N-
dimethyipropyleneurea (DMPU), which could be bought anhydrous; and increasing 
the number of equivalents of electrophile used from 1.1 to 2. Under these conditions 
the kinetic enolate is favoured, ensuring alkylation always occurs adjacent to the 
carbonyl group.' °° An X-ray crystal structure of the alkylated tert-butyl derivative 
53a was obtained to prove this conclusively (Figure 2.2). No alkylated product 
arising from formation of the thermodynamic enolate was ever observed. 
Scheme 2.8 
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Table 2.2 
Entry R Product Yield/% 
1 But02CCH2- 53a 90 
2 (CH3)2CCHCH2- 53b 81 
3 Et02CCH2- 53c 61 
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Figure 2.2 X-ray crystal structure of 53a (Entry 1, Table 2.2). 
In the light of this promising result the reaction was repeated with a selection of 
electrophiles (Entries 2-4, Table 2.2). Yields were improved when compared to 
similar reactions involving dimedone 33 and the new conditions proved favourable to 
previously unreactive electrophiles (Entry 4). However, the reaction involving tert-
butyl bromoacetate (Entry 1) was still the highest yielding suggesting its base 
stability was still an important factor. The poor yield (23 %) for the reaction 
involving bromoacetophenone (Entry 4) can be explained by the product 53d co-
eluting with unreacted starting material, despite a range of solvents being tried. 
Alternative purification systems such as prep-HPLC could be used in future to 
acquire a greater yield for this product. 
Scheme 2.9 
2M HC1 (aq) 	R> 
0 	OMe acetone or THF — 0) 	LO 
53a, c, d 	 45a, d, e 
Table 2.3 
Entry Reactant R Product Yield/% 
1 53a But02CCH2- 45d 76 
2 53c Et02CCH2- 45e 60 
3 53d PhCOC142- 45a 69 
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A further advantage of using an enol ether derivative for the alkylation reaction is 
that it can be easily hydrolysed back to the diketone by treatment with aqueous acid 
(Scheme 2.9). To demonstrate this, compounds 53a, 53c and 53d were dissolved in 
acetone or THF and treated with 2M HC1 (aq). After stirring overnight at room 
temperature and working-up, the three diketone derivatives 45a, 45d and 45e were 
obtained in good yield (Entries 1-3, Table 2.3). Importantly, the strong acidic 
conditions did not affect the side chains, which remained intact. 
The development of a successful and robust method for the regioselective alkylation 
of a dimedone analogue 51 provided the basis for an investigation into whether this 
method could work using amino acid derivatives as electrophiles. However, before 
this could be tested it was necessary to develop a route for converting amino acids 
into their bromomethylketone derivatives. 
2.5 Synthesis and Reactions of Bromomethylketones 
2.5.1 Monobromination of /3-ketoesters 
The most common route for synthesising bromomethylketones 36 from their amino 
acid equivalents 54 involves, first, activating the acid 54 as its acid chloride 55; 
followed by treatment with diazomethane to generate the diazoketone 56; and finally 
reacting this with HBr (Scheme 2.10). 10 ' 
Scheme 2.10 
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However, a search of the literature uncovered another method, published by Hoffman 
et al., which was applicable to CBz-protected amino acids and avoided the use of 
diazomethane (Scheme 2.1 1).102  This approach was advantageous since 
diazomethane is toxic and potentially explosive resulting in the need for special 
glassware and extra safety precautions. 103  In addition, the common diazomethane 
precursor, Diazald® (N-methyl-N-nitroso-p-toluenesulfonamide), was no longer 
commercially available and would have to be synthesised. 
Scheme 2.11 
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Following Hoffman's procedure, CBz-L-alanine 54a was converted to the 
corresponding tert-butyl /J-ketoester 57 by reaction with 1,1 -carbonyldiimidazole 
(CDI) and subsequent treatment with the lithium enolate of tert-butyl acetate. The fi-
ketoester 57 was then dissolved in MeOH and N-bromosuccinimide added along with 
a catalytic amount of 2,6-lutidine as base. The result was a mixture of the mono-58 
and dibrominated 59 species shown in Scheme 2.12. Surprisingly, storage of the 
mixture at —20 °C for 24 hours led to a predominance of the monobrominated 
material 58. The authors noted that the base was crucial for reaction to occur and 
postulated that it may be converting the monobrominated compound to its enolate, 
thereby shifting the equilibrium to the left. The crude monobrominated material was 
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decarboxylated by refluxing in a benzeneiTFA mixture to afford pure 
bromomethylketone 36a after recrystallisation. 
Scheme 2.12 
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2.5.2 Alkylations with N-CBz alanyl bromomethane 
The enolate of the methoxy-dimedone derivative 51 was treated with N-CBz alanyl 
bromomethane 36a using the conditions described previously (Scheme 2.13). 
However, the reaction was unsuccessful, with only dimedone 33 and unreacted 
starting material being recovered after chromatography. A possible explanation for 
this could be that the enolate is simply abstracting a proton from the NH of the 
electrophile, thus reforming the starting material 51. Hence, the reaction was 
repeated using two equivalents of LDA in order to deprotonate the amine and form 
the enolate. Unfortunately, although the reaction led to a greater number of 
compounds by TLC, the desired product could not be isolated after chromatography. 
It was felt that the deprotonated amine may be undergoing side reactions leading to 
unwanted by-products. A way to overcome this would be to replace the CBz-
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2.5.3 Phthaloyl- and Dibenzyl-Protected Amino Acids 
Phthaloyl and dibenzyl are two common bis-protecting groups for amines as they are 
easily attached, are unreactive to a range of reaction conditions, and can be easily 
removed by treating with hydrazine (phthaloyl) or hydrogenation (dibenzyl). 
A two-step procedure was used to protect L-alanine 63 as its phthaloyl derivative 64 
as shown in Scheme 2.14. 104  The first step involved forming the reactive species 3-
chloro-3 -(dimethoxyphosphoryl)isobenzofuran- 1 (3H)-one 62 by treating phthaloyl 
dichloride 60 with trimethyl phosphite 61. Pure product 62 was obtained as a white 
solid after work-up, and this was reacted with L-alanine 63 in the presence of DIPEA 
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A dibenzyl analogue was formed by refluxing L-alanine ethyl ester hydrochloride 
40a with benzyl bromide in the presence of DIPEA overnight (Scheme 2.15). This 
reaction gave the dibenzyl ester 65 in 65 % yield after chromatography, although it 
remained contaminated with a small amount of benzyl bromide starting material. An 
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improved synthesis was achieved by treating commercially available methyl-(L)-
lactate 66 with triflic anhydride and 2,6-lutidine, followed by dibenzylamine 
(Scheme 2.16). 10 This reaction gave the dibenzyl ester 67 in 85 % yield exclusively 
as its (R)-enantiomer (stereoinversion occurs as a result of SN2 attack by 
dibenzylamine). 
Scheme 2.15 
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2.5.4 Conversion of Protected Amino Acids to their Bromomethylketones 
Attempts to convert N-phthaloyl-L-alanine 64 to its bromomethylketone derivative, 
via Hoffman's method, proved largely unsuccessful with yields of less than 20 % of 
final product obtained. Hence, attention was turned to the more classical 
diazomethane route described previously (Scheme 2.10). The diazomethane 
precursor, Diazald®, 69 was synthesised from the commercially available 
sulfonamide 68 as shown in Scheme 2.17. The product could be made successfully 
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Diazomethane was distilled as an ethereal solution by adding Diazald® 69, dissolved 
in ether, to a warmed mixture of potassium hydroxide solution and diethylene glycol 
ethyl ether. N-Phthaloyl-L-alanine 64 was activated as its acid chloride 70 and added 
to a cooled solution of diazomethane, which was then allowed to warm to room 
temperature (Scheme 2.18). After work-up, a mixture of diazoketone 71 and 
chioromethylketone was obtained. The latter arises from the diazoketone 71 reacting 
with HC1 in situ. Using an excess of diazomethane should limit this problem but in 
practice some impurity always remained. Fortunately, the diazoketone 71 was found 
to be stable to chromatography, enabling a pure sample to be isolated. Treating this 
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An alternative recently published route  106  was used to synthesise the corresponding 
dibenzyl-protected bromomethylketone 74. This route enabled the previously 
synthesised dibenzyl-ester 67 to be used directly, eliminating the need to convert it to 
its free acid. However, reacting the ester with dibromomethane, followed by 
methyllithium at —78 °C and quenching with aqueous ammonium chloride solution 
failed to give any of the desired bromomethylketone 74 (Scheme 2.19). Despite 
repeated attempts, the authors' claims of high yields and minimum purification could 
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not be realised. Nevertheless, after a thorough investigation into the reaction 
conditions a modified method was developed which proved to be much more 
successful. It involved replacing the base with n-butyllithium (BuLi) and increasing 
the number of equivalents used from 1.8 to 4. The bromomethylketone derivative 74 
was successfully formed and found to be 90 % pure by 'H NMR, with the only 
impurity identified as the aminoester starting material 67. 
Scheme 2.19 
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2.5.5 Alkylations with Phthaloyl- and Dibenzyl-Protected 
Bromomethylketones 
N-Phthaloylalanyl bromomethane 72 was reacted with the methoxy-dimedone 
derivative 51 under standard conditions and an analysis of the crude product by ESI-
MS found a base peak corresponding to the mass of the desired alkylated compound 
75a (Scheme 2.20). However, TLC revealed a number of species present. Flash 
chromatography isolated a high running fraction whose 1 H NMR spectrum contained 
peaks indicative of the alkylated product 75a. Nevertheless, the spectrum was not 
clean and included peaks which appeared to correspond to bromomethylketone 
starting material 72. Numerous solvent systems failed to reveal two distinct species 
by TLC and attempted mass-directed purification using a Waters ZMD 4000 
instrument also proved unsuccessful. 
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Repeating the reaction using only one equivalent of the electrophile failed to aid 
attempts to isolate pure product. In addition, significant amounts of methoxy -
dimedone starting material 51 were recovered suggesting that either it is being 
reformed from the enolate during reaction, or the electrophile 72 is relatively 
unreactive. In an effort to find conditions amenable to alkylation, reagents such as 
sodium iodide were added to try to form a more reactive halomethylketone in situ, 
but to little effect. Lewis acids, such as zinc chloride, have been known to enhance 
enolate alkylations' °7 but repeating the reaction with this reagent did not rectify the 
overall problems of numerous by-products, poor separation and low yields. 
Analogous reactions with the dibenzyl-protected bromomethylketone 74 gave 
broadly similar results with over 50 % of methoxy-dimedone starting material 51 
recovered after purification. In addition, product 75b was never detected by ESI-
MS. 
If the bromomethylketones were proving unreactive, this might be explained by the 
presence of a neopentyl centre adjacent to the site of alkylation. Whilst this did not 
appear to hinder the small chain ester or alkyl electrophiles, those involving bulkier 
groups may find the steric environment more restricting. To investigate if this was 
the case, the commercially available isomer of dimedone, 4,4-dimethyl-cyclohexane-
1 ,3-dione 76, was converted to its enol ether derivatives 77 and 78 using the standard 
method (Scheme 2.21). The reaction was high yielding (81 %) but complicated by 
the fact that there were now two possible products, depending on which side the 
methoxy group adds to. However, it was possible to separate the isomers by flash 
chromatography with 3-methoxy-6,6-dimethyl-cyclohexane-2-enone 78 favoured 3:1 
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over its more sterically hindered neighbour 77. It should be noted that altering the 
position of the gem-dimethyl group was not expected to have a detrimental effect on 
binding, as molecular modelling studies had indicated that the hydrophobic binding 
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Repeating the alkylation reaction with the phthaloyl-protected bromomethylketone 
72 and the enolate of the methoxy-isomer 77 did not afford isolable product (Scheme 
2.22). Whilst the expected mass could be detected by ESI-MS, many by-products 
were again produced thus complicating attempts to purify. Mass directed 
purification on the ZMD 4000 appeared to separate fractions containing the mass of 
the product from those corresponding to starting material. However, the 'H NMR 
spectrum of the purified compound was complex and contained many unassignable 
peaks. This experiment would appear to rule out steric hindrance at the site of 
alkylation as the dominant factor for the failure of these reactions. 
Scheme 2.22 
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The failure of the reaction with bromomethylketones is in stark contrast to the 
success found when using alkyl halides or simple bromomethylesters as 
electrophiles. A possible explanation for this may lie with the acidity of the protons 
adjacent to the bromine atom of the electrophiles. In the case of 
bromomethylketones, these protons will be significantly more acidic than those 
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flanked by ester or alkyl group functionality. Hence, the enolate formed may act as a 
base and abstract a proton, thereby regenerating the staring material and forming a 
carbanion, which could decompose or undergo side reactions. The prospect of the 
enolate acting as a base would be less with electrophiles containing less acidic 
protons, suggesting why these reactions proceed in a much cleaner fashion. A 
possible solution would be to use an enolate equivalent such as an enamine that is 
only weakly basic. 
2.5.6 Synthesis and Alkylation Reactions of Enaminone Derivatives 
The enaminone derivative 80 can be easily formed in high yield by refluxing 
dimedone 33 and pyrollidine in toluene in the presence of a Dean-Stark trap to 
remove water (Scheme 2.23).b08  80 can then be reacted with methyl iodide to form a 
quarternary ammonium salt 81. Attempts to transform this to an enamine 82 by 




oo 	 ON 	(98%) MeO toluene 
(98%) 





Enaminone derivatives, such as 80, can be regioselectively alkylated in a similar 
manner to their enol ether analogues (Scheme 2.24).109110  It was felt that the 
enaminone functionality might display different reactivity towards the 
bromomethylketones. 
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However, attempts to alkylate enaminone 80 with the phthaloyl-protected 
bromomethylketone 72 produced a mixture of compounds that could not be easily 
separated by flash chromatography. ESI-MS did detect the correct mass of the 
alkylated product 83 but an analysis by TLC appeared to indicate it ran very close to 
the baseline and was perhaps masked by unreacted enaminone starting material 80. 
Further studies using LC-MS seemed to confirm this and a solvent system was found 
to separate the fractions. This method was transferred to the ZMD 4000 platform, 
which was able to collect fractions with the correct mass, albeit, slightly 
contaminated with small amounts of starting material 80. However, after combining 
the relevant fractions and removing the solvent, an analysis of the product revealed it 
to be mixture of compounds. This mixture may have resulted from the instrument 
collecting other substances that do not ionise well in the mass spectrometer. 
2.6 Summary 
The problems associated with the regioselective alkylation of dimedone 33, such as 
poor yields, limited substrate range and a lack of reproducibility have been largely 
overcome by replacing dimedone 33 with its methoxy enol ether analogue 51. 
Bromomethylketone derivatives 72 and 74 were successfully synthesised from 
protected a-amino acids in an attempt to introduce varied functionality into the target 
molecules. However, the new optimised alkylation conditions failed with these 
compounds as electrophiles. Subsequent experiments have served to eliminate, or at 
least reduce, the notion that this was due to either steric hindrance at the alkylation 
site, or problems associated with free NH functionality in the amino acid derived 
electrophiles. The most plausible conclusion is that the protons adjacent to the 
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bromine group have a low enough pK a to enable the enolate to act as a base, thereby 
reforming the starting material and reducing product formation to a minimum. 
Attempts at using enaminones 80 as alternative reagents for alkylation were not 
successful. 
Since the current synthetic strategy had not proved fruitful, despite thorough 
examination, attention turned to the alternative route described in Section 2.1 
(Scheme 2.2). This approach proposed condensing aminoesters 40 with dimedone 33 
to form enaminone derivatives 41, which could be subsequently hydrolysed and 
converted to their diazoketone equivalents 43. The diazoketones 43 offered scope 
for ring-closure via carbene mediated C-H insertion reactions. Despite reservations 
over the degree of control allowed by the final step, it was felt this route now merited 
further investigation. 
2.7 Alternative Strategy Part I: Enaminones to Diazoketones 
As described in Section 2.5.6, dimedone33 readily reacts with amines under Dean-
Stark conditions to form enaminone derivatives. 108  The same is true when the amine 
is an amino acid." Hence, L-alanine ethyl ester hydrochloride 40a underwent a 
condensation with dimedone 33 to form the enaminone 41a in very good yield 
(Scheme 2.25). The ester group was hydrolysed by refluxing in saturated sodium 
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The knowledge gained from forming diazoketones from protected amino acids was 
now used to convert the acid derivative 42a to its diazoketone equivalent 43a. 
However, this step did not prove straightforward with a number of compounds 
detected by TLC and no evidence of product 43a was found by ESI-MS. It was 
thought that acid chloride formation might have, been hindered by side reactions 
involving other functional groups in the molecule. An alternative approach was to 
activate the acid as its mixed anhydride. This method involved treatment of a 
solution of the acid 42a with iso-butyl chioroformate in the presence of N-
methylmorpholine (Scheme 2.26). The mixture was filtered and quickly added to the 
ethereal diazomethane solution. After work-up, a yellow oil was obtained that was 
shown to contain only two compounds by TLC. Flash chromatography separated the 
fractions as a colourless and viscous yellow oil respectively. The former, which was 
the major product, was found to have a mass of n/z = 326, with the latter having a 
mass of m/z = 336. Neither of these corresponded to the expected mass of the 
product (m/z = 235). Spectroscopic analysis revealed the presence of iso-butyl 
functionality in both fractions. It was proposed that this may have been caused by 
reaction of the amine with iso-butyl chloroformate to form a carbamate. Further 
NMR studies confirmed the formation of the carbamate and successfully identified 
the colourless oil as the N-protected methyl ester 84 and the yellow oil as the N-
protected diazoketone 85. 
Scheme 2.26 










The formation of these derivatives was useful, not only for the progress made 
towards the development of a reliable route to the target compounds, but also as 
potential ligands for CypA in their own right. Previous work 9° had shown 
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enaminone derivatives to be inhibitors of CypA so highly functionalised molecules 
such as 84 and 85 could contribute significantly to the understanding of protein-
ligand interactions in this family. 
The poor yield (13 %) of the diazoketone 85, however, was a problem. The poor 
yield can be explained by competition between the amino and hydroxyl groups for 
iso-butyl chioroformate, with any free acid present being readily methylated on 
exposure to diazomethane. Attempts to protect the nitrogen atom prior to the 
diazoketone step were not successful (Scheme 2.27). Despite trying a variety of 
functional groups (CBz, Boc, isobutylcarbonyl), and a range of conditions (Table 
2.4), none of the desired products 86 were obtained. 
Scheme 2.27 
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Table 2.4 
Entry Reagent Base Solvent R 
1 BuO2CC1 NMM or NaHCO3 H20fDioxane or THF Bu'02C- 
2 CBz-C1 NMM or NaH TI-IF or toluene CBz- 
3 (Boc)O DMAP MeCN Boc- 
The failure of these reactions was surprising, especially considering how rapidly the 
amine reacts under the acid activation conditions described in Scheme 2.26. It would 
imply that, rather than reacting with iso-butyl chloroformate directly, the amine 
prefers to attack the mixed anhydride formed in situ, thereby yielding the carbamate 
and regenerating the carboxylic acid. The conjugated nature of the amine renders it 
more like an amide in terms of reactivity than a secondary amine. The nitrogen's 
lack of nucleophilicity would explain its failure to react directly with the range of 
protecting groups and suggests its reaction with the mixed anhydride must be driven 
by favourable transition state geometry in the molecule. Despite the problem of 
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chemoselectivity, the formation of the diazoketone moiety 85 was pleasing as it 
demonstrated the feasibility of the step. It was envisaged that using two equivalents 
of NMM and iso-butyl chloroformate would ensure complete conversion to the N-
protected mixed anhydride, thereby eliminating the possibility of forming the methyl 
ester by-product 84. This reaction was tried and the yield of the diazoketone 85 did 
indeed increase (26 %), but not appreciably so. 
An alternative approach to overcome the problem of N-alkylation would be to form 
enaminones containing a tertiary nitrogen atom. Standard N-protected amino acids 
are not suitable as the nitrogen is too deactivated to undergo condensation with 
dimedone 33. However, N-methyl amino acids offered greater potential. 
Commercially available N-methyl-L-alanine hydrochloride 87 was converted to its 
methyl ester 88 by treating with a mixture of thionyl chloride and methanol (Scheme 
2.28). 88 was then reacted with dimedone 33 under the standard conditions to give 
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The most likely explanation for the low yield is that increased steric bulk around the 
nitrogen atom hinders attack on the dimedone ring. Since this was only the first step 
in the reaction it was not felt that the low yields could be tolerated, so attention 
reverted to the synthesised diazoketone 85, which could be used to test the validity of 
the ring-closing step. 
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2.8 Alternative Strategy Part II: Ring-Closure via Carbenoid-
Induced C-H Insertion 
2.8.1 Introduction 
Carbenes 92 are important reactive intermediates that can be conveniently prepared 
from diazocarbonyl compounds 90 by thermal or photolytic loss of nitrogen gas 
(Scheme 2.29). Carbenes 92 undergo a variety of chemical reactions, such as 
cyclopropanation, 113  C-H heteroatom-H insertion,' 4 ylide generation, 115 
and Wolff rearrangements. 116  These processes, however, are often unselective and 
uncontrollable. By employing transition metal catalysts, the carbene can be trapped 
as a carbenoid species that exhibits much greater chemo-, regio-, and 
stereoselectjvjty. 1 ' 7 In general, those based on dirhodium complexes have proved the 
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Figure 2.3 Structures of dirodium catalysts for carbenoid formation (axial ligands, 
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Carbenoid-mediated C-H insertion reactions have been extensively investigated, with 
much of the work concentrating on intramolecular ring-closure in complex 
molecules. 118  It has proved a powerful technique as it negates the need to activate 
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the site of ring-closure, an important consideration when many reactive functional 
groups may be present in the molecule. Several groups have reported that five-
membered ring formation is favoured over larger or smaller ring sizes; and that the 
order of reactivity of C-H sites to insertion is methine> methylene >> methyl.' 19' 120 
However, steric factors can affect this selectivity and lead to the formation of four or 
six-membered rings respectively. Often, simply changing the ligands around the 
metal centre can drastically affect the chemoselectivity of the reaction. For example, 
Padwa et al. found that treating diazoketone 96 with Rh2(OAc)4 93 gave 
approximately a 1:1 mixture of C-H insertion 97 and cyclopropane 98 products 
(Scheme 2.30).121 However, changing the catalyst to dirhodium perfluorobutyrate, 
Rh2(pth)4  94, resulted in exclusive formation of the insertion product 97. In contrast, 
when the dirhodium carboxamide catalyst, Rh2(cap) 4 95, was used only the 
cyclopropanation pathway was followed. By including electron-withdrawing 
fluorine atoms around the metal, the electrophilicity of the carbenoid was increased 
resulting in a more reactive carbene species that was capable of inserting into a 
tertiary C-H bond. Conversely, the introduction of electron-donating amide ligands 
resulted in a less electrophilic carbenoid species, which preferentially reacted with 
the nucleophilic alkene double bond. 
Scheme 2.30 
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2.8.2 Ring-Closure of Diazoketone 85 
An analysis of diazoketone 85 revealed that formation of a five-membered ring was 
unlikely, raising the possibility that C-H insertion could be driven to create the 
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desired six-membered version exclusively. The presence of a double bond in the 
molecule was not considered a problem, as its involvement in a conjugated system 
should decrease the likelihood of it undergoing cyclopropanation reactions. The 
diazoketone 85 was dissolved in anhydrous DCM and added dropwise to a stirred 
solution of Rh2(OAc)4 93 (2.5 mol %) in anhydrous DCM (Scheme 2.31). The 
resulting solution was stirred at room temperature overnight. A green residue was 
obtained after work-up, which on TLC analysis contained a mixture of compounds. 
ESI-MS found the correct mass for the product (m/z = 308), but the only fraction that 
could be isolated by chromatography that corresponded to this mass, did not give a 
1 H NMR spectrum consistent with the cyclised material. Furthermore, the spectrum 
was not clean, complicating attempts to identify the compound formed. The 
reaction was repeated with varying amounts of catalyst (from 1-5 mol %) and 




85 	 — 99 
(i) Rh2(OAc)4 93, Rh2(Pfb)4  94, or Rh2(cap)4 95, DCM or toluene, room temp. or co (300W, 100 °C, 5mins) 
Catalytic reactions can often be enhanced by the use of microwave radiation. 122 
Hence, diazoketone 85 was dissolved in anhydrous DCM in a microwave test-tube 
and Rh2(OAc)4 93 added (Scheme 2.31). Bubbles of nitrogen gas were given off and 
the tube sealed and placed in a CEM microwave Discover unit and heated to 100 °C 
at 300 W for 5 mins. Flash chromatography of the crude material obtained after 
work-up isolated two main fractions: a yellow oil and a yellow solid. Spectroscopic 
analysis of the former gave inconclusive results but the correct mass (m/z = 308) was 
detected. Similar analysis of the yellow solid revealed the presence of iso-butyl 
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functionality and some peaks corresponding to dimedone signals, along with a mass 
of m/z = 250. These results suggested the yellow solid was a fragment of the starting 
material but the quality of the data was insufficient to prove this conclusively. In 
case DCM's poor ability to absorb microwave radiation was hindering the reaction, 
the solvent was replaced by toluene. Toluene was chosen as it is commonly used in 
the literature as an alternative to DCM for these type of reactions and, despite its 
relative lack of polarity, has been found to be effective at absorbing microwave 
radiation. However, the product obtained after work-up was found to be a similar 
mixture of compounds to that seen previously, suggesting the change of solvent had 
not made a significant difference to the course of the reaction. 
Since the type of catalysts employed in these reactions can have a profound effect on 
the substrate's reactivity, it was decided to react the diazoketone 85 with Rh2(pfb)4 
94 and Rh2(cap) 4 95 respectively. Each reaction was run under standard conditions 
at room temperature using DCM as solvent. After work-up, both reactions gave 
products whose predominant mass was in/z = 326. A spot running close to the 
baseline using 1:1 hexane/ethyl acetate as eluent dominated both TLC's. The mass 
found could be explained by the substrate undergoing a Wolff rearrangement as 
shown in Scheme 2.32. However, an analysis of the 'H NMR spectra of both 
compounds did not indicate the presence of the acid derivative 102. It may be the 
case that some other nucleophile has quenched the ketene intermediate 101. One of 
the surprising features of these last two experiments is how two electronically 
distinct catalysts gave rise to a similar product, when the literature suggests they 
should have differing selectivities. 
Scheme 2.32 
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Since steric effects can have a significant impact on the course of carbenoid 
reactions, it was decided to synthesise the less sterically hindered diazoketone 106 by 
starting from the dimedone isomer 76. Hence, 4,4-dimethyl-cyclohexane-1,3-dione 
76, was reacted with D/L-alanine ethyl ester hydrochloride 103, as shown in Scheme 
2.33, to give the enaminone 104. The reaction proceeded cleanly and did not give 
rise to any of the undesired isomer, presumably as a result of steric influences. The 
enaminone was successfully hydrolysed to its carboxylic acid derivative 105, which 
was then converted to the diazoketone 106 upon activation and treatment with 
diazomethane. Two equivalents of iso-butyl chloroformate were again required to 
ensure yields were as high as possible, with the nitrogen again reacting to form the 
carbamate. The diazoketone 106 was dissolved in anhydrous DCM and added 
dropwise to a stirred solution of Rh2(OAc)4 93 in anhydrous DCM. The resulting 
solution was stirred at room temperature overnight. After work-up, a brown solid 
was obtained which ESI-MS found to contain m/z = 326 as the base peak. No peak 
at m/z = 308 was detected. Analysis by TLC suggested the presence of a number of 
by-products. Repeating the reaction with Rh 2(pfb)4 94 gave similar results although 
this time the mass spectrum contained a small peak at m/z = 308. Attempts to purify 
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Despite attempts to alter the selectivity of the reaction, either through changing the 
reaction conditions, the type of catalyst used, or the steric environment of the 
molecule, it appears that C-H insertion at the site required is disfavoured. The poor 
control over the site of C-H insertion may ultimately be due to the electronic nature 
of the methylene group. Ideally, the site of insertion should be able to stabilise the 
build-up of positive charge as the bond cleaves, however, the conjugated nature of 
the dimedone fragment does not allow for this. As it is both impractical and 
undesirable to significantly alter the structure of the molecule, it is difficult to prove 
this theory. It does appear, however, that the reaction is sensitive to a number of 
factors and controlling them is a considerable challenge. 
2.9 Summary 
The development of a second strategy towards the synthesis of the novel target 
compounds uncovered a number of important points: 
Dimedone 33 reacts readily with amino acids to form enaminone derivatives 
in good yields and high purity. 
• 	The formation of the required diazoketones is achievable, albeit allowing for 
a side reaction involving the vinylogous amide. This side reaction in itself is 
synthetically interesting and warrants further investigation into the reaction 
mechanism. 
• 	Since previous work had shown that dimedone-based enaminone derivatives 
were inhibitors of CypA, the synthesis of novel diazoketone derivatives 
offered scope for exploring the binding properties of this family. 
• 	The use of carbenoid C-H insertion as a method for ring-closure was 
ultimately unsuccessful. Whilst the visible liberation of gas and detection of 
the correct product mass suggested the carbenoid intermediaite had formed, 
its reactive nature ensured controlling the site of insertion was difficult. 
• 
	
	Changing the ligands around the rhodium catalyst or altering the reaction 
conditions did not improve the selectivity. 
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This chapter has served to highlight a range of important chemistry that has been 
developed during the search for a viable synthetic route to the target compounds. 
This work has led to the synthesis of a series of molecules based on dimedone 33, 
which contain a variety of functional groups. The plan is to test the most interesting 
of these against CypA. 
The knowledge gained from the syntheses described in this chapter was used to 
design an improved synthetic strategy for the lead compounds. This approach built 
on the successful development of a regioselective alkylation procedure for methoxy-
dimedone 51; coupled with the fact that dimedone 33 can undergo facile enaminone 
formation with amines or amino acids. With the chemistry in place to alkylate 
dimedone at the 4-position and ring-close at the 3-position, attention turned to 
developing substrates amenable to both processes, which would form the basis of the 
second ring This research is discussed in Chapter 3. 
Chapter 3 	 Results and Discussion II 
3 	Results and Discussion II 
3.1 Development of Synthetic Route to Cyclised Derivatives 
3.1.1 Synthesis of Acid Derivative 
As described in the previous chapter, tert-butyl bromoacetate 108 was found to be 
the best electrophile for the alkylation of the methoxy-dimedone derivative 51. An 
additional advantage to the high yields and excellent purity of the alkylated 
compound 53a was its potential to be derivatised by hydrolysing the tert-butyl ester 
to the carboxylic acid 109. The hydrolysis was achieved by treating the ester with 
TFA in the presence of triethylsilane as a carbocation scavenger (Scheme 3.1). 123 
Importantly, the acid labile enol ether remained intact under these conditions, most 
likely as a result of the reaction being kept strictly anhydrous. Despite the reaction 
proceeding relatively cleanly, yields were lower than expected due to difficulties 
associated with removing excess TFA from the crude product. This problem was 
overcome by using zinc bromide as a replacement for TFA (Scheme 3.l).124 
Although a large excess of the Lewis acid was required (5 eq), yields were excellent 
(87 %) and the acid obtained after work-up required no further purification. The acid 
derivative 109 now provided a route for incorporating amines or amino acids into the 
ligands, as a means of increasing their structural diversity. 
Scheme 3.1 
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3.1.2 Incorporation of Amines 
Allylamine 110 was chosen as a simple, readily available non-chiral amine with 
which to test the peptide coupling conditions. 110 was coupled to the acid derivative 
109 using the standard EDCI-HOBt method (Scheme 3.2). Gratifyingly, this gave 
rise to the desired peptide 111 in good yield after chromatography. The enol ether 
functionality was found to be stable under these conditions, whereas the analogous 
diketone derivative would have been expected to undergo competing condensation 
reactions with the amine 110. Hence, the importance of preserving the enol ether 
during formation of the acid derivative became apparent. 
Scheme 3.2 
o 	 HOBt, EDCI 
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Now that the allyl derivative 111 had been successfully formed, the enol ether could 
be hydrolysed in standard fashion by treating with 2M HCl (aq) (Scheme 3.2). Two 
species were identified by ESI-MS after work-up: the diketone 112 and the cyclised 
enaminone 113. The formation of a five-membered ring provided a strong 
thermodynamic driving force, explaining why spontaneous cyclisation occurred 
during the hydrolysis reaction. However, diketone 112 remained the major product, 
suggesting the cyclisation process was slow. The reluctance of 112 to cyclise fully is 
likely to be due to the poor nucleophilicity of the amide nitrogen atom. Stirring a 
solution of the crude diketone 112/enaminone 113 mixture in the presence of 
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molecular sieves did not drive the cyclisation reaction towards completion. 
Increasing the reaction temperature also made little difference to the yield of cyclised 
material 113. It was discovered that more forcing conditions were required to ensure 
complete cyclisation. These conditions involved refluxing the mixture in toluene for 
two hours with a Dean-Stark trap to remove the water. The cyclised product 113 was 
obtained as a yellow solid in 29 % overall yield from the enol ether 111. The 
structure of the cyclised product 113 was confirmed by X-ray crystallography 
(Figure 3.1). This compound now met the requirements of the proposed lead and had 
its binding to CypA tested using electrospray mass spectrometry (ESI-MS). This 
technique will be discussed in more depth in Chapter 4, but it is used primarily as a 
qualitative screen in order to identify the most promising ligands, which are then 
submitted for further testing. This method did not find the cyclised allyl derivative 
113 to be a potent inhibitor of CypA. The failure of 113 to bind CypA was not 
surprising as dimedone 33 itself binds only very weakly to CypA (Kd = 22 mM) and 
the second ring of 113 is not very functionalised, reducing its ability to make 
additional contacts with the protein. However, the main aim of finding a route to the 
cyclised compounds had been fulfilled, and the challenge now was to develop and 
expand the chemistry to make it applicable to a wider range of substrates. 
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3.1.3 Incorporation of a-Amino Acids 
The incorporation of cc-amino acids into the lead compounds would increase the 
functionality with which to probe CypA's active site. L-phenylalanine methyl ester 
hydrochloride 114 was used as the test compound due to it being readily available as 
a stock item. Reacting 114 with the acid 109 under the same conditions as before 
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Fortunately, these could be separated by flash chromatography. It was not possible, 
however, to obtain an X-ray crystal structure of either diastereomer in order to 
determine their absolute stereochemistry. Both were subjected to the hydrolysis and 
cyclisation steps to form the desired cyclised compounds 116a and 116b in yields of 
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Such low yields may have been due to cyclisation being incomplete after 2 hours. In 
hindsight, reflux times should have been extended to overcome the steric hindrance 
imposed by the bulky phenylalanine side-chain. However, the route provided 
enough of the compounds required for testing, and had been shown to be suitable for 
the incorporation of amino acids. In addition, the separation of the diastereomers 
115a/b was encouraging, as the nature of the fused ring system should ensure they 
have significant cOnformational differences. It was hoped that CypA would show a 
preference for one diastereomer, thereby identifying a higher affinity ligand than if 
only the diastereomeric mixture had been screened. However, an initial screen by 
ESI-MS found no evidence of binding for either diastereomer. In order to 
understand this observation, preliminary molecular modelling studies were carried 
out using the known X-ray crystal structure of CypA in complex with a synthetic 
ligand, EM2/34 117 (Figure 3.2). 0 This template was not ideal due to the lack of 
similarities between the structures of EM2/34 117 and 116. However, both contain 
the essential binding elements of the dimedone moiety, whose location in the active 
site should be relatively conserved. 





Hence, by overlaying the carbonyl and dimethyl functionalities of the ligands, it was 
possible to get an idea of where additional favourable contacts could be made. This 
process revealed the benzyl side-chain of ligand 116b to impart unfavourable steric 
bulk into the binding pocket (Figure 3.3A). The configuration of the other 
diastereomer 116a resulted in poor alignment of the key dimedone residues in the 
active site. Interestingly, ESI-MS found the uncyclised versions to bind, indicating 
the importance of screening the intermediates for new lead compounds. It was not 
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on similar structures prevented their flexible side-chains from being orientated in the 
active site with any degree of certainty. Further binding studies on these ligands are 
discussed in Chapter 4. 






Figure 3.4 The use of molecular modelling to highlight structural modifications 
that would aid binding to CypA's active site. 
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Modelling the ally! ligand 113 helped to confirm the hypothesis that the molecule's 
lack of functionality was responsible for its poor binding, as it is unable to make 
significant contacts with CypA's active site (Figure 3.3B). In addition to offering an 
insight into why the current ligands were not potent inhibitors, the modelling studies 
also provided options with which to improve the affinities of the molecules in 
question. It was proposed that incorporating lysine 118 or arginine 119 residues into 
the cyclised structures would improve binding by making contacts with the Abu 































a Ac-NH(CH2)4- 76 7 N/A 
b 02N-NHC(NH)NH(CH2)3- 85 3 9 
c CBz-NH(CH2)4- 97 Negligible 27 
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To test this theory, protected lysine and arginine amino acids 120a-c were 
successfully coupled to the acid derivative 109 (Scheme 3.5). These reactions were 
high yielding but it was not possible this time to separate the diastereomers obtained. 
The diastereomeric mixtures 120a-c were carried through to the hydrolysis and ring-
closing steps to furnish the cyclised compounds 122a-c. However, the yields for 
steps 2 and 3 were disappointing (Table 3.1). Changing the solvent from THF to 
acetone and monitoring the reactions to completion by TLC improved the yields of 
the hydrolysis step. This improvement was probably due to a solvent effect or a 
result of limiting the time the enol ethers 121 a-c were exposed to acid. It was felt the 
diketone compounds formed during step 2 would be more hydrophilic than the 
starting enol ethers 121a-c resulting in product being lost in the aqueous phase 
during work-up. Hence, further attempts to improve the yield of the reaction 
involved basification and re-extraction of the aqueous phases. However, the amounts 
of product recovered were negligible. 
Particular problems were encountered when attempting to cyclise the arginine 
derivative 121b. The crude diketone product from the hydrolysis step was found to 
be insoluble in a range of solvents, even at elevated temperatures. Such solubility 
issues posed particular problems for the cyclisation step, which required toluene as 
the solvent. The addition of a catalytic amount of acetic acid improved the solubility 
and allowed the cyclised product 122b to form. Yields were still low but sufficient 
to provide enough of 122b for testing. It was hoped that the more rigid conformation 
of the cyclised molecules would aid attempts to separate the diastereomers but this 
was not found to be the case. The exception to this was 122a, which appeared as a 
single diastereomer by NMR. It was assumed that problems associated with the 
purification of this compound had resulted in the loss of the other diastereomer. 
Preliminary studies of the three new ligands 122a-c by ESI-MS revealed all three to 
bind CypA. These breakthrough results supported the crude molecular modelling 
data and justified the overall design of cyclised dimedone-based ligands as potential 
inhibitors of CypA. The ligands were submitted for further binding studies, which 
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revealed 122c to have the highest affinity with a dissociation constant of between 5-
20 LM, as determined by fluorescence assay. This Kd represented at least a 1000-
fold improvement on the original lead dimedone 33 and provided the impetus to 
examine the effect of 122c on parasitic organisms. These studies and the binding 
results of the other ligands are discussed in Chapter 4. 
One of the problems that arose from initial testing of the cyclised ligands was their 
poor solubility in protic solvents, which hindered their analyses by biological assay. 
Although the nature of the protecting group could have a significant effect on the 
ligand's ability to bind CypA, deprotection would generate a primary amine that 
should prove much more soluble in protic solvents. To test this theory, the CBz 
group of 122c was removed by treating a solution of the ligand in DCM with HBr in 
acetic acid (Scheme 3.6). Whilst ESI-MS found the correct mass for the deprotected 
material 123, the 'H NMR spectrum was complex. The replacement of HBr with 
iodotrimethylsilane (TMSI) provided a better method for producing pure 
compound. 125  The new ligand 123 was found to retain 122c's affinity for CypA 
whilst proving much more soluble in protic inedia. Therefore, 123 was an ideal 
candidate for in vivo testing, which is discussed in Chapter 4. 
Scheme 3.6 
H 	 HBr/AcOH 
or 
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122c 	 123 
3.1.4 Summary 
A viable synthetic route to cyclised dimedone derivatives had now been established 
and the ability to incorporate amino acids into the structure of the lead compounds 
had been demonstrated. Molecular modelling was used to tailor the synthesis 
towards compounds that would stand a greater chance of forming complexes with 
CypA. Such studies led to the synthesis of novel lysine and arginine based ligands 
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122a-c, which were the first molecules of their kind to show affinity for CypA. The 
CBz-lysine derivative 122c in particular was a potent inhibitor, with a dissociation 
constant 1000-fold less than dimedone 33. Removal of the protecting group from 
122c did not affect the binding to CypA but did give rise to a ligand 123 with 
improved solubility in protic media. This was important for studies in vivo. It was 
now desirable to design a complementary series of ligands, which could probe what 
affect other structural features had on the binding to CypA. 
3.2 Development of Second Ligand Series 
3.2.1 Aim 
One of the original driving forces behind the design of the lead compounds was that 
the amide carbonyl group might act as a mimic of the twisted peptide bond in prolyl 
substrates. It was of interest, therefore, to synthesise an analogous set of ligands, 
which were devoid of this carbonyl group and compare the binding of both sets. 
Such a comparison would help elucidate the role played by the amide carbonyl and 
lead to the development of structure-activity relationships (SAR). 
The most straightforward route to such compounds would be to simply reduce the 
amide bonds of the cyclised ligands 122a-c respectively. However, the presence of a 
range of reactive functional groups in the molecules was suspected to have a 
detrimental effect on chemoselectivity. A better option was to generate the aldehyde 
and carry out a series of reductive aminations using amines or amino acids. This 
approach is discussed below. 
3.2.2 Synthesis of Aldehyde Derivative 
One option for obtaining the desired aldehyde 126 was to reduce the carboxylic acid 
derivative 109 to the alcohol 124 and then re-oxidise back to the aldehyde. 
However, the common reducing agents for the process, such as LiA1FL or borane, 
were unlikely to be compatible with the enol ether functionality. A recent report in 
the literature suggested forming an activated derivative using the peptide-coupling 
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agent, 	benzotriazol- 1 -yloxytripyrrolidinophosphonium 	hexafluorophosphate 
(PyBOP), in the presence of DIPEA.' 26  It was reported that the HOBt ester formed 
in situ could be easily reduced to the, alcohol by treating with sodium borohydride 
(NaBH4). This reaction was attempted on the acid derivative 109, but no evidence of 
product 124 was found after work-up (Scheme 3.7). TLC analysis revealed the 
presence of a number of compounds, so the reaction was not taken any further. 
Scheme 3.7 
I) PyBOP, 
o 	 DIPEA 	HO-K 
OH 
OOMe 0 	OMe ii)NaBH4 
109 	 124 
An alternative procedure was to start from an alkylated alkene derivative 53b, which 
could then be subjected to ozonolysis to form the aldehyde 126.127  This route was 
appealing as it built upon the familiar, robust chemistry that had been developed for 
the regioselective alkylation of methoxy-dimedone 51. The commercially available 
3,3-dimethylallylbromide 125 was chosen as a suitable electrophile as it had the 
advantage that the acetone by-product from the ozonolysis step would be volatile. 
Methoxy-dimedone 51 was successfully alkylated with this reagent under the 









53b was then treated with ozone, in the presence of pyridine and Sudan red 7B as 
indicator for 8 hours (Scheme 3.9), after which time the red colour still persisted. 
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acetic acid added. The aldehyde 126 was obtained in 11 % yield after work-up and 













The low yield can be partly explained by the recovery of a significant amount (28 %) 
of the starting alkene 53b. Ozone generation appeared inefficient as represented by 
the long reaction time and, failure of the indicator colour to pale completely. Since 
overcoming this problem proved difficult, an alternative oxidation protocol involving 
osmium tetroxide was pursued. This method involved treating the alkene derivative 
53b with osmium tetroxide (as a solution in tert-butanol), in the presence of N-
methylmorpholine N-oxide (NMO) for 2 hours (Scheme 3.10). After work-up, ESI-
MS found the crude product to contain a peak matching the mass of the expected diol 
127. 127 was reacted directly with sodium periodate (Na104) to afford the aldehyde 
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The yields were improved considerably by suspending the Na10 4 on silica gel before 
adding a solution of the diol 127 in DCM dropwise. 128 This method allowed the 
aldehyde 126 to be obtained in yields of up to 96 % after purification by Kugelrohr 
distillation. A common problem with aldehydes is their tendency to degrade on 
storage, however, it was found that 126 could be refrigerated for weeks without any 
indication of degradation by NMR. The aim now was to investigate whether 
reductive aminations on the aldehyde 126 were possible. 
3.2.3 Reductive Amination Reactions 
The classical and most common procedure for forming secondary amines is reductive 
amination. 129 ' 130' 131 Hence, it was the method of choice for incorporating amines into 
the dimedone derivatives. Allylamine 110 was again used to test the reaction 
conditions, which generally involved mixing the amine 110 and aldehyde 126 in the 
presence of catalytic acetic acid, followed by the addition of sodium 
cyanoborohydride (NaCNBH3) (Scheme 3.11). However, despite repeated attempts, 
none of the desired product 129a was isolated. ESI-MS found peaks at m/z = 275 
and 300 but it was not apparent what these corresponded to. The reaction often 
produced mixtures of products and the fractions isolated after chromatography had 
complicated and unassignable NMR spectra. A search of the literature revealed 
additives such as zinc chloride (ZnC1 2) 132 or sodium acetate (NaOAc)' 33 could 
enhance reductive amination reactions but this was not found to be the case for our 
aldehyde 126. To check that the problem did not rest with allylamine 110, the 
reactions were repeated with benzylamine 128 (Scheme 3.11). However, similar 
problems, such as a lack of product formation and the presence of many by-products 
were encountered. 
Scheme 3.11 
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These results forced an examination into whether imine formation was occurring. A 
stirred solution of the aldehyde 126 and allylamine 110 over molecular sieves was 
monitored by ESI-MS (Scheme 3.12). Mass spectrometry did not reveal the imine 
130 to be present, but since most imines are relatively unstable, it may be that they 
are not preserved under the electrospray conditions. 
Scheme 3.12 
H O
OMe mol. sieves 	 N 0) 
126 	 130 	J 
Alternatively, imine formation may require more forceful conditions; hence, 
allylamine 110, aldehyde 126 and catalytic acetic acid were refluxed in DCM for 3 
hours (Scheme 3.13). Again, the imine 130 was not detected by ESI-MS, but 
subsequent reduction of the mixture with NaCNBH 3 produced some of the alcohol 
124. NaCNBH3 should not reduce aldehydes in preference to iminium ions, hence 
the presence of the alcohol 124 would suggest that imine formation is disfavoured 












The reaction was repeated with benzylamine 128, which, due to its higher boiling 
point, was used in conjunction with toluene as the solvent. A Dean-Stark trap was 
fitted to remove the water, but there was still no evidence of imine formation. After 
adding the reducing agent and working up, a brown oil was obtained, which did not 
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appear to contain any of the foreseen alcohol 124. However, there was again no 
trace of the desired product 129b and the material stuck to the baseline on TLC, 
complicating attempts to purify. 
Reports in the literature suggested the use of titanium isopropoxide in combination 
with sodium borohydride as an effective means of reductive amination.' 34 The worry 
with using a stronger reducing agent was the tendency for the enol ether to react, but 
in light of the failures experienced so far it was felt worthwhile to try  this method. 
The aldehyde 126 and benzylamine 128 were stirred in the presence of the Lewis 
acid overnight (Scheme 3.14), at which point a sample was taken for ESI-MS. Mass 
spectrometry detected a peak with the correct mass for the imine 131, the first time 
this had been observed. Sodium borohydride was added and the reaction stirred at 









However, ESI-MS analysis of the crude product obtained after work-up failed to 
reveal a peak corresponding to the mass of the amine derivative 129b (#/z = 288). 
Instead, a peak at m/z = 272 was visible, which could be explained by the structure 
133 shown in Scheme 3.15. 133 would arise from amine 129b undergoing 
intramolecular cyclisation to form the iminium species 132. In the presence of 
sodium borohydride, this would be reduced to the tertiary amine derivative 133. 
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Unfortunately, it was not possible to obtain a viable NMR spectrum to prove the 
existence of this compound. Attempts to purify the crude product were unsuccessful, 





[Ph OMe1 132 
NaB H4 
Ph 	 OMe 
133 
The difficulties encountered with the reductive amination reactions were surprising, 
considering the relative simplicity of the reagents. From the experiments described 
above, it appears imine formation involving the aldehyde 126 is generally 
disfavoured. In the few cases where the presence of the imine was detected, the 
reaction tended to give rise to a number of by-products. The use of more forcing 
conditions in order to drive imine formation were also unsuccessful. It had 
previously been noted that the aldehyde 126 appeared stable over long periods and 
could even be subjected to column chromatography and emerge intact. Since 
aldehydes are generally reactive and unstable species, this suggests some feature of 
the molecule is conferring stability on the aldehyde fragment. The a,f3-unsaturated 
ketone of dimedone is in close proximity to the aldehyde functionality and a 
hydrogen bond between them would form a favoured six-membered ring. The 
oxygen atom would be particularly electron rich due its conjugation with the lone 
pair on the methoxide group, making this hypothesis more plausible. It could be 
imagined that this structure would confer a high degree of stability on the molecule 
and could hinder attack at the aldehyde by nucleophiles. In addition, attack at the 
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methoxide position on the ring may be favoured due to its greater electrophilic 
character. However, NMR and JR studies were not conclusive in proving the 
existence of a hydrogen bond between the aldehyde and ketone. Also, since the 
aldehyde 126 was a liquid at room temperature, it was not possible to obtain an X-
ray crystal structure to reveal any hydrogen bonding present in the molecule. 
To further investigate if hydrogen bonding between the aldehyde and ketone was the 
reason for the former's lack of reactivity, a second aldehyde derivative 136 was 
synthesised (Scheme 3.16). It was felt that the incorporation of an extra CH 2 group 
into the aldehyde chain might deter hydrogen bonding, as adopting a seven 
membered ring conformation should be less stable. Alkylating methoxy-dimedone 
51 with commercially available 5-bromo-2-methyl-2-pentene 134 gave rise to the 
desired alkene derivative 135 in 13 % yield. The low yield can be explained by the 
use of only 1.1 equivalents (instead of 2) of the electrophile, which resulted in the 
recovery of methoxy-dimedone starting material 51 at the end of the reaction. 
Nevertheless, there was a sufficient quantity of the alkene 135 to take forward to the 
next step. Conversion to the aldehyde 136 was achieved by using the osmium 
tetroxide/Na104 method, which gave the product 136 in 70 % overall yield. 
Scheme 3.16 
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The reductive amination of 136 with allylamine 110 and NaCNBH 3 (Scheme 3.17) 
afforded an orange oil, which contained a peak in the mass spectrum representative 
of the mass of the desired product 137. Evidence of the correct mass was 
encouraging, as the secondary amine product had never been detected using the other 
aldehyde 126. However, the crude product was found to run close to the baseline by 
TLC, even in polar solvent systems, which complicated attempts to purify. Flash 
chromatography isolated the main fraction as an off-white oil but the 'H NMR 
spectrum contained many unassignable peaks and appeared to be a mixture of 
compounds. Due to progress made elsewhere and a lack of material, the reaction 
was not repeated. Nevertheless, it offered the first potential evidence of success in 
these reactions and hinted that the problems previously encountered were associated 






cat. AcOH 	HN 
NaCNBH3 L 	
OOMe II 137 
3.2.4 Methods to Overcome Problems Associated with Unreactive Aldehyde 
Two alternative methods presented themselves as a means of overcoming the 
problems associated with the unreactive aldehyde. The first of these involved 
reducing the aldehyde 126 to the primary alcohol 124, and then carrying out a series 
of nucleophilic substitution reactions involving amines. The first step was achieved 
by treating a solution of the aldehyde 126 in anhydrous MeOH with solid-supported 
borohydride reagent (Scheme 3.18). Filtration and several resin washes afforded the 
alcohol 124 in 91 % yield after removal of the solvent. The 'H NMR spectrum was 
clean and revealed no evidence of enol ether hydrolysis, implying that the system 
was tolerant of the stronger reducing agent. The alcohol was then activated as its 
mesylate derivative and treated with benzylamine 128 in the presence of a catalytic 
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amount of cesium carbonate (Scheme 3.18).135  An analysis of the crude product 
obtained after work-up revealed no presence of the desired secondary amine 129b. 




















In light of this, it was decided to convert the alcohol to its bromide equivalent to 
facilitate SN2 reactions with the amine. Hence, the alcohol 124 was reacted with 
phosphorus tribromide at 0 °C (Scheme 3.19). This reaction did not give rise to any 
of the alkyl bromide 139, but instead produced the furan 138 as the major product. 
Whilst this is an interesting molecule to test against CypA, it appeared to be a major 








124 	 139 
The second approach to resolving the issues related with the aldehyde 126, was to 
hydrolyse the enol ether back to the diketone, thereby eliminating a potential source 
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of the poor reactivity. Hydrolysis was achieved in standard fashion by treating a 
solution of the aldehyde 126 in acetone with 2M HCl (aq) (Scheme 3.20). The 
correct mass for the diketone was detected after work-up, but the 'H NMR spectrum 
was not straightforward. Further analysis revealed the diketone had rearranged to the 
hemiacetal 140, which was present as the sole product. Exclusive formation of 140 
was not surprising as the diketone exists predominantly as its enol tautomer and will 
therefore favour attack on the aldehyde. The formation of the hemiacetal was not a 
serious problem, however, as it was expected to be able to undergo reductive 
aminations. 
Scheme 3.20 
o 	 2M HC1 (aq) 
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To test if this was the case, the hemiacetal 140 was reacted with benzylamine 128 in 
the presence of molecular sieves for 2 hours (Scheme 3.21). A sample of the 
reaction mixture was tested by ESI-MS and found to contain the imine 131. 
NaCNBH3 was then added, the pH adjusted with acetic acid, and the mixture stirred 
for a further 3 hours at room temperature. The crude product obtained after work-up 
did not contain a peak in the mass spectrum for the expected secondary amine, but 
instead was shown to contain a mass which matched that of the fully cyclised 
compound 141. The presence of 141 was confirmed by NMR, after purification by 
flash chromatography. The successful synthesis of 141 was a significant result as not 
only had the problems associated with the reductive aminations been overcome, but a 
route had been found that led directly to the cyclised compounds of interest. On 
reflection, the tendency of the molecules to ring-close was not surprising, as they 
would be subject to a strong thermodynamic driving force once the secondary amine 
had formed. The reaction also demonstrated the increased nucleophilicity of the 
amine functionality compared to its amide equivalent. 
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Scheme 3.21 
i) BnNH2 128, 
mol.sieves 




3.2.5 Scope of Reductive Aminations on Hemiacetal 
To test the robustness of the newly discovered reductive amination method, the 
reaction on the hemiacetal 140 was repeated with allylamine 110 (Scheme 3.22). 
The same conditions as before were used and the imine and cyclised compounds 
were again detected by ESI-MS. The correct product 142 was isolated by column 
chromatography but appeared contaminated by a small amount of unidentified 
impurity. Attempts to remove the impurity by re-columning using other solvent 
systems or by distillation were not successful. This problem was not encountered in 
the analogous reaction with benzylamine 128, so it is most likely associated with a 
side reaction involving allylamine 110. The reaction was repeated but purified by 
Kugelrohr distillation as opposed to chromatography. Distillation failed to isolate 
either the product 142 or impurity but gave a dark oil which was identified as the 
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143 may have formed under the high temperatures employed during purification or 
may have resulted from the enamine cyclising to form the conjugated product. 
Nevertheless, the synthesis of a new cyclised compound was pleasing as it increased 
the range of structures available for testing. Further attempts to obtain a pure sample 
of 142 were not made as the onus shifted on to testing the method with amino acids 
as this would lead into the fully functionalised derivatives. 
Scheme 3.23 
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A solution of the hemiacetal 140 and Z-L-lysine methyl ester hydrochloride 120c in 
DCM were stirred at room temperature for 6 hours (Scheme 3.23), but no trace of the 
imine was detected by ESI-MS. It was presumed this was due to the amino acid 
being unreactive whilst present as its hydrochloride salt. Hence, DIPEA was added 
to generate the free amine and stirring was continued overnight. ESI-MS now 
showed the imine to be present, so NaCNBH 3 was added and the pH adjusted with 
acetic acid. After stirring for a further 24 hours, the reaction was worked up and the 
crude product shown to contain the cyclised derivative 144 by ESI-MS. Purification 
by flash chromatography afforded the required compound 144 in 56 % yield as a 
mixture of diastereomers. The success of this method with an amino acid was 
satisfying as it achieved the aim of synthesising an analogous ligand to the lead 122c 
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that was devoid of amide functionality. The fact that the cyclised compound 144 was 
obtained in a single step (neglecting the synthesis of the hemiacetal) was particularly 
beneficial as it avoided the potentially problematic and low yielding ring-closing 
conditions. 144 could be deprotected with TMSI to afford the free amine 145 for 
comparison with the analogous amide containing ligand 123. 
3.2.6 Summary 
A new series of lead compounds had now been synthesised that contained a tertiary 
amine instead of an amide functional group. The route to such compounds involved 
the synthesis of an alkylated aldehyde derivative 126, obtained in excellent yield, 
which then rearranged to a hemiacetal 140 upon treatment with HC1. 140 was found 
to undergo a range of reductive amination reactions, which failed when started from 
the aldehyde 126 itself. Satisfyingly, these reactions gave rise to the cyclised 
products directly, avoiding the need for a separate ring-closing step. This method 
proved applicable to both amines and amino acids, and provided an interesting set of 
molecules for testing. 
3.3 Use of Hydrazine to Demonstrate Six-Membered Ring 
Formation 
In order to further examine which features of the cyclised lead compounds were 
crucial for binding CypA, it was necessary to increase their structural diversity. 
Since the original design had allowed for the incorporation of a second six-
membered ring, it was worthwhile to see if the existing chemistry could be adapted 
for this purpose. Hydrazine was chosen as a simple, inexpensive and readily 
available molecule with which to perfect the chemistry. It was envisaged that 
substituted hydrazine derivatives could be used in future to synthesise more 
functionalised molecules. 
Hydrazine is significantly more nucleophilic than other primary amines due to the 
contribution of the lone pair on the adjacent nitrogen atom, the so called a-effect. 
Hence, standard peptide coupling conditions cannot usually be used, as di-addition 
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frequently occurs. It is more common to form hydrazides by reacting hydrazine with 
esters. 136 The alkylated tert-butyl derivative 53a cannot be used for this purpose as 
the ester group is base stable and is therefore unreactive towards hydrazine. 
However, it was thought the equivalent ethyl ester derivative 53c would be more 
applicable. 53c had previously been synthesised in 61 % yield as a test ligand for the 
alkylation reaction (Entry 3, Table 2.2). Hydrazine was added dropwise to a solution 
of the ester 53c in ethanol and the reaction stirred at room temperature overnight 
(Scheme 3.24i). TLC indicated only starting material was present, so the reaction 
was heated under reflux for 18 hours (Scheme 3.24ii). However, this failed to 
produce any of the hydrazide 146, with the ester 53c recovered after work-up. More 
forceful conditions involving refluxing in toluene with a Dean-Stark trap were tried 
(Scheme 3.24iii), but again the ester 53c proved unreactive. Finally, microwave 
heating was employed, with ethanol as the solvent (Scheme 3.24iv). The reaction 
was held at a temperature of 140 °C for 15 minutes, but ESI-MS revealed only the 
presence of the ester 53c. TLC showed some baseline material but this produced a 
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Conditions: (i) EtOH, room temp; (ii) EtOH, reflux; (iii) toluene, reflux; (iv) 0) (300W, 140 °C, 15 
mins) 
The failure of the reaction with the ester derivative 53c led us to focus attention on 
the acid analogue 109 as an alternative reagent. The acid was activated in standard 
fashion with EDCI and HOBt (Scheme 3.25). 137  Once TLC had shown the complete 
disappearance of the free acid, the solution containing the activated species was 
added dropwise to a solution of hydrazine in DCM at 0 °C. The high nucleophilicity 
of hydrazine was expected to facilitate a quick reaction, however, none of the 
hydrazide 146 was detected after work-up. Extending the reaction times also failed 
to give rise to the desired product 146. As an alternative activation protocol, the acid 
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derivative was converted to the acid chloride, which was then slowly added to 
hydrazine at 0 °C. This method gave a poor overall yield and a number of 
compounds by TLC. These findings suggested that hydrazine was undergoing side 
reactions such as di-addition, implying the reaction conditions had to more carefully 
controlled. To achieve this, the reaction with EDCI and HOBt was repeated but with 
the hydrazine solution cooled to —20 °C. The reaction was allowed to warm slowly 
to room temperature and then quenched with water. A yellow solid was obtained in 
good yield (58 %) after work-up, and was correctly identified as the hydrazide 146. 
Scheme 3.25 
OY0 	
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146 was of sufficient purity to be used directly in the next step, hydrolysis of the enol 
ether (Scheme 3.26). It was feared that the presence of a primary amine may make 
this step problematic and as anticipated, a number of species were detected by TLC 
at the end of the reaction. Purification by flash chromatography isolated a single 
pure fraction as an off-white solid, but analysis by NMR did not reveal it to be the 
expected diketone derivative. The NMR spectra suggested that the compound had 
cyclised but the retention of a peak corresponding to the methoxy group was 
puzzling. In combination with ESI-MS (m/z = 208), the compound was eventually 
identified as the ring-closed structure 147. 
It appeared that under acidic conditions, formation of the imine was favoured 
kinetically over the hydrolysis of the enol ether. It was envisaged that prolonged 
exposure to acid would result in 147 rearranging to the more stable enaminone 
derivative, but in practice this led to a number of by-products. This reaction requires 
further attention but it served to demonstrate that the synthetic route could be adapted 
to accommodate hydrazides and subsequent six-membered ring functionality. Future 
work in this area could involve the use of substituted hydrazides that could offer 
potential for further derivatisation. 
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3.4 Route to Enantiomerically Pure Ligands 
Chemistry had now been developed that allowed for the synthesis of a diverse range 
of cyclised ligands. It had proved reliable for the incorporation of amines or amino 
acids and had been tailored to meet the requirements for successful reductive 
amination reactions. The chemistry had also been shown to be flexible enough to 
manage the construction of six, as well as five-membered ring systems. However, a 
potentially serious drawback with the methods used to date was their lack of 
stereocontrol. The use of racemic carboxylic acid 109 or aldehyde 126 derivatives 
inevitably led to mixtures of diastereomers when reacted with chiral amine or amino 
acid starting materials. Whilst it was true that the diastereomers could sometimes be 
separated by chromatography, this was structure dependent and not very reliable. 
Human proteins are often very selective for a particular substrate conformation and 
can readily distinguish enantiomers. With one chiral centre present at a bridgehead 
carbon atom in the cyclised ligands, the two diastereomers were likely to have 
significant conformational differences. With these two points in mind, it was felt 
there was a strong possibility of CypA favouring one diastereomer over the other. 
Hence, a method was sought that would provide the lead compounds as single 
diastereomers. 
3.4.1 Resolution of the Carboxylic Acid Derivative 
A chemical resolution of the carboxylic acid derivative 109 appeared to offer the best 
opportunity for obtaining an enantiomerically pure synthetic route to the lead 
compounds. The acid derivative 109 had the advantage of being readily synthesised 
in large quantities and the potential to be resolved via chiral salt formation. Based on 
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similar work reported in the literature, enantiomerically pure a-methyl benzylamine 
was chosen as the basic component. 138  Both enantiomers of this are commercially 
available and relatively inexpensive. The racemic acid derivative 109 was dissolved 
in isopropyl alcohol (IPA) and one equivalent of (R)-(+)-a-methyl benzylamine 148a 
added (Scheme 3.27). After a few minutes a precipitate formed, which was filtered 
and recrystallised twice from IPA. The salt 149a was then hydrolysed back to the 
free acid by dissolving in EtOAc and washing with 1M HC1 (aq). After drying the 
organic phase and removing the solvent, the acid derivative 150a was found to have 
an ee = 73 % by chiral HIPLC. This result was encouraging as it appeared that the 
method was working, so the above process was repeated on the enantiomerically 
enriched acid and the material obtained at the end found to have an ee = 97 %. This 
value was acceptable for 150a to be used in the amino acid coupling step. 
The above process was repeated using the other enantiomer of a-methyl 
benzylamine 1481b. After two cycles this gave rise to the other acid enantiomer 150b 
with an ee = 95 %. Although the yields (-1 5 %) were moderate at best, the 
resolution could be carried out on a large enough scale to provide a sufficient amount 
of material for subsequent reactions. However, it was still necessary to identify the 
configuration of the chiral centre, hence crystals were grown of the salt 149a formed 
from the reaction with (R)-(+)-a-methyl benzylamine 148a. Since the chirality of 
the amine was unambiguous, X-ray crystallography was used to identify the 
complexed acid as the (R)-enantiomer 150a (Figure 3.4). It logically follows that 
(S)-(-)-a-methyl benzylamine 148b must be selective for the (S)-enantiomer 150b of 
the acid. Both single enantiomers of the acid could now be coupled to chiral amino 
acids to obtain single diastereomers as products. 
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Scheme 3.27 
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Figure 3.4 	X-ray crystal structure of salt formed between (R)-(+)-a-methyl 
benzylamine 148a and acid derivative 109. 
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3.4.2 Synthesis of Enantiomerically Pure Cyclised Derivatives 
Z-L-Lysine methyl ester hydrochloride 120c was chosen as the amino acid for the 
peptide-coupling step, as the cyclised ligand 122c based on this compound had been 
found to be a potent inhibitor of CypA. Any selectivity of one diastereomer in 
preference to the other by CypA should become evident from an analysis of the 
dissociation constants. The amino acid 120c was coupled to both (R)- and (8)-
enantiomers 150a and 150b of the acid using the standard method (Scheme 3.28). 
After work-up and purification by flash chromatography, the peptide products were 

















/ HOBt, EDCI 	 H  
DIPEA 
30 	 H 




These were then carried forward to the hydrolysis and cyclisation steps. However, 
the products isolated by chromatography after the final step were found to have 
undergone epimerisation at the bridgehead carbon. Whilst the ratios were better than 
1:1, this was still a disappointing result. It was initially felt that the acid hydrolysis 
step had caused the epimerisation but repeating this reaction on 151b and isolating 
the products revealed the small amount of cyclised compound 153b present to be a 
single diastereomer (Scheme 3.29). 
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Scheme 3.29 
H 
CBz -" NH 
CO2Me 152b 
H 	









Hence, it became apparent that the epimerisation had occurred under the vigorous 
conditions employed during the final ring-closing step. As described in Section 
3.1.2, refluxing in toluene had been the only successful method discovered for this 
process but more research may be needed in future to try and find an alternative 
means of ring-closure. Nevertheless, by isolating the cyclised ligands after the 
hydrolysis step, a sufficient quantity of each diastereomer 153a and 153b could be 
obtained for testing. 
3.5 Conclusions 
This chapter has served to highlight the development of a novel ligand series for 
human CypA. The key achievements were: 
The successful, large-scale synthesis of a methoxy-dimedone based 
carboxylic acid derivative 109 in excellent yield and high purity. 
• 	The successful coupling of both amines and amino acids to the acid 
derivative 109, which increased the molecules' structural diversity. 
• 
	
	The development of hydrolysis and ring-closing conditions that afforded the 
target cyclised ligands, albeit in low yields. 
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• 	The use of molecular modelling to alter the structure of the lead compounds 
to provide high affinity ligands for CypA, the first of their kind based on the 
cyclised structure. 
The synthesis of a complementary series of ligands, which were devoid of 
amide functionality, by a novel route that overcame problems encountered 
with reductive amination reactions. 
The incorporation of hydrazine into the cyclised structures to demonstrate 
six-membered ring formation was possible via this route. 
• 	The modification of the synthetic route to afford enantiomerically pure 
ligands, by successfully resolving the acid derivative 109 using chiral amine 
salt formation. 
3.6 Suggestions for Future Work 
The synthetic route's ring-closing step requires some development in order to 
improve yields and make it more applicable to a greater range of starting materials. 
In addition, the step's current tendency to induce epimerisation would have to be 
overcome if any subsequent method is going to prove useful at synthesising single 
diastereomers. 
Whilst the incorporation of hydrazine had demonstrated the route's ability to 
incorporate a second six-membered ring into the lead compounds, the hydrazine 
derivative 147 did not leave much scope for further derivatisation. N-Stabilised 
carbanions, formed from species such as 154, could be used as alternative reagents 
for constructing the second ring system. It could be envisaged that nucleophilic 
attack by the carbanion on the activated acid species 155, followed by deprotection 
and cyclisation would generate a functionalised six-membered ring system 157 
(Scheme 3.30). 
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Scheme 3.30 
>--N--\ 	 30 
i) LDA 	
O OMe 










The success of the resolution of the carboxylic acid derivative 109 offers a potential 
route towards the analogous enantiomerically pure aldehyde via a two-step reduction 
and oxidation protocol. Obviously, conditions would have to be carefully monitored 
to ensure that no racemisation occurs but if achievable, it would allow for the 
synthesis of the second ligand series as separate diastereomers. 
Work carried out previously within our group has revealed that the presence of allyl 
functionality attached to dimedone 33 can confer high affinity for CypA.' 39 Hence, it 
would be interesting to observe what effect the incorporation of an allyl group 
adjacent to the dimethyl of the dimedone ring would have on the binding of the 
cyclised ligands. However, synthesising such a molecule is unlikely to be trivial. 
The easiest approach would be to carry out a regioselective alkylation with ally! 
bromide 158 on a single diastereomer i.e. 153b to provide 159 (Scheme 3.31). 
However, the strong basic conditions may not be tolerated by the other functional 
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An alternative strategy would be to synthesise the alkylated ally! derivative 160, 
hydrolyse back to the diketone 161, then reform the enol ether in the hope that a 
mixture of isomers 162 and 163 would be formed (Scheme 3.32). These could then 
be separated and the minor one 162 used as the basis for the synthetic route to the 
cyclised compound 159. Notable drawbacks of this method are: 1) the generation of 
a large number of diastereomers; 2) the need to carry out the reaction on a large scale 
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4 	Results and Discussion III 
4.1 Analysis of Ligand Binding 
The previous chapter detailed the successful development of a route for the synthesis 
of novel cyclised ligands based around the dimedone template. These ligands had 
their binding to CypA tested by a variety of techniques as described below. The 
protein production and assay work was carried out by Dr. Martin Wear and Dr. Brian 
McHugh at the Institute of Cell and Molecular Biology at Edinburgh University. 
4.1.1 Protein Production 
Human CypA was cloned into a pET vector and overexpressed in E. coli BL2 1 cells. 
Protein purification protocols were developed in-house to give good yields of pure 
protein using affinity or ion exchange chromatography. Typical yields of 7 mg of 
pure protein per litre of culture were routinely obtained. 
4.1.2 Fluorescence Binding Assay 
When CypA was isolated in 1984 and named after its affinity for the 
immunosuppressive drug CsA 11, a method was sought for determining the strength 
of the protein-drug interaction. Handshumacher et al. used fluorescence 
spectroscopy to detect changes in the intrinsic fluorescence emitted from a single 
tryptophan residue (Trp-121) located in the active site of CypA. 39 Upon binding 
CsA 11, they observed a two-fold enhancement in fluorescence intensity, which they 
attributed to an increase in hydrophobicity of the environment surrounding the 
tryptophan. The close contact between CsA 11 and Trp- 121 and the associated 
fluorescence change enabled the researchers to calculate a dissociation constant (Kd) 
for CsA 11 of 200 nM. Further studies refined this value to between 30 and 40 
nM .43,89  The X-ray crystal structure of CsA 11 bound to CypA revealed a strong 
hydrogen bond interaction between Trp- 121 and the carbonyl oxygen of MeLeu-9 in 
CsA 11.41  It is this contact that is believed to account for the significant changes 
observed in the fluorescence of Trp-121 upon complex formation. For the assay to 
be applicable to ligands other than CsA 11, it is necessary that the compounds bind 
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close enough to Trp-121 ('-' 5-6 A) in order to perturb the microenvironment around 
the residue and cause a corresponding change in the observed fluorescence spectrum. 
Small molecular weight inhibitors do not always cause a change in the Trp-121 
fluorescence as this residue is located at least 6 A from the proline binding pocket 
where such molecules are thought to bind. 
The fluorescence assay was performed using a PTI QuantmasterTM 
spectrofluorometer (Protein Technology International, Santa Clara, CA) on samples 
of CypA in the absence or presence of increasing amounts of ligand. Tryptophan 
fluorescence was excited at 295 nm and the emission scanned from 310 to 430 nm. 
Each spectrum was obtained from separate incubations of CypA/ligand and not from 
sequential additions of ligand to the same sample of CypA. Any change in the 
corrected fluorescence signal was assumed to be directly proportional to the 
concentration of the CypA/ligand complex. The observed fluorescence (fbs)  was 
buffer background subtracted and corrected for dilution and inner filter effects and 
the corrected fluorescence values plotted against ligand concentration. The data was 
least squares fit to Equation 4.1 to obtain a value for the Kd. 
=fi + (fi, —fi) x {(K + [CypA] + [Lig]) - I((Kd + [CypA] + [Lig])2 - (4 x [CypA] 
x [Lig]))12 x [Lig])} 
	
Equation 4.1 
where J = corrected fluorescence signal 
fluorescence of uncomplexed CypA 
fb = fluorescence of CypAlligand complex 
Kd = dissociation equilibrium constant 
[CypA] = total CypA concentration 
[Lig] = total ligand concentration 
For example, Figure 4.1B shows the plot obtained for a CypAICsA 11 complex. A 
least squares fit of this data to Equation 4.1 gave an apparent Kd of 25 ± 6 nM for 
CsA 11. This value is in good agreement with those determined by other 
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researchers. 43 ' 89 Figure 4.1A displays the 2 to 3-fold enhancement that is observed 
from the tryptophan fluorescence of CypA when bound to CsA 11. As can be seen 
from the spectrum, this enhancement is also accompanied by an 8 nm blue shift in 
the emission maxima from 350 nm to 342 nm. 
Figure 4.1 (A) Fluorescence spectrum of a) 20 jiM CsA alone; b) 0.35 jiM CypA 
alone; c) 0.35 jiM CypA in the presence of 20 jiM CsA. (B) Fluorescence 
enhancement at 342 nm of CypA plotted against concentration of CsA in [LM. Each 
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The above measurements for CsA 11 highlight the potential of the fluorescence assay 
for determining dissociation constants for ligands that bind CypA. However, as was 
stated previously, smaller, weaker binding ligands may not bind close enough to the 
Trp-121 to affect its fluorescence. This lack of perturbation can result in weak 
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inhibitors producing fluorescence spectra barely above the background, making it 
very difficult to accurately calculate the Kd'S. Whilst this problem can be overcome 
to a certain extent by increasing the protein concentration, this is not desirable as it 
rapidly depletes valuable protein stocks. Another common problem encountered 
concerns ligand solubility. In order to calculate an accurate Kd it is common to take 
readings over a wide range of ligand concentrations. If the ligand precipitates out of 
solution, this can cause scattering effects, which result in poor signal to noise ratios 
and a subsequent loss of sensitivity. 
4.1.3 Peptidyl-Prolyl cis-trans Isomerase (PPIase) Assay 
The ability of the synthetic ligands to inhibit CypA's PPIase activity was assessed 
using an in vitro protease-coupled enzymatic assay (Figure 4.2).' ° cc-Chymotrypsin 
selectively cleaves the C-terminal p-nitroanilide (pNA) bond of a commercially 
available peptide substrate (Suc-Ala-Ala-Pro-Phe-pNA) only when the prolyl amide 
bond is in the trans configuration. CypA catalyses the conversion from cis to trans, 
and the subsequent release of the chromogenic pNA fragment can be monitored over 
time at 400 urn. The initial rate of substrate conversion by CypA combined with 
various concentrations of inhibitor is used to calculate an IC 50 value for each 
compound (i.e. the amount of inhibitor required to reduce the enzymatic activity by 
half). 
Figure 4.2 Mechanism of PPIase assay. 
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In proline containing peptides about 10 % of the prolyl amide bonds are in the cis 
conformation. 50  Such low amounts of active substrate can result in poor signal to 
noise ratios, which can obscure the results from the assay. This problem can be 
overcome by suspending the peptide substrate in a solution of LiCIITFE, which 
converts most of it 
(P-' 
70 %) to the cis form. CypA is incubated together with 
varying concentrations of ligand in 'buffer and transferred to a plastic cuvette. The 
reaction is initiated by addition of a-chymotrypsin, followed by peptide substrate (in 
LiCIJTFE), and immediately monitored spectrophotometrically at 4 °C. The trans-
peptide present at equilibrium is cleaved within the deadtime, ensuring that any 
subsequent release of pNA can be attributed to isomerisation of the cis isomer. 
Potent inhibitors of CypA will retard this process and a plot of rate of chromophore 
release against the log of ligand concentration will allow an IC 50 value to be 
calculated for each ligand. The low temperature of the reaction is necessary to limit 
thermal isomensation of the substrate, however, this caused problems with ligand 
solubility and in practice adjustments had to be made to ensure the ligand stayed in 
solution. 
In addition to problems with ligand solubility, the assay has a number of other 
limitations: 
The calculations assume that the rate of isomerisation is directly comparable to the 
rate ofp-nitroanilide release. 
Only the cis to trans and not the reverse trans to cis isomerisation can be 
investigated. 
Ligands were initially dissolved in MeOH but problems arose due to increased 
absorbance at 400 nm. DMSO proved to be more effective (and improved solubility 
issues) but was hampered by fact it is a known, albeit weak, inhibitor of CypA. 90  
The assay is fairly laborious and time-consuming and several repetitions are often 
required to achieve reproducible results. 
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4.1.4 Electrospray Mass Spectrometry Assay 
Whilst the in vitro assays described above are well-established and important 
methods for ascertaining binding and determining dissociation constants, they are 
hampered by restrictions placed on the type of ligands that can be screened, or by the 
length of time the assay takes to perform. Their use would be better served by 
concentrating on obtaining data for a small number of key ligands with a high 
probability of binding CypA. A method was therefore needed that could quickly 
identify promising ligands by the nature of their interaction with CypA. 
Electrospray mass spectrometry (ESI-MS) has previously been used as a moderately 
high-throughput method for screening protein-ligand complexes to identify 
compounds with high affinities. 141  The small amounts of sample required and the 
speed of the method make it an attractive technique for screening small compound 
libraries against a particular protein target. The soft-ionisation conditions are 
generally thought to preserve non-covalent interactions between the protein and 
ligand during transition from the solution to the gas phase. The versatility of the 
instrument can then allow a range of parameters including flow rate, pH, cone 
voltage and temperature to be varied in order to ensure the survival of the native 
complex. Another advantage of the electrospray process is that proteins often 
become multiply charged, giving characteristic charge-ion series within the operation 
range of common quadrupole analysers. 
One of the first proteins to be studied by ESI-MS was FKBP, a member of the same 
immunophilin family as CypA. 142" 43 In addition to displaying a specific charge-ion 
series for FKBP, the method could detect the complexes formed between the protein 
and its known inhibitors, FK506 10 and RAPA 12. Furthermore, by measuring the 
relative peak intensities for free and complexed FKBP, and knowing the initial 
concentrations of protein and inhibitor, the researchers were able to determine 
dissociation constants for FK506 10 and RAPA 12 that were in good agreement with 
those found by other assays. These findings offered the potential to study 
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interactions between CypA and CsA 11 in a similar way, and ultimately to extend 
this to complexes formed with the synthetic ligands. 
In work carried about by Sally Shirran and continued by Hannah Florance, CypA 
was dialysed into 10 mM ammonium acetate at pH 6.8 (the physiological pH of 
CypA). A working protein concentration of 20 .tM was used for analysis by ESI-
MS. The experiment was conducted on a Micromass ZMD mass spectrometer and 
introduction of the sample was by direct infusion. The charge-ion series observed 
for CypA contains a narrow charge distribution over three charge states, the 8+ being 
the most dominant. This relatively low charge range suggests CypA is still in its 
folded, native form. Deconvolution of the spectrum reveals a mass of CypA of 
18144 Da (Figure 4.3). This mass represents the documented mass of human CypA 
(18012 Da) plus a methionine residue that is involved in the transcription of the 
CypA gene. 
Figure 4.3 Mass spectrum of CypA. 
A: 	 1514494t1eS 
The successful ionisation and detection of CypA by ESI-MS was encouraging and 
focused attention onto whether the process could be repeated with CypA complexed 
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to CsA 11. Hence, a 1:1 mixture of CsA 11 and CypA (20 pM) in ammonium 
acetate buffer/ 10 % MeOH (the methanol was necessary to dissolve the ligand but its 
concentration was kept as low as possible so as not to disrupt the protein structure) 
was directly infused into the mass spectrometer. The deconvoluted mass spectrum 
clearly revealed a peak corresponding to the combined mass of CypA plus CsA 
(19348 Da) (Figure 4.4). The signal determines the exact stoichiometry for the 
complex, which as expected is 1:1. The experiment ably demonstrates the ability of 
ESI-MS to observe CypA complexes in the gas-phase. 
Figure 4.4 Mass spectrum of 1:1 CypAICsA 11 complex. 
k 	14..4a.Orn 
4.2 Binding Results for the Synthetic Inhibitors 
4.2.1 Results from ESI-MS Assay 
Due to the speed of the method, new ligands were first tested using the ESI-MS 
assay in order to identify promising inhibitors, which could then be taken forward for 
further in vitro or in vivo testing. The ability of the method to use the relative peak 
intensities to determine dissociation constants was taken advantage of to generate a 
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Table 4.1 Results from ESI-MS assay. 
Ligand Structure ESI-MS Instrument 
Kd_(M)*  
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CO2Me 
123 H 72.6± 16.2 ZMD 
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CO2  Me 
122a 85.1 ± 19.0 ZMD 
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153a H 120.6± 11.7 Nanomate® 
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109 181.6± 40.5 ZMD 
O*T•XLOMe 
O H0 




0 	 CO2Me 




0 	 CO2Me 
144 H Very weak Nanomate® 
CN1CL binding 
0 	 CO2Me 
145 H No binding Nanomate® 
H2N 
CO2  Me 
116 No binding ZMD o:(I5 
Ph''I 
CO2Me 
113 No binding ZMD 
* All ligands were screened at 100 jtM conc. against CypA (20 l.tM) 
The last column in the table details the instrument used to obtain the data. The ZMD 
was connected to a Waters 2700 HPLC pump to enable automated sample 
introduction. However, this approach proved problematic as in order to maintain 
adequate sensitivity, flow rates had to be kept to a minimum. Reduced flow rates 
resulted in increased run times and ensured only approximately 10 samples per hour 
could be tested. The ZMD also suffered from problems associated with sample carry 
over. These were largely overcome through the use of an elution gradient but this 
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had the downside of further increasing the sample run time. The Nanomate® 
employs nanospray ionisation, resulting in reduced sample volumes and flow rates. 
The unit is closed to the atmosphere, which prevents sample evaporation or 
contamination and helps the instrument maintain a steady back pressure. These 
conditions are important for ensuring high levels of reproducibility and throughput. 
When coupled to a sensitive analyser such as a Q-TOF micro (Quadrupole-Time of 
Flight) the Nanomate® was capable of screening 50 samples per hour with a high 
degree of accuracy. Unfortunately, the Nanomate® was located at Oxford 
University placing time constraints on its access. 
From Table 4.1 it can be seen that both the lysine and arginine containing cyclised 
ligands bind strongly to CypA, with significantly higher affinities than the parent 
dimedone 33 (Kd = 22 mM by fluorescence - too weak to be observed by ESI-MS 
assay). In contrast, ligands 113 and 116 showed no binding to the protein and helped 
to corroborate the molecular modelling studies described in Section 3.1.3. The 
arginine derivative 122b proved to be the most potent binder by ESI-MS and the 
mass spectrum of its complex with CypA is shown in Figure 4.5. 
Figure 4.5 Mass spectrum of CypA/122b (1:5) complex. 
CypA 
CypA + 1 hg. 	
A. 	 l811h44 




CypA +4 hg. 
1-1 
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The spectrum clearly shows a peak for the CypAI122b complex. However, the 
stoichiometry of ligand binding appears ambiguous due to the presence of peaks 
representing the binding of multiple ligands. It was felt that the extra peaks arose 
from ligand-ligand aggregation, a common problem in ESI-MS assays. 141  On 
dilution into the aqueous environment favoured by the protein, small hydrophobic 
ligands can form strong interactions with each other. These interactions cause the 
ligands to cluster together to form micelle like structures. In the case of ligand 122b, 
it would appear that the micelles display affinity for CypA and could, in theory, be 
competing with one another for access to the active site. Such competition between 
different structures would obviously affect the validity of Kd calculations. Reports in 
the literature suggest aggregation can be minimised by reducing the ligand 
concentration, implying that at high concentrations the ligands preferentially form 
clusters as opposed to complexes with the protein. A CypA/ligand (1:5) ratio was 
found to be optimum for detecting complexes using the ZMD, with poor sensitivity a 
factor at lower proteinlligand ratios. Spectrums run on the Nanomate®, however, 
have significantly improved signal to noise ratios for reasons described above, hence 
this was used to detect complexes at lower ligand concentrations. For example, 
Figure 4.6 shows the spectrum for a CypA/122b (1:2) complex. 
Figure 4.6 Mass spectrum of CypA/122b (1:2) complex. 
CypA 
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As can be seen from the spectrum, aggregation has been considerably reduced 
suggesting the process is concentration dependent. 
Aggregation could also be detected in CypAICsA 11 complexes proving that even 
the strongest inhibitors of CypA exhibit this effect under certain electrospray 
conditions. Using the CypAICsA 11 complex as a model system, tandem mass 
spectrometry (MS/MS) experiments were carried out to investigate the strength of 
cluster binding (Figure 4.7). 
Figure 4.7 Spectra depicting the breakdown of the isolated peak 2308.8 [CypA + 
2CsA + 9H] 9t As the voltage was increased a) 20.0 V; b) 30.8 V; c) 39.2 V the 
complex degraded in stages, reducing the charge state with each ligand loss. At high 
voltages, d) 50.3 V, both ligands were lost simultaneously. 
[CYPA+8H] 	 [CYPA+7H] 7 	 d) 
ICYPA + CsA + 8H] 
244&3 
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a) 
This experiment involved selecting peaks corresponding to CypA + 1 CsA and CypA 
+ 2 CsA respectively. The ligands were dissociated from the protein by accelerating 
them into a cell filled with argon gas at a pressure of 10-5  Ton. By increasing the 
acceleration voltage the strength of the protein to ligand binding could be assessed. 
This experiment found the second CsA 11 ligand to be much more weakly bound, 
with low acceleration voltages (20 V) able to dissociate it from CypA. The first 
ligand required significantly more energy to dissociate, implying that it is bound 
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much more tightly to CypA. In addition, at high voltages (50 V) both ligands were 
lost simultaneously but the detection of the 8+ charge state suggested the ligands 
may have been lost as a dimer, giving support that ligand-ligand aggregation is 
occurring as opposed to non-specific binding of two CsA's at separate sites on 
CypA. 
The results from the previous experiment suggest that a single ligand is binding in 
CypA's active site and others are aggregating to it, especially at high concentrations. 
Therefore, it can be assumed that the calculated Kd is a reliable measure of the 
affinity of a single ligand for CypA. Although the possibility of non-specific binding 
by ligand clusters cannot be completely ruled out, reducing the ligand concentration 
should help to minimise this. The Kd'S were calculated by comparing the intensity of 
the peaks due to proteinlligand complexes against those for protein alone. In general, 
it was found that the highest affmity ligands gave the most reliable Kd's by this 
method. This was probably a result of their strong interactions with CypA helping to 
preserve the proteinlligand complex during desolvation. Weaker binding ligands 
would be more liable to dissociate from the protein under the electrospray conditions. 
Nevertheless, the primary function of this assay was to quickly identify tight-binding 
inhibitors for further investigation, and it has proved to be an excellent tool for this 
purpose. 
Referring back to Table 4.1, a number of interesting trends come to light. For 
example, the uncyclised ligands 121a-c all show affinity for CypA with Kd'S  2 to 4-
fold greater than their cyclised equivalents. This supports the argument that locking 
the molecules into a particular conformation improves their affinities as a result of 
reducing the entropic cost of binding. An exception to this was 115, which binds 
relatively strongly to CypA (Kd = 91.9 jtM) in contrast to the cyclised version 116 
which shows no binding to CypA by this assay. Section 3.1.3 described molecular 
modelling studies that suggested the steric bulk of the phenyl ring in 116 would be 
unfavourable for binding and this is borne out from the ESI-MS data. However, the 
success with the uncyclised ligand 115 implies that the structure's increased 
flexibility enables it to orientate itself in such a way as to minimise unfavourable 
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interactions. Whether the low Kd is due to additional contacts made by the side-chain 
or by the release of steric strain is, however, open to question. 
As reported in the previous chapter, it was of interest to synthesise the cyclised 
ligands as individual diastereomers in order to investigate whether the protein had a 
preference for one particular configuration? From the results of the ESI-MS assay, it 
would appear that the (SR)-diastereomer 153a binds more strongly to the protein 
than the (SS)-diastereomer 153b. Whilst this conclusion must be viewed in light of 
the fact that the error in the method is relatively large, a difference in Kd of 
approximately 30 % is significant and worth investigating further. Since the 
preliminary data indicates that improvements in Kd could be achieved by screening 
individual enantiomers as opposed to the racemic mixture, future work should 
include the design of more methods for accessing the lead compounds in 
enantiomerically pure form. In addition to potentially leading to tighter binding 
compounds, this work should help to reveal more about the nature of CypA's active 
site, aiding subsequent design efforts. 
The final interesting result obtained from the ESI-MS assay centres on the ligands 
123 and 145. The former displays affinity for CypA, whereas the latter was found 
not to bind the protein. Since the only difference between the structures is the lack of 
an amide carbonyl group in 145, this raises the possibility that this functionality 
could be a key recognition site. for CypA. In the original design of the cyclised 
ligands it was suggested that the amide carbonyl group might mimic the twisted 
amide bond of prolyl peptide substrates. To investigate this hypothesis, molecular 
modelling was used to manually dock the structure of 123 into CypA's active site 
and compare this to the known X-ray crystal structure of the bound dipeptide Ala-Pro 
(Figure 4.8). 144  Asn-102 in CypA's active site is known to form a hydrogen bond 
with the oxygen atom of thô prolyl amide in Ala-Pro. This interaction is highly 
conserved in most CypA complexes with linear peptides and, in the case of Ala-Pro, 
was measured to be 2.17 A. In comparison, the amide oxygen atom of the docked 
ligand 123 was found to be 2.59 A from Asn-102, thereby lending support to the 
view that this ligand could act as a transition state mimic. The lack of an amide bond 
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in 145 would explain its inability to bind CypA. An alternative hypothesis, however, 
is that the removal of the carbonyl group could change the pK a and hybridisation 
state of the ring nitrogen thereby changing both the electronic and configurational 
properties of the molecule. 
Figure 4.8 Molecular modelling of 
123 (red) using the known X-ray 
crystal structures of CypA (blue) 
bound to Ala-Pro (green) and CypA 
(black) bound to EM2/34 117 (not 
shown) as templates. The 
intermolecular distance between the 
amide oxygen atom of 123 and the 
Asn-102 residue is 2.59 A. In the 
dipeptide the prolyl amide oxygen 
atom is 2.17 A from Asn-102. 
4.2.2 Results from In Vitro Assays 
Following the primary screen by ESI-MS, a selection of the cyclised ligands had 
their binding determined by fluorescence and/or PPIase assay (Table 4.2). The best 
hit was ligand 123, which was shown to bind CypA with high affinity. The Kd Of 
16.1 ± 2.3 j.tM represents a greater than 1000-fold improvement compared to the 
parent compound dimedone 33; and the calculated IC 50 of 6.8 ± 1.9 jiM confirms 123 
as a potent inhibitor of CypA's PPIase activity. A plot of the corrected fluorescence 
against the concentration of 123 is shown in Figure 4.9. The apparent Kd was 
obtained from a least squares fit of the data to Equation 4.1 but with an extra linear 
term (hg. 123fl uor x [hg. 123]) added to take account of the concentration dependent 
increase in the fluorescence signal of 123 (in this case hg. 123fl uor = 3,800 
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Table 4.2 Results from in vitro assays. 
Ligand Structure Fluorescence PPlase 
Kd (PM) 1050  (JIM) 
123 H 16.1 ±2.3 6.8± 1.9 
CO2  Me 
145 H Not tested No inhibition 
C,40 
CO2  Me 
122c 5.0-20.0 No inhibition 
H 
Ph"-.10 Y 
0 	 CO2 Me 
122b 5.0-30.0 No inhibition 
NH 	o1 
02N N AN 
H 	H 
CO2Me 
122a Not tested No inhibition 
H 
N 
0 	 CO2  Me 
Evidence of binding but range quoted due to poor signal to noise ratios arising from 
scattering caused by poor ligand solubility. 
Figure 4.9 Corrected intrinsic tryptophan enhancement at 348 nm of CypA plotted 
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The small IC 50 value obtained for 123 by the PPIase assay is in stark contrast to the 
lack of inhibition found for 145. These findings support the earlier data from the 
ESI-MS assay and strengthen the view that the amide carbonyl group in 123 is 
required for the effective binding of CypA. As described above (Figure 4.8) this 
view offers the exciting possibility that 123 may bind as a transition state analogue. 
Such a result would be important for the design of new inhibitors and would confirm 
the logic of the original design process that proposed such structures. Efforts are 
currently focused towards obtaining an X-ray crystal structure of the CypAI123 
complex, which would help elucidate the exact position of the amide carbonyl in the 
protein's active site. 
In contrast to the excellent results obtained with 123, many of the other compounds 
highlighted by ESI-MS failed to inhibit the PPIase activity of CypA or gave poor 
signal to noise ratios in the fluorescence assay (Table 4.2). Whilst this may be a 
result of false hits generated by the original screen, it is more likely due to inherent 
problems concerning ligand solubility. As stated in the opening sections of this 
chapter, the in vitro assays are reliant on the compound being completely soluble in 
the respective buffers used in the reactions. With most of the cyclised ligands shown 
in Table 4.2, this was not the case. The notable exceptions were ligands 123 and 
145, where the free amine moieties significantly enhanced their solubility in polar 
solvents. Ligand solubility must therefore be taken into consideration during the 
design of such compounds, particularly in relation to studies in biological systems. 
DMSO is often the solvent of choice when issues concerning solubility arise but its 
use in the above assays was hindered by the fact that DMSO is a known, albeit weak, 
inhibitor of CypA,90 and could therefore distort the results. 
In summary, the in vitro assays support the findings from the ESI-MS assay and 
provide a further means of confirming and quantifying a particular ligand's affinity 
for CypA. However, the amount of information attainable is reliant on the ligands 
being compatible with the requirements of the assay, with solubility a major factor. 
Both in vitro assays are time-consuming to perform so the value of using the ES I-MS 
assay as a fast, initial screen becomes apparent. The promising results obtained for 
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123 provide a strong case for this analytical approach, with this compound 
representing a completely new class of inhibitor of CypA. Furthermore, 123's 
excellent solubility in polar solvents makes it an attractive candidate for in vivo 
testing. 
4.2.3 In Vivo Activity Screen 
Caenorhabditis elegans, a free-living nematode worm, is an excellent model system 
for the study of nematode parasites. It is not only genetically tractable, but is easily 
and quickly cultured in liquid media and has a relatively rapid reproductive life cycle 
(of the order of 24 hours). 68 C. elegans has been shown to express multiple isoforms 
of cyclophilin that appear to have important roles in reproduction and larval 
development, body-wall muscle formation and in the proper folding and processing 
of proteins involved in cuticle formation. 73 However, this area is still poorly 
understood and little is known about the exact mode of action of cyclophilins and 
other folding proteins in C. elegans. 
CsA 11 has been shown to cause biological effects such as cuticle shedding and gut 
structural defects in C. elegans, which have been attributed to the inhibition of 
cyclophilins PPIase activity. 145,146  The large molecular weight, poor bioavailability 
and immunosuppressive functions of CsA 11 render it an unsuitable candidate for 
studying the effects of cyclophilin inhibition in C. elegans. However, chemical 
intervention by small molecule inhibitors could provide an important tool for probing 
the biological properties of parasitic cyclophilins in vivo. 
A C. elegans in vivo screen has been developed to investigate the biological effect of 
the synthetic human CypA inhibitors. A fixed number of sexually mature worms 
were cultured in liquid media plus 2 % ethanol (to aid ligand solubility) in 24 well 
plates, exposed to varying doses of 123, and analysed over the course of five days 
(this allows for several reproductive cycles). Biological effects were then assessed 
by several parameters, including morphological and developmental abnormalities 
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fecundity or sterility. High concentrations (> 500 LM) of 123 were lethal resulting in 
rapid death of the worms (Table 4.3). Compared to control conditions, worms 
exposed to concentrations < 500 p.M had growth defects - the worms were shorter 
and "dumpier" in general and showed reduced motility (Table 4.4). 
Table 4.3 Observations after 24 hours of C. elegans treated with varying 
concentrations of 123. 
Conc. of Ligand 123 Observations 
0 mlvi [Control: liquid 
media +2_% EtOH]  
Normal 
2 mlvi Instantly dead 
1 mm Instantly dead 
500 jiM All dead 
250 p.M Adults stunted and sluggish 
100 p.M Adults stunted and sluggish 
75 p.M Short but motile 
50 p.M Short but motile 
25 p.M Short but motile 
10 [IM Short but motile 
5 p.M Short but motile 
Table 4.4 Observations after 5 days of C. elegans treated with varying 
concentrations of 123. 
Cone. of Ligand 123 Observations 
0 mM [Control: liquid 
media +2 % EtOH]  
Normal 
2 mM Dead 
1 mm Dead 
500 p.M Low numbers of worms - 
sluggish with gut damage 
250 p.M Stunted and sluggish with 
gut damage 
100 p.m Stunted and sluggish with 
gut damage 
75 p.M Stunted 
50 p.M Normal 
25 p.M Normal 
10 p.m Normal 
5 p.M Normal 
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The organisms treated with 123 also had cuticle shedding defects and severe gut 
development defects, similar in phenotype to those observed in organisms treated 
with CsA 11 (Figure 4.10). Furthermore, exposure to 123 markedly affected the 
reproductive abilities of the worms as reflected in large loss/reduction of larvae and 
embryo numbers. 
Figure 4.10 Representative light-micrographs of worms grown in the absence or 
presence of either 123 (100 tM) or CsA 11 (25 .iM) are shown in panels (A), (B) 
and (C), respectively. In (B) and (C), the cuticle shedding defect, absent in (A), is 
highlighted by red arrows. (D) Higher magnification light micrograph showing the 
abnormal gut tissue development present in worms exposed to 123 (100 tM) (red 
arrows). 
A. 	 B. 
Control 	 100 jjM LIgand 123 
C. 	 D. 
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The results with 123 were very encouraging and the data was used to determine an 
1050 value for its action against C. elegans. Figure 4.11 shows the dose-response 
curves for 123 after 48 hours exposure. Although the data is noisy, a specific trend 
exists and it is possible to calculate apparent 10 50 values by non-linear fitting the data 
to a standard model. An average 10 50 for 123 of 156 ± 80 tM was calculated by this 
method. For comparison, the 10 50 value for CsA 11 from a similar experiment was 
found to be 28 ± 13 tM. Hence, the biological effects of 123 compare well with 
those of CsA 11, and the small molecule inhibitor possesses the additional 
advantages of ease of synthesis and better bioavailability compared to the large 
cyclic undecapeptide. 
Figure 4.11 Dose response curves for 123 based on (A) embryo numbers and (B) 
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Although it is possible that the biological effects of 123 are due to its toxicity in vivo, 
the evidence suggests it is the ability of 123 to inhibit parasitic cyclophilins that is 
responsible for its mechanism of action. The fact that 123 has been shown to be a 
potent inhibitor of human CypA by in vitro assay and to cause phenotypes similar to 
those found using CsA 11 provides a strong case for this conclusion. 
In contrast to the results obtained with 123, the protected analogue 122c was found to 
possess no activity against C. elegans, despite it being shown to inhibit CypA by 
fluorescence assay (Table 4.2). This finding again demonstrates the importance of 
good solubility and bioavailablity, with the lipophilic protecting group of 122c 
rendering it much less soluble than the free amine containing inhibitor 123. The 
uptake of the former into C. elegans would thus be limited, thereby explaining its 
lack of activity in vivo. These results suggest that further improvements in activity 
could be achieved through modifications that increase the ligand's solubility in 
aqueous environments. For example, it could be envisaged that hydrolysis of the 
ester moiety of 123 would lead to the formation of a zwitterion that should further 
enhance its solubility in biological systems. 
Ligands such as 123 offer great potential for the design of new antiparasitic drugs. 
Alternatively, these compounds could be employed as chemical probes to elucidate 
the role of cyclophilins in different stages of C. elegans development. Such an aim 
could be realised by linking the observed phenotype with the biochemical 
mechanism of action of the small molecule inhibitors. This forward chemical 
genetics approach would provide valuable information about the biological actions of 
the cyclophilins in C. elegans and hence, should identify new targets for antiparasitic 
drugs. For this approach to be successful, it will be necessary to investigate the 
uptake and localisation of ligands within C. elegans. A convenient way to achieve 
this is to attach fluorescent labels to the compounds of interest to allow for their 
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4.2.4 Synthesis of Fluorescently Labelled Derivatives 
In order to incorporate fluorescent labels into the lead compounds, the commercially 
available dansyl lysine amino acid 165 was successfully converted to its methyl ester 
166 by treating with thionyl chloride in methanol (Scheme 4.1). The ester 166 was 
then coupled to the racemic carboxylic acid derivative 109 to form the dansylated 
peptides 167a and 167b respectively. In this case it was possible to separate the 
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After previously experiencing problems with epimerisation during the cyclisation of 
individual diastereomers (Section 3.4.2) it was decided to isolate the products after 
the hydrolysis of the enol, ether moieties of 167a and 167b (Scheme 4.2). This 
approach allowed small quantities of the desired cyclised dansyl derivatives 169a 
and 169b (arising from intramolecular cyclisation of the diketone compounds 168a 
and 168b in situ) to be obtained for testing. 
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Unfortunately, the cyclised compounds 169a and 169b were not suitable candidates 
for crystallography hindering attempts to assign their absolute configurations. 
However, comparing their NMIR spectra with those obtained for the enantiomerically 
pure ligands 153a and 153b enabled a tentative assignment to be made. 
4.2.5 In Vitro Testing of Fluorescently Labelled Derivatives 
Each diastereomer had its binding to CypA determined by ESI-MS, and then 
subsequently by in vitro assay (Table 4.5). The initial screen by ESI-MS revealed 
both compounds to bind CypA with the (SR)-diastereomer 169a displaying slightly 
higher affinity for the protein than its (S,5)-analogue 169b. These results mirror 
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those found for ligands 153a and 153b (Table 4.1), thereby hinting at a possible 
preference for the ring proton to be in the R-configuration. 
Table 4.5 Binding results for fluorescently labelled derivatives 169a and 169b. 
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CO,Me 
169a was found to inhibit CypA's PPIase assay with an IC 50 value of 207.0 ± 57.8 
tM, whereas no inhibition could be detected for the other diastereomer 169b. On 
initial reflection these results contradict those from the ESI-MS assay by suggesting 
only one of the diastereomers 169a possesses affinity for CypA. However, it should 
be stated that both diastereomers had poor solubility under the conditions used for 
this assay, thus affecting the reliability of the data. A truer reflection of the binding 
of 169a was obtained from intrinsic fluorescence measurements. A value for the Kd 
of 21.9 ± 3.5 pM was obtained, based on the calculated change in the Trp-121 
fluorescence of CypA. It should be stated that this value arises from a best fit of the 
data after correcting for absorbance and auto fluorescence of the ligand. The 
strength of the fluorescence signal of the ligand masks that from the protein 
preventing a direct measurement from being made. Nevertheless, the low Kd value 
obtained by this method suggests that the Trp-121 fluorescence is 'changed by a 
significant amount by 169a. Future work will involve looking at the dansyl specific 
fluorescence in order to further refine the value for the Kd. 
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Comparing the Kd for 169a with that obtained for 123 reveals that the incorporation 
of a dansyl tag does not significantly affect the binding to CypA. This was an 
important result, since the benefits afforded by the inclusion of a fluorescent label 
would be negated if the change in structure seriously affected the ligand's ability to 
bind CypA. This finding also indicates that modifications to 123 involving coupling 
to the free amino group would not necessarily have a detrimental effect on binding. 
Hence, a range of analogues of 123 could be synthesised and used as probes to 
determine the nature of the interactions in the Abu pocket of CypA's active site. 
However, the fact that the Kd for 169a is approximately 30 % weaker than that found 
for 123 implies that bulky groups such as dansyl might experience some 
unfavourable steric interactions upon binding to CypA. Having shown that 169a 
binds to CypA with high affinity, it was now tested in vivo in order to follow the 
passage of the ligand in C. elegans, thus helping to shed light on its molecular 
targets. 
4.2.6 In Vivo Testing of Fluorescently Labelled Derivatives 
C. elegans in liquid culture was treated with 169a and found to display cuticle 
shedding defects and gut malformation similar in phenotype to that found in 
organisms treated with 123 or CsA 11. In addition, the fluorescence of 169a was 
monitored using a florescence microscope fitted with a DAPI filter set. The results 
are shown in Figure 4.12. 169a was found to permeate throughout the gut lumen into 
areas where cyclophilins are thought to be present. There role here is proposed to 
involve the correct formation of the gut lining, which would correlate well with the 
structural defects observed after administration of the inhibitor 169a. The fact the 
ligand's passage through the gut can be detected suggests its effect is not merely 
toxic, as one would expect the compound to kill the organism shortly after ingestion 
if this was the case. The results from the fluorescence study indicate that 169a 
locates and inhibits its particular target(s) thereby causing the effects described 
above. Whilst the evidence points to cyclophilins as the molecular targets, further 
work is necessary to rule out other potential candidates such as FKBP's. Whether 
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Figure 4.12 Fluorescence microscopy studies of C. elegans after treatment with 
169a. (A) Strong fluorescence detected throughout gut lumen in areas where 
cyclophilin proteins are thought to be present; (B) Fluorescence detected from gut 
lumen, which is malformed (red arrow). Small fluorescent vesicles are also visible 
(yellow bracket) but these are due to auto-fluorescence of the organism and not to 
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4.3 Conclusions 
This chapter detailed the results obtained for the synthetic inhibitors in complex with 
CypA. The key results were: 
. 	A novel ESI-MS binding assay has been developed to provide a quick means 
of assessing the ligands' affinity for CypA. This assay found a number of the 
cyclised compounds to bind to CypA and the method provided a rank-order 
to allow the most promising inhibitors to be identified for further testing. 
• In vitro assays were used to quantitatively assess the strength of ligand 
binding and inhibition of CypA's PPIase activity. These confirmed ligand 
123 as a potent inhibitor of CypA with an apparent Kd = 16 j.tM and an 10 50 
= 6.8 j.tM respectively. These figures represent a greater than 1000-fold 
improvement on the original lead dimedone 33. 
• 	Evidence from ESI-MS and PPIase assays suggested the amide carbonyl of 
123 plays a critical role in binding CypA. This view arose from studies on 
the de-oxy analogue 145, which showed no affinity for the protein. 
Molecular modelling studies indicated that the amide carbonyl of 123 might 
mimic the twisted amide transition state of a bound prolyl peptide. If 
confirmed, this would satisfy one of the original design requirements and 
provide support for the structure-based design approach. 
• 	123 was tested in vivo against the free-living nematode C. elegans and was 
found to cause cuticle shedding defects and severe gut development defects, 
similar in phenotype to those observed in organisms treated with CsA 11. In 
addition, 123 drastically reduced C. elegans reproductive capabilities. These 
findings imply that 123 is acting on cyclophilins present in C. elegans, which 
have been proposed to be involved in the correct folding of collagens 
required for cuticle formation. 145" 46 
• 	Fluorescently labelled derivatives 169a and 169b were successfully 
synthesised by incorporating a dansyl containing lysine residue into the 
dimedone motif by the route described in Chapter 3. 
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• 	Dansyl derivative 169a was found to bind to CypA by ESI-MS and 
fluorescence assay with a Kd = 20 j.iM. It therefore appears that the bulky 
dansyl tag can be successfully incorporated into CypA's active site. 
169a displayed similar effectsto 123 and CsA 11 in vivo and its fluorescence 
was detected throughout the worms' gut lumen in areas where cyclophilins 
are thought to be involved in structural formation of the gut lining. The site-
specific fluorescence provided strong evidence that the ligands were 
localising in cyclophilin dense regions and causing specific effects as a result 
of inhibiting these proteins. 
4.4 Suggestions for Future Work 
The success with 123 was due in no small measure to its excellent solubility in polar 
solvents. Whilst other cyclised ligands showed evidence of binding to CypA, their 
testing was hampered by poor solubility and/or bioavailability. Future work will 
therefore need to take into consideration methods to improve the solubility of the 
lead compounds. The hydrolysis of the ester moiety of 123 would yield a carboxylic 
acid derivative, which should enhance the ligand's solubility and would be of 
particular importance if additional groups were attached to the free amine. 
Further work is required to elucidate the role of the amide carbonyl group in CypA's 
active site. X-ray crystallography could be used to solve the structure of the 
proteinlligand 123 complex and hence, determine the location of the amide carbonyl 
in the active site. Work is currently ongoing into obtaining crystals of 123 bound to 
CypA. A successful structure determination would also provide new possibilities for 
future ligand modifications by revealing which residues are in close contact with the 
molecule in the active site. Such studies could also reveal whether CypA has a 
preference for one diastereomer over the other? 
This chapter highlighted the potential of using synthetic ligands, such as 123, for 
studying the role of parasitic cyclophilins in model organisms like C. elegans. An 
extension of this approach would be to study the effect of selectively inhibiting one 
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or more of the cyclophilin isoforms present in the nematode. A recently developed 
technique known as 'proximity accelerated alkylation' could be used for this 
purpose. Levitsky et al., 147  have recently reported the generation of specific cysteine 
mutants of human CypA (e.g. P105C) which retain wild-type PPIase activity but can 
be irreversibly inhibited in the presence of CsA analogues possessing a thiol specific 
electrophilic group such as the acrylamide derivative 170. Compound 170 is easily 
prepared from CsA, according to the sequence shown in Scheme 4.3, in which the 
MeBmt-1 side-chain is modified to provide an electrophilic acrylamide unit which is 
insufficiently reactive to alkylate endogenous thiols (e.g. glutathione) in a non-
specific manner and can only conjugate to a protein after initial docking at the 
binding site. Crucially, modification at this region of CsA does not interfere with 
binding to cyclophilins. 
Scheme 4.3 
Me 	 Me - i)03 	 = 
HO, 	- ii)NaBH4 
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This approach provides a powerful way of using chemical probes to switch off one or 
more cyclophilins in an allele specific manner and could be extended to incorporate 
acrylamide units into the fluorescent inhibitors 169a and 169b. Inhibitors such as 
these would allow inactivated cyclophilin isoforms to be visually identified and 
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ligand needs to be Ca. 8-12A from the cysteine-105 residue suggesting that 
derivatives of type 171 would be suitable. Optimisation of both the length of spacer 
and also the specific residue on the cyclophilin to be modified could be carried out in 
order to fine tune the specificity of inhibition. 
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5 	Experimental 
5.1 General Procedures 
'H and ' 3C NMIR spectra were recorded on Bruker AC250, DPX-360 or Varian 
Gemini-200 instruments. The following abbreviations are used: 8, chemical shift; d, 
doublet; dd, doublet of doublets; dt, doublet of triplets; dq, doublet of quartets; J, 
coupling constant; m, multiplet; q, quartet; s, singlet; t, triplet. Chemical shifts () 
are reported in parts per million (ppm) and coupling constants (1) in Hz. Residual 
protic solvent, CHC13 (6H  7.26, s) was used as the internal standard in 'H NMR 
spectra, and ' 3C NIvIR shifts were referenced using CDC1 3 (c  77.0, t) with broad 
band decoupling. Electrospray (ES) nominal mass spectra were recorded using a 
Micromass Platform II mass spectrometer (CV=35). Fast Atom Bombardment 
(FAB) high resolution mass spectra were recorded on a Kratos MS50TC instrument. 
LC-MS was performed on a C18 Luna Phenomenex column using an acetonitrile 
(0.1 % TFA)/water gradient over 30 minutes. Preparative LC-MS was performed on 
a Micromass ZMD 4000 with Gilson 215 liquid handler, eluting with a 
acetonitrile/water gradient over 30 minutes. Infrared absorption spectroscopy was 
performed on a Jasco-FT/IR-410 Spectrophotometer using standard techniques and 
Vmax values are quoted in cm 1 . Microwave reactions were carried out in a CEM 
Discover Microwave Synthesiser with Explorer Carousel. The reaction conditions 
were monitored using a pressure probe which was inserted through the septum of the 
reaction tube and black body irradiation measured to monitor the temperature of the 
sample. Normal phase high performance liquid chromatography (}IPLC) was 
performed on a Waters 600 controller/pump utilising a 486 tunable absorbance 
detector and equipped with a Chiracel-ODH column with dimensions 25 x 0.46 cm. 
Samples were injected via a 20 xl loop with a flow rate of 1 ml/min, and eluted with 
an isocratic system of hexane/ethanol (9:1) with 0.1 % TFA as modifier. A 
wavelength of 254 nm was used for sample detection. CHN analysis was obtained 
for crystalline solids. A small sample was recrystallised three times then submitted 
for combustion analysis. CHN was not obtained for gummy solids or oils. Optical 
rotations were performed on an AA1000 polarimeter from Optical Activity Ltd. 
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(measurements made at the sodium D-line). Concentrations are given in g/100 ml. 
Melting points were obtained on a Gallenkamp melting point apparatus and are 
uncorrected. Analytical TLC was carried out on Merck aluminium-backed plates 
coated with silica gel 60 F 254, 0.25 mm. Components were visualised using ultra-
violet fluorescence (254 run) and ammonium molybdate or permanganate dips. 
Flash chromatography was carried out using silica gel 60H (Merck 9385, 0.04-0.063 
mm, 230-400 mesh). Diisopropylamine was distilled from solid sodium hydroxide 
and stored under dry nitrogen over 4K molecular sieves. Anhydrous solvents were 
purchased from Aldrich or Baker and used as received. Other solvents and reagents 
were standard laboratory grade and used without further purification. Starting 
materials were purchased from Sigma-Aldrich, Acros or Novabiochem unless 
otherwise stated, and used as received. 
5.2 Experimental Procedures 
5.2.1 Alkylation of Dimedone 
5.2.1.1 (2,2-Dimethyl-4,6-dioxo-cyclohexyl)-acetic acid tert-butyl ester 45d 
> 0 'T)bz~" r 0 	0 
A solution of lithium diisopropylamide (2.0 M, 7.13 ml, 14.26 mmol) in anhydrous 
THF (15 ml) was cooled to —78 °C under a dry nitrogen atmosphere. A solution of 
dimedone 33 (1.00 g, 7.13 mmol) and hexamethylphosphoric triamide (4.4 ml, 21.40 
mmol) in anhydrous THF (7 ml) was then added dropwise over 5 mm. After stirring 
for 1 hr at —78 °C, a solution of tert-butylbromoacetate 108 (1.05 ml, 7.13 mmol) in 
anhydrous THF (7 ml) was added and the mixture allowed to warm to room 
temperature overnight. The reaction was quenched with water (5 ml), diluted with 
ether (35 ml), and washed with 2M HC1 (2 x 35 ml), then water (35 ml). The 
combined aqueous phase was extracted with ether (2 x 35 ml), and the total organic 
phase washed with brine (35 ml), dried (MgSO4), and rotary evaporated to give a 
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dark orange oil (1.84 g). Flash column chromatography on silica gel using DCM 
fEtOAc (20:1) yielded a yellow oil (0.94 g, 52 %): Vm a,, (CHC13) 1725.0, 1615.1; 6H 
(250 MHz, CDC1 3) 0.67 (3H, s, C(CAH3CBH3)),  1.14 (3H, s, C(CAH3CI3H3)),  1.43 
(C(CH3)3), 2.29 (1H, dd, J 16.7, 3.8, CHAHBCO2But),  2.44 (1H, dd, J 14.6, 2.5, 
CI?HBC(CH3)2), 2.66 (1H, dd, J 16.7, 9.4 CHflBCO2But),  2.73 (1H, d, J 14.6, 
CHAIIBC(CH3)2), 3.13 (1H, dd,J9.4, 3.7, CHCFI2CO2Büt), 3.29 (1H, dd,J16.5, 2.4, 
COCHAHBCO), 3.54 (1H, d, J 16.5, COCHAIIBCO); 8c (63 MHz, DEPT, CDC13) 
22.0 (C(CH3C3H3)),  27.9 (C(C113)3), 28.3 (C(CAH3CBH3)),  29.9 (CH2CO2Bu), 
33.4 (C(CH3)), 55.7 (CHCH2CO2But), 56.0 (CH2C(CH 3)2), 58.2 (COCH2CO), 80.9 
C(CH3)3), 171.8 (CO2Bu), 202.7 (COCH2CO), 202.9 (COCH2CO); MS FAB (+ve) 
found m/z 255 (MJ{, 48 %), 181 (MtOBut, 89); HRMS FAB (+ve) found m/z 
255.15972 (MH), C 14H2304 requires 255.15963. 
5.2.2 Silylation of Dimedone 
5.2.2.1 5,5-Dimethyl-3-trimethylsilanyloxy-cyclohex-2-enone 47 
OOTMS 
Hexamethyldisilazane (2.00 ml, 9.42 mmol) was added to a solution of dimedone 
(33) (1.00 g, 7.13 mmol) in anhydrous DCM (20 ml). The solution was stirred under 
nitrogen at room temperature for 2 hrs. Excess hexamethyldisilazane was removed 
in vacuo to leave an orange liquid, which solidified to a white solid in the freezer 
(1.44 g, 95 %): mp 55-58 °C [lit.97 56-58 'Cl; 8H (200 MHz, CDC13) 0.28 (9H, s, 
Si(CH3)3), 1.06 (6H, s, C(CH3)2), 2.17 (2H, s, CH2C(CH3)2), 2.22 (2H, s, 





5.2.2.2 5,5-Dimethyl-1 ,3-bis-trimethylsilanyloxy-cyclohexa-1 ,3-diene 46 
TMSO 	OTMS 
5,5-Dimethyl-3-trimethylsilanyloxy-cyclohex-2-enone 47 (6.30 g, 29.66 mmol) was 
dissolved in anhydrous THIF (25 ml) and added dropwise via a cannula to a stirred 
solution of lithium diisopropylamide (2.0 M, 15.00 ml, 30.00 mmol) at —78 °C. The 
resulting solution was stirred at this temperature for 45 mm, quenched with 
chlorotrimethylsilane (7.61 ml, 60.00 mmol), and allowed to warm to room 
temperature. The mixture was filtered, concentrated under reduced pressure to about 
25 ml and filtered again. Further concentration produced a cloudy yellow liquid 
which was distilled under reduced pressure to give a colourless oil (3.80 g, 45 %): bp 
57 °C (0.075 Ton) [lit. 94 112-113 °C (3 Ton)]; Vmax (neat) 1653.7 (C=C), 1604.0 
(C=C); oH (250 MHz, CDC13) 0.18 (9H, s, Si(CH3)3), 0.22 (9H, s, Si(CH3)3), 1.01 
(6H, s, C(CH3)2), 2.04 (2H, d, J 1.1, CH2C(CH3)2), 4.39 (1H, m, CH=CO), 4.90 (1H, 
m, (OCCH=CO); 0c  (63 MHz, DEPT, CDC13) 0.13 (Si(CH3)3), 0.27 (Si(CH 3)3), 28.9 
(C(CH3)2), 32.6 (C(CH 3)2), 44.61 (CH2C(CH3 )2), 103.0 (CH=CO), 108.3 
(COCH=CO), 147.0 (CO), 154.5 (CO); MS ES (+ve) found m/z 285.2 (MH, 25 %). 
5.2.3 Alkylation Reactions on Bis-Silyl Enol Ether of Dimedone 
5.2.3.1 4-(Hydroxy-phenyl-methyl)-5,5-dimethyl-cyclohexane-1,3-dione 48 
OH 
Ph 
A solution of benzaldehyde (0.074 g, 0.70 mmol) in anhydrous DCM (6 ml) was 
cooled to —78 °C and titanium tetrachloride (0.08 ml, 0.73 mmol) added. The 
resulting yellow mixture was stirred for 10 mins and a solution of 5,5-dimethyl-1,3-
bis-trimethylsilanyloxy-cyclohexa- 1 ,3-diene 46 (0.20 g, 0.70mmol) in anhydrous 
DCM (4 ml) added via a cannula. The mixture was stirred at —78 °C for 3 hrs, then 
allowed to warm to room temperature during which time the colour changed from 
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yellow to dark red. Saturated NaHCO 3 solution (5 ml) was added and after gas 
evolution had ceased, the mixture was extracted with ether (3 x 5 ml). The total 
organic phase was washed with water (5 ml), brine (5 ml), dried (MgSO4), and rotary 
evaporated to give a yellow residue (0.14 g). Flash column chromatography on silica 
gel using EtOAc yielded an oily off-white solid (0.03 g, 17 %): v (CHC1 3) 3683 
(OH), 1728 (C0), 1702 (CO); 6H  (250 MHz, CDC13) 1.06 (3H, s, C(CAH3CBH3)), 
1.22 (3H, s, C(CAH3CBH3)),  2.45 (1H, d, J 15.4, CHLHBC(CH3)2),  2.69 (1H, m, 
CHCH(OH)), 3.04 (1H, d, J 15.4, CHAHI3C(CH3)2), 3.36 (1H, d, J 16.8, 
COCHAHBCO), 3.66 (1H, dd, J 16.8, 1.3, COCHAHI3CO), 5.29 (111, d, J 2.7, 
CHCH(OH)Ph), 7.26-7.37 (5H, m, CH(OH)Ph); 8c (63 MHz, DEPT, CDC13) 25.6 
(C(CAH3CBHA, 29.6  (C(CAH3CBH3)),  33.4 (C(CH3)), 53.1 (GH2C(CH3)2), 595 
(OCCH2CO), 65.7 (CHCH(OH)), 72.2 (CH(OH)Ph), [125.5 (CH), 127.8 (CH), 128.5 
(CH), 5C, Ar-H], 143.0 (Ph), 204.4, (CO), 205.3 (CO); MS FAB (+ve) found m/z 
247 (MH, 75 %), 229 (MIH-H20, 100); HRMS FAB (+ve) found m/z 247.13313 
(Iv1IH) C 15H 1 903 requires 247.13342. 
5.2.3.2 Benzoic acid 5,5-dimethyl-3-oxo-cyclohex-1-enyl ester 49 
0 Ph 
To a solution of 5,5-dimethyl- 1 ,3-bis-trimethylsilanyloxy-cyclohexa- 1,3 -diene 46 
(0.20 g, 0.70 mmol) in anhydrous DCM (15 ml) was added benzoyl chloride (0.12 g, 
0.85 nimol) and the resulting solution cooled to —78 °C. A solution of trimethylsilyl 
trifluoromethanesulfonate (0.02 ml, 0.10 mmol) in anhydrous DCM (3.5 ml) was 
then added via a cannula. The mixture was allowed to reach room temperature over 
6 hrs, and was then stirred at this temperature over the weekend. Brine (5 ml) was 
added and the layers separated. The aqueous phase was extracted with ether (4 x 2.5 
ml) and the total organic phase dried (MgSO 4) and rotary evaporated to give a brown 
oil (0.16 g). Flash column chromatography on silica gel using DCM/EtOAc (4:1) 
yielded a yellow liquid (0.08 g, 47 %): Vmax (neat) 1740.4 (ester), 1673.0 (a,fi- 
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unsaturated ketone); 8H  (250 MHz, CDC1 3) 1.15 (6H, s, C(CH3)2), 2.33 (2H, s, 
CH2C(CH3)2), 2.53 (2H, d, J 1.2 CH2C(CH 3 )2), 6.06 (1H, m, COCHCOMe), 7.46-
7.67 (3H, m, Ar-H), 8.06-8.12 (2H, m, Ar-H); öc (63 MHz, DEPT, CDC1 3) 28.1 
(C(CH3)2), 33.2 (C(CH3) 2), 42.2 (Ph02CCCH2), 50.8 (COCH2C(CH 3)2), 116.8, 
(COCH=CO), [128.7 (CH), 130.2 (CH), 134.1 (CH), 5C, Ar-H], 163.3 (OCOPh), 
168.6 (CH=COCOPh), 199.6 (COCH=CO); MS ES (+ve) found m/z 245.2 (MW, 28 
%), 283.2 (MK, 8); HRMS FAB (+ve) found. m/z 245.11731 (M}), C 1 5H1703 
requires 245.11777. 
5.2.3.3 5,5-Dimethyl-4-(3-oxo-butyl)-cyclohexane-1 ,3-dione 50 
0 	0 
A solution of methyl vinyl ketone (0.059 ml, 0.71 mmol) in anhydrous DCM (6 ml) 
was cooled to —78 °C and titanium tetrachloride (0.077 ml, 0.71 mmol) added. The 
mixture was stirred for 10 mins and a solution of 5,5-dimethyl-1,3-bis-
trimethylsilanyloxy-cyclohexa-1,3-diene 46 (0.20 g, 0.70mmol) in anhydrous DCM 
(4 ml) added dropwise via a cannula. The mixture was stirred at —78 °C for 3 hrs and 
then allowed to warm to room temperature. Saturated NaHCO 3 solution (5 ml) was 
added and the layers separated. The aqueous phase was extracted with ether (3 x 5 
ml) and the total organic phase dried (MgSO 4) and rotary evaporated to give a 
gummy yellow residue (0.08 g). Flash column chromatography on silica gel using 
DCM/EtOAc (4:1) as eluent isolated a yellow oil (0.02 g, 14 %). MS ES (+ve) found 
m/z 211.4 (MJ{, 19 %), 233.4 (MNa, 32), 141.4 (dimedoneH, 58). However, 1 H 
NMR spectrum was complex and contained many unassignable peaks. 
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5.2.4 Synthesis and Alkylations of Methoxy-Dimedone Derivative 
5.2.4.1 3-Methoxy-5,5-dimethyl-cyclohex-2-enone 51 
OOMe 
Dimedone 33 (25.00 g, 178.32 mmol) was dissolved in anhydrous methanol (200 ml) 
and chiorotrimethylsilane (23.75 ml, 187.23 mmol) added. N,N-
diisopropylethylamine (DIPEA) (65.23 ml, 356.63 mmol) was then added dropwise 
and the mixture stirred at room temperature overnight. The methanol was removed 
on the rotary evaporator and the residue dissolved in EtOAc (150 ml), washed with 
water (75 ml), saturated NaHCO3 solution (75 ml), and then brine (75 ml). The 
organic phase was dried (MgSO 4) and rotary evaporated to give a pale yellow liquid 
(27.22 g, 99 %) which did not require further purification: Vmax (neat) 1660.4 (a,,& 
unsaturated ketone), 1609.3 (C=C); oH (250 MHz, CDC1 3) 1.04 (6H, s, C(CH02), 
2.18 (2H, s, CH2C(CH3)2), 2.24 (2H, s, CH2C(CH3 )2), 3.66 (3H, s, OCH3), 5.33 (1H, 
s, COCH=COCH3); 8c  (63 MHz, DEPT, CDC13) 28.1 (C(CH3)2), 32.4 (C(CH3)2), 
42.5 (CH2COCH3), 50.6 (CH2CO), 55.5 (OCH), 101.0 (COCH=CO), 176.8 
(CH=COCH3), 199.3 (COCH=CO); MS ES (+ve) found m/z 155.0 (MH, 14 
177.1 (MNa, 10). 
5.2.4.2 (4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid tert-butyl 
ester 53a 
0 
BuXD   OMe 
n-Butyllithium (1.6 M, 22.29 ml, 35.67 mmol) was added dropwise to a solution of 
dry diisopropylamine (5.00 ml, 35.67 mmol) in anhydrous TI{F (12.5 ml) at 0 °C. 
After 30 min the mixture was cooled to -78 °C and a solution of 3-methoxy-5,5-
dimethyl-cyclohex-2-enone 51 (5.00 g, 32.43 mmol) and dry N,N-
dimethyipropyleneurea (DMPU) (12.5 ml) in anhydrous THF (12.5 ml) was added 
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dropwise. After stirring for 1.5 hrs at —78 °C, a solution of tert-butyl bromoacetate 
108 (9.45 ml, 64.86 mmol) and dry DMPU (2 ml) in anhydrous THF (6 ml) was 
added dropwise and the mixture allowed to reach room temperature overnight. The 
reaction was quenched with saturated ammonium chloride solution (20 ml), diluted 
with ether (50 ml) and washed with 2M KHSO 4 (20 ml), water (20 ml), and saturated 
NaHCO3 solution (20 ml). The combined aqueous phase was extracted with ether (2 
x 20 ml), and the total organic phase washed with brine (30 ml), dried (MgSO4) and 
rotary evaporated to give a viscous yellow oil (11.85 g). Flash column 
chromatography on silica gel using hexane/EtOAc (7:3-1:1) yielded a white solid 
(7.82 g, 90 %): mp 48-50 °C; Vm (nujol) 1732.7 (ester), 1664.3 (a,#-unsaturated 
ketone), 1620.8 (C=C); 6H  (250 MHz, CDC13) 0.86 (3H, s, C(CH3CBH3)),  1.09 (3H, 
S, C(CAH3CBH3)) ,  1.46 (9H, s, OC(CH3) 3), 2.13 (1H, d, J 17.4, CHAHBC(CH3)2), 
2.17 (lH, dd, J 16.0, 4.5, CHAHBCO2(CH3)3),  2.54 (1H, dd, J 17.4, 1.7, 
CHAJIBC(CH3)2) ,  2.63 (1 H, dd, J 16.0, 8.2, CHAI/3CO2(CH3)3),  2.79 (1H, dd, J 8.2, 
4.5, CHCH2CO2(CH3)3), 3.67 (3H, s, OCH3), 5.35 (111, d, J 1.7, COCH=COCH3); öc 
(63 MHz, DEPT, CDC1 3) 21.2 (C(CH3CBHA, 27.9 (OC(CFI3)3), 28.8 
(C(CAH3CBHA, 30.6 (CH2CO2(CH3)3), 35.5 (C(CH3)2), 44.2 (C.H2C(CH3) 2), 52.8 
(CHCH2CO 2(CH3 )3), 55.5 (OCH3), 80.1 (OC(CH3)3), 100.7 (COCH=COMe), 172.6 
(CO2(CH3)3), 175.1 (COCH=COCH 3), 198.8 (COCH=COCH3); MS FAB (+ve) 
found m/z 269 (MITF,  48 %), 291 (MNa); HRMS FAB (+ve) found m/z 269.17579 
(MH), C15H2 504 requires 269.17528. 
5.2.4.3 3-Methoxy-5,5-dimethyl-6-(3-methyl-but-2-enyl)-cyclohex-2-enone 53b 
OMe 
n-Butyllithium (1.6 M, 22.29 ml, 35.67 mmol) was added dropwise to a solution of 
dry diisopropylamine (5.00 ml, 35.67 mmol) in anhydrous THF (12.5 ml) at 0 °C. 
After 30 min the mixture was cooled to —78 °C and a solution of 3-methoxy-5,5-
dimethyl-cyclohex-2-enone 51 (5.00 g, 32.43 mmol) and dry DMPU (12.5 ml) in 
anhydrous THF (12.5 ml) was added dropwise. After stirring for 1.5 hrs at —78 °C, a 
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solution of 3,3-dimethylallyibromide 125 (7.00 ml, 60.73 mmol) and dry DMPU (2 
ml) in anhydrous THF (6 ml) was added dropwise and the mixture allowed to reach 
room temperature overnight. The reaction was quenched with saturated ammonium 
chloride solution (20 ml), diluted with ether (50 ml) and washed with 2M KHSO4 (20 
ml), water (20 ml), and saturated NaHCO 3 solution (20 ml). The combined aqueous 
phase was extracted with ether (2 x 20 ml), and the total organic phase washed with 
brine (30 ml), dried (MgSO 4) and rotary evaporated to give an orange oil (8.73 g). 
Flash column chromatography on silica gel using hexane/EtOAc (4:1-1:1) yielded a 
yellow oil (5.83 g, 81 %): v,( (neat) 1656.6 (a,/3-unsaturated ketone), 1616.1 (ring 
C=C); 8H (250 MHz, CDC1 3) 0.96 (3H, s, C(CAH3CH3)),  1.04 (3H, s, C(CAH 
3CBH3)), 1.56 (3H, s, CH=C(CAH3CBH3),  1.64 (3H, d, J 1.2, CH=C(CAH3CBH3),  1.97 
(1H, dd, J7.2, 5.9, COCHC(CH 3)2), 2.16 (111, d, J 17.5, CHAHBC(CH3)2),  2.19 (214, 
m, CH2CH=CMe2), 2.31 (1H, d, J 17.6, CHAI]13C(CH3)2),  3.64 (311, s, OCH3), 5.38 
(114, m, CH=CMe2), 5.25 (1H, s, COCH=COCH3); 8c  (63 MHz, DEPT, CDC1 3) 17.7 
(CH=C(CAH3 CBH3)), 24.4  (C(CAH30143)),  24.9 (CH2CH=CMe2), 25.7 
(CH=C(CAH3 d3H3)), 28.7 (C(CAH3  0H3)), 35.1 (C(CH3 )2), 41.6 (CH2C(CH3)2), 
55.4 (OCH3), 57.5 (COCHC(CH 3)2), 100.3 (COCH=COCH 3), 123.1 
(CH2CH=CMe2), 131.6 (CH=CMe2), 174.8 (COCH=COCH 3), 201.8 
(COCH=COCH3); MS FAB (+ve) found m/z 223 (M1H, 100 %), 207 (M-CH 3 , 50); 
HRMS FAB (+ve) found m/z 223.16977 (MW), C 14H2302 requires 223.16981. 






n-Butyllithium (1.6 M, 17.87 ml, 28.53 mmol) was added dropwise to a solution of 
dry diisopropylamine (4.00 ml, 28.53 mmol) in anhydrous THF (10 ml) at 0 °C. 
After 30 min the mixture was cooled to —78 °C and a solution of 3-methoxy-5,5-
dimethyl-cyclohex-2-enone 51(4.00 g, 25.94 mmol) and dry DMPU (10 ml) in 
anhydrous THF (10 ml) was added dropwise. After stirring for 1 hr at —78 °C, a 
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solution of ethyl bromoacetate (3.16 ml, 28.53 mmol) and dry DIVIPU (1.5 ml) in 
anhydrous THF (5 ml) was added dropwise and the mixture allowed to reach -45 °C 
and kept at this temperature for 1 hr. The reaction was quenched with saturated 
ammonium chloride solution (20 ml), diluted with ether (50 ml) and washed with 2M 
KHSO4 (20 ml), water (20 ml) and saturated NaHCO 3 solution (20 ml). The 
combined aqueous phase was extracted with ether (2 x 20 ml), and the total organic 
phase washed with brine (30 ml), dried (MgSO 4), and rotary evaporated to give a 
viscous yellow oil (6.43 g). Flash column chromatography on silica gel using 
hexane/EtOAc (4:1) yielded a yellow oil (3.79 g, 61 %): Vmax (neat) 1733.7 (ester), 
1658.5 (a,/1-unsaturated ketone), 1617.0 (C=C); 8H  (250 MHz, CDC1 3) 0.84 (3H, s, 
C(CAH3 CBH3)) ,  1.07 (3H, s, C(CAH30H3)),  1.24 (3H, t,J7.1 OCH2CH3), 2.11 (1H, 
d, J 17.4, CHAH3C(CH3)2),  2.21 (1H, dd, J 16.0, 4.2, CHAHBCO2Et),  2.53 (1H, dd, J 
17.4, 1.2, CHAHI3C(CH3)2),  2.67 (1H, dd, J 16.0, 8.6, CH'H'3CO2Et), 2.83 (1H, dd, J 
8.6, 4.2, CHCH2CO2Et), 3.64 (314, s, OCH3), 4.13 (2H, m, OCH2CH3), 5.32 (111, d, J 
1.7, COCH=COCH3); 6c  (63 MHz, DEPT, CDC13) 14.1 (OCH2CH3), 21.1 
(C(CkH3 CBHA, 28.7  (C(CAH3d3H3)),  29.4 (CIT2CO2Et), 35.5 (C(CH3)), 44.2 
(CH2C(CH3)2), 52.8 (CHCH2CO2Et), 55.6 (OCH3), 60.4 (OGH2CH3), 100.6 
(COCIHI=COCH3), 173.4 (CO2Et), 175.2 (COCH=COCH 3), 198.6 (COCH=COCH 3); 
MS FAB (+ve) found m/z 241 (M}T, 52 %), 195 (MtOEt, 100); JIRMS FAB (+ve) 
found m/z 241.14349 (MH), C1 3H2104 requires 241.14398. 





n-Butyllithium (1.6 M, 4.46 ml, 7.14 mmol) was added dropwise to a solution of dry 
diisopropylamine (1.Olml, 7.14 mmol) in anhydrous T1{F (5.5 ml) at 0 °C. After 30 
min the mixture was cooled to —78 °C and a solution of 3-methoxy-5,5-dimethyl-
cyclohex-2-enone 51 (1.00 g, 6.49 mmol) and dry DMPU (1.68 ml, 19.50 mmol) in 
anhydrous THF (7.0 ml) was added dropwise. After stirring for 1 hr at —78 °C, a 
solution of 2-bromoacetophenone (1.29 g, 6.48 mmol) in anhydrous THF (1.5 ml) 
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was added dropwise and the mixture allowed to reach room temperature overnight. 
The reaction was quenched with water (2.5 ml), diluted with ether (25 ml), and 
washed with 2M HC1 (3 x 25 ml), then water (25 ml). The combined aqueous phase 
was extracted with ether (2 x 25 ml), and the total organic phase washed with brine 
(25 ml), dried (MgSO4) and rotary evaporated to give a brown oil (1.55 g). Flash 
column chromatography on silica gel using DCMlhexane (7:3) yielded a yellow oil 
(0.05 g, 23 %): v x (neat) 1685.5 (PhC=O), 1653.7 (a,/3-unsaturated ketone), 1616.1 
(C=C); oH (250 MHz, CDC13) 0.93 (3H, s, C(CAH3CBH3)),  1.08 (311, s, C(CAH 
3CBH3)) ,  2.17 (111, d, J 173, CHAHBC(CH3)2),  2.68 (1H, dd, J 17.3, 1.3, 
CHAHBC(CH3)2), 2.70 (1H, dd,J 17.1, 4. 1, CHAHBCOPh),  3.26 (1H, dd,J7.5, 4. 1, 
CHCH2COPh), 3.69 (1H, dd, J 17.1, 7.5, CH1HBCOPh),  3.73 (311, s, OCH3), 5.37 
(1H, d, J 1.8, COCH=COCR3), 7.41-7.54 (3H, m, Ar-H), 7.99-8.03 (2H, m, Ar-H); 
8c (63 MHz, DEPT, CDC13) 21.3 (C(CAH3CBH3)),  29.0  (C(CAH3d3H3)),  33.0 
(CH2COPh), 357 (C(CH3)), 44.4 (CH2C(CH3)2), 52.0 (CHCH 2COPh), 55.6 (OcHI3), 
100.7 (COCH=CO), [128.1 (CH), 128.4 (CH), 132.6 (CH), 5C, Ar-H], 137.3 
(COPh), 175.3 (COCH=COCH3), 198.9 (COPh), 199.2 (COCH=COCH 3); MS ES 
(+ve) found m/z 273 (MH, 44 %); HRMS FAB (+ve) found m/z 273.14944 (ME), 
C 17H21 03 requires 273.14907. 
5.2.5 Enol Ether Hydrolysis 
5.2.5.1 (2,2-Dimethyl-4,6-dioxo-cyclohexyl)-acetic acid ethyl ester 45e 
oc) L0 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid ethyl ester (53c) (0.55 
g, 2.29 mmol) was dissolved in THF (20 ml) and 2M HC1 (20 ml) slowly added. The 
mixture was then stirred at room temperature overnight. The solvent was removed in 
vacuo and the residue taken up in EtOAc (50 ml) and washed with saturated 
NaHCO3 solution (25 ml), then water (25 ml). The aqueous phase was extracted 
with EtOAc (2 x 25 ml) and the total organic phase washed with brine (30 ml), dried 
(MgSO4) and rotary evaporated to give a yellow oil (0.54 g). Flash column 
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chromatography on silica gel using hexane/EtOAc (4:1-1:1) as eluent yielded a 
yellow oil (0.31 g, 60 %): v,, ( (CHC13) 1726.9, 1608.3; 8H  (360 MHz, CDC13) 0.71 
(3H, s, C(CAH3CB1-13)),  1.17 (314, s, C(CAH3CBH3)),  1.27 (3H, t, J 7. 1, CH3CH20), 
2.38 (1H, dd, J 16.8, 3.6, CI?HBCO2Et),  2.48 (1H, dd, J 14.7, 2.5, CHAHBC(CH3)2) , 
2.77 (1H, dd, J 16.8, 9.5 CH"R8CO2Et), 2.77 (1H, td, J 14.7 9  0.9 CHAHBC(CH3)2), 
3.21 (1H, dd, J 9.5, 3.6, CHCH2CO2Et), 3.34 (lH, dd, J 16.5, 2.5, COCHAHBCO), 
3.57 (1H, td, J 16.5, 0.9 COCHAHBCO),  4.16 (2H, m, CH3CH20); 5 c (63 MHz, 
DEPT, CDC13) 14.1 (CH3 CH20), 21.5 (C(CAH3CBHA,  28.3  (C(CAH3d3H3)),  28.8 
(CH2CO2Et), 33.4 (C(CH3)), 55.6 (CHCH2CO2Et), 56.0 (CH2C(CH3)2), 58.1 
(COCH2CO), 60.8 (CH3CH 20), 172.6 (CO2Et), 202.6 (COCH 2CO), 202.8 
(COCH2CO); MS FAB (+ve) found m/z 227 (MH, 87 %), 249 (MNa, 66), (Mt 
OEt, 84); HRMS FAB (+ve) found m/z 227.12786 (MM), C12H1904 requires 
227.12833. 
5.2.5.2 5,5-Dimethyl-4-(2-oxo-2-phenyl-ethyl)-cyclohexane-1 ,3-dione 45a 
Oy- 
3-Methoxy-5 ,5-dimethyl-6-(2-oxo-2-phenyl-ethyl)-cyclohex-2-enone 53d (0.20 g, 
0.73 mmol) was dissolved in anhydrous THF (20 ml) and 2M HC1 (20 ml) added. 
The resulting solution was stirred at room temperature overnight. The reaction 
mixture was diluted with DCM (50 ml) and the layers separated. The organic phase 
was washed with saturated NaHCO3 solution (25 ml), water (25 ml) and brine (25 
ml), then dried (MgSO4) and rotary evaporated to give an orange oil (0.13 g, 69 %): 
oH (360 MHz, CDC1 3) 0.78 (3H, s, C(CAH3CBH3)),  1.18 (3H, s, C(CAH3CJ3H3)),  2.51 
(1H, dd, J 14.7, 2.5, CHAHBC(CH3)2),  2.84 (1H, d, J 14.7, CH1I]BC(CH3)2),  2.84 
(1H, dd, J 17.2, 2.7 CHAHBCOPh),  3.34 (1H, dd, J 16.4, 2.5, COCHAHBCO),  3.57 
(1H,dd, J9.0, 2.5, CHCH2COPh), 3.63 (1H, d )  J 16.4, COCHAHBCO),  3.65 (1H, dd, 
J 17.2, 9.0, CHAIII3COPh),  7.42-7.60 (311, m, Ar-H), 7.99-8.02 (2H, m, Ar-H); Oc 
(63 MHz, DEPT, CDC13) 21.9 (C(CAH3CBHA,  28.6  (C(CAH3d3H3)),  32.5 
(CH2COPh), 33.5 (C(CH3)), 54.7 (CHCH 2COPh), 56.2 (CH2C(CH3)2), 58.3 
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(COCH2CO), [128.0 (CH), 128.6 (CH), 133.2 (CH), SC, Ar-H], 136.7 (COP/i), 198.2 
(COPh), 202.8 (COCH2CO), 202.9 (COCH2CO); MS FAB (+ve) found m/z 259 
(MH, 3.5 %), 281 (MNa, 6 %); HRMS FAB (+ve) found m/z 259.13349 (Mu), 
C16H 1 903 requires 259.13342. 
5.2.6 Synthesis of Bromomethylketones - Method 1 





1,1-Carbonyldiimidazole (2.30 g, 14.18 mniol) was added to a stirred solution of 
CBz-L-alanine 54a (3.00 g, 13.44 mmol) in anhydrous THF (45 ml), and the 
resulting mixture stirred at room temperature for 1 hr. Meanwhile, n-butyllithium 
(2.5 M, 16.90 ml, 42.25 mmol) was added dropwise to a stirred solution of dry 
diisopropylamine (5.96 ml, 42.25 mmol) in anhydrous THF (30 ml) at 0 °C. After 
30 min this mixture was cooled to —78 °C and a solution of tert-butyl acetate (5.69 
ml, 42.25 mmol) in anhydrous THF (10 ml) added dropwise. After stirring the 
lithium enolate solution for 1 hr at —78 °C, the imidazole solution was added 
dropwise and the resulting mixture stirred at —78 °C for 40 mm. The reaction was 
quenched with 1M HC1 (100 ml) and extracted with EtOAc (3 x 50 ml). The total 
organic phase was washed with brine (100 ml), dried (MgSO 4), passed through a 
short silica pad and rotary evaporated to give an orange oil (4.00 g). Flash column 
chromatography on silica gel using hexane/EtOAc (4:1) yielded an orange oil (2.43 
g, 56 %): 8H  (250 MIHz, CDC13) 1.60 (3H, d, J7.2, CaCH3), 1.69 (9H, 5, OC(CH3)3), 
3.66 (111, d, J 15.8, COCHAHBCO),  3.73 (1R, d, J 15.8 COCHAIIBCO),  4.70 (1H, m, 
C,,,-H), 5.32 (2H, s, CH2Ph), 5.89 (1H, d, J 7.4, NH), 7.57 (5H, s, Ar-H); 8 C (63 
MHz, DEPT, CDC13) 17.0 (C aCH3), 27.8 (OC(CH3)3), 47.0 (COGH2CO), 55.6 (Ca), 
66.8 (CH2Ph), 82.2 (OC(CH 3)3), [127.9 (CH), 128.1 (CH), 128.4 (CH), SC, Ar-HI, 
136.1 (CH2Ph), 155.6 (CONH), 165.9 (CO2(CH 3)3), 202.1 (NHC(CH3)CO); MS 
FAB (+ve) found 322 (M1H, 17 %); HRMS FAB (+ve) found m/z 322.16553, 
C1 7H24N05 requires 322.16545. 
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5.2.6.2 (S)-(3-Bromo-1-methyl-2-oxo-propyl)-carbamic acid benzyl ester 36a 
0 Me 
Solid N-bromosuccinimide (0.83 g, 4.66 mmol) was added to a solution of (S)-4-
benzyloxycarbonylamino-3-oxo-pentanoic acid tert-butyl ester 57 (1.50 g, 4.66 
mmol) and 2,6-lutidine (0.054 ml, 0.46 mmol) in anhydrous methanol (9.30 ml). The 
mixture was stirred at room temperature for 2.5 hrs, then stored in the freezer for 20 
hrs. EtOAc (70 ml) was added and the mixture extracted with 50 % saturated brine 
(28 ml), and then saturated brine (28 ml). The total organic phase was dried 
(MgSO4) and rotary evaporated to give a pale red oil (1.76 g). This was dissolved in 
benzene/TFA (8:1) (30 ml) and heated under reflux for 2 hrs. After cooling, the 
reaction was washed with water (2 x 14 ml), saturated NaHCO 3 solution (2 x 14 ml) 
and brine (2 x 14 ml). The total organic phase was dried (MgSO 4) and rotary 
evaporated to give a pale orange solid (0.84 g). Recrystallisation from 
hexane/EtOAc yielded a white solid (0.5 g, 36 %): mp 82-84 °C [lit.' 01 83-84 °C]; 8H 
(250 MHz, CDC13) 1.40 (311, d, J 7.2, CaCH3), 4.02 (1H, d, J 13.4, COCHAHBBr) , 
4.08 (111, d, J 13.4 COCHAHBBr),  4.65 (111, m, Ca-H), 5.10 (2H, S, CH2Ph), 5.52 
(1H, d, J 5.5, NH), 7.34 (5H, s, Ar-H); 8C (63 MIHz, DEPT, CDCI 3) 17.7 (CaCH3), 
31.4 (COCH2Br), 53.5 (Ca), 67.1 (CH2Ph), [128.1 (CH), 128.2 (CH), 128.5 (CH), 
SC, Ar-H], 136.0 (CH2Ph), 155.6 (CONH), 201.0 (NHC(CH3)CO); MS FAB (+ve) 
found 300, 302 (MB, 34 %), 256, 258 (IVIHtCO2, 7); HRMS FAB (+ve) found m/z 
300.02389, 302.02129, C12H, 5NO3Br requires 300.02353, 302.02161. 
5.2.7 Phthaloylation of Amino Acids 
5.2.7.1 3-Chloro-3-(dimethoxyphosphoryl)isobenzofuran-1 (3H)-one 62 
9 
Cl POM e)2 
0 
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Trimethyl phosphite 61(8.14 ml, 69.01 mmol) was added dropwise to neat phthaloyl 
dichloride 60 (9.94 ml, 69.01 mmol) over 25 mins at such a rate that the temperature 
was kept below 50 °C. The mixture was then stirred at room temperature for 15 
mins until gas evolution had ceased. Excess trimethyl phosphite was removed in 
vacuo and the pale yellow residue triturated with ether to afford a white crystalline 
solid (13.9 g, 73 %): mp 71-75 °C [lit) 03 78-80 °C]; 8. (250 MIHz, CDC13) 3.71 (3H, 
d, J 10.6, OCH3), 4.05 (3H, d, J 10.6, OCH3), 7.68-7.96 (411, m, Ar-H); MS ES (+ve) 
found m/z 299 (MNa, 100 %). 






3-Chloro-3-(dimethoxyphosphoryl)isobenzofuran- 1(3H)-one 62 (12.16 g, 43.96 
mmol) and L-alanine 63 (4.11 g, 46.17 mmol) were dissolved in MeCN/1120 (200 
ml, 1:1), and DIPEA (30.63 ml, 175.84 mmol) added. The mixture was stirred at 
room temperature for 40 mins when TLC showed no trace of starting material. The 
mixture was concentrated in vacuo to a small volume, acidified to pH 1 with 2M 
HC1, and cooled to 0 °C for 30 mins. The white precipitate formed was filtered, 
washed with ice-cold 2M HC1 and dried in vacuo over P205 to afford a white solid 
(8.10 g, 84 %): [aID —23 (c 1.0, EtOH) [lit. 114 [a]D -22.5 (c 1.0, EtOH)J; mp 145-147 
°C [lit.' ° 152-154 °C]; 8H (250 MHz, CDC1 3) 1.70 (3H, d, J7.4, CH3), 5.02 (1H, q, J 
7.4, C,-R), 7.67-7.75 (2H, m, Ar-H), 7.81-7.88 (211, m, Ar-H), 9.62 (111, br, 011); 
(63 MHz, DEPT, CDCI3) 15.0 (CH 3), 47.2 (CCH3), [123.5 (CH), 2C, Ar-H], 131.7 
(ArCO), [134.2 (CH), 2C, Ar-H], 167.3 (CONCO), 175.4 (CO 2H); MS ES (+ve) 
found m1z218 (MM, 100 
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5.2.8 Dibenzylation of Amino Acids 
5.2.8.1 (S)-2-Dibenzylamino-propionic acid ethyl ester 65 
Me 
Bn2N'( OR 
To a solution of L-alanine ethyl ester hydrochloride 40a (4.80 g, 31.25 mmol) and 
DIPEA (11.43 ml, 65.62 mmol) in anhydrous DCM (150 ml) was added benzyl 
bromide (7.81 ml, 65.62 mmol) dropwise. The solution was then heated under reflux 
overnight. The mixture was allowed to cool, then washed with water (50 ml), 
saturated NaHCO3 solution (2 x 50 ml) and brine (50 ml). The total organic phase 
was dried (MgSO4) and rotary evaporated to give an orange oil (8.60 g). Flash 
column chromatography on silica gel using hexane/EtOAc (4:1) as eluent yielded a 
yellow oil (6.00 g, 65 %) which was contaminated with some beazyl bromide 
starting material: Vmax (neat) 1729.8 (ester); 6H  (250 MHz, CDC13) 1.57 (311, d, J7.1, 
Ca CH3), 1.57 (3H, t, J 7. 1, OCH2CH3), 3.74 (1H, q, J 7. 1, C"'—H), 3.90 (211, d, J 
14.0, CH2Ph), 4.10 (211, d, J 14.01  CH2Ph), 4.45 (2H, q, J7.1 OCH2CH3), 7.44-7.66 
(1 OH, m, Ar-H); öc (63 MHz, DEPT, CDC13) 14.5 (Ca-CH3), 14.9 (OCH 2 CH3), 54.4 
(CH2Ph), 56.1 (Ca-H), 60.1 (OCH2CH3), [126.9 (CH), 128.2 (CH), 128.6 (CH), IOC, 
Ar-H], 139.9 (PhCH2), 173.6 (CO2Et); MS FAB (+ve) found m/z 298 (M}f, 98 
224 (MtCO2Et, 100). 




To a stirred solution of methyl-(S)-lactate 66 (2.29 ml, 24.01 mmol) in anhydrous 
DCM (50 ml) at 0 °C was added triflic anhydride (4.44 ml, 26.41 mmol) followed by 
2,6-lutidine (3.07 ml, 26.41 mmol). After stirring for 15 mins at 0 °C, a solution of 
dibenzylamine (14.31 ml, 74.44 mmol) in anhydrous DCM (25 ml) was added 
dropwise. The resulting mixture was stirred for 2 hrs at room temperature. The 
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mixture was concentrated in vacuo and the residue dissolved in hexane. This caused 
a yellowish solid to precipitate, which was filtered off and the filtrate passed through 
a short silica pad using ether as eluent. Evaporation of the ether yielded an orange 
oil (5.80 g, 85 %): [aID +98.2 (c 2.2, CRC13) [lit- 105 [aID +88.5 (c 2.2, CHC13)]; Vmax  
(neat) 1734.2 (ester); oH (250 MHz, CDC13) 1.53 (311, d, J7.1, Ca—CH3), 3.71 (111, 
q,J7.1, Q,—R), 3.83 (2H, d,J14.0, CH2Ph), 3.93 (3H, 5, OCH3), 4.03 (2H, d,J14.0, 
CH2Ph), 7.42-7.60 (1011, m, Ar-H); 0c  (63 MHz, DEPT, CDC1 3) 15.00 (Ca-Gil3), 
51.2 (OCH3), 54.4 (GH2Ph), 56.1 (CaH), [126.9 (CH), 128.2 (CH), 128.6 (CH), 
1OC, Ar-H], 139.8 (PhCH2), 174.2 (CO2Me); MS ES (+ve) found m/z 284 (MH, 100 
%). 
5.2.9 Synthesis of Bromomethylketones - Method 2 





N-Methyl-para-toluenesulfonamide 68 (25.00 g, 134.95 mmol) was dissolved in 
acetic acid (250 ml) and the solution cooled to 0 °C. A solution of sodium nitrite 
(13.97 g, 202.43 mmol) in water (65 ml) was then added dropwise with vigorous 
stirring. The mixture was stirred at 0 °C for 20 mins, then diluted with water (500 
ml). The yellow precipitate that formed was filtered off and dried in vacuo over 
P205 to provide a yellow crystalline solid (27.20 g, 94 %): mp 60-62 °C [lit. 148 60.5-
61.5 °C]; vna, (CHC13) 1504.7 (N=O), 1377.9 (SO2 anti-sym), 1171.5 (SO2 sym); 0H 
(250 MHz, CDC13) 2.44 (3H, s, CH3-Ar), 3.11 (3H, s, N-CH3), 7.37 (211, d, J8.6, Ar-
II), 7.86 (2H, d, J8.6, Ar-H); 0c  (63 MHz, DEPT, CDC13) 21.7 (CH3-Ar), 28.8 (N-
CH3), [127.9 (CH), 130.3 (CH), 4C, Ar-H], 134.0 (Ar-CH 3), 146.1 (Ar-S02); MS ES 
(+ve) found m/z 215 (MH, 4 %), 237 (MNa, 7). 
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5.2.9.2 2-((S)-3-Diazo-1 -methyl-2-oxo-propyl)-isoindole-1 ,3-dione 71 
0 Me 
J N(N 
To a solution of N-phthaloyl-L-alanine 64 (1.00 g, 4.56 mmol) in anhydrous DCM 
(15 ml) at 0 °C was added oxalyl chloride (0.60 ml, 6.84 mmol) followed by 3 drops 
of anhydrous DMF. The resulting solution was stirred at 0 °C for 2.5 hrs and the 
volatiles removed in vacuo. Diazomethane was prepared by adding a solution of 
Diazald® 69 (5.00 g) in ether (45 ml) dropwise to a mixture of KOH (2.5 g), water 
(4 ml) and diethylene glycol mono-ethyl ether (14 ml) held at 50 °C. The distilled 
ethereal diazomethane solution (-j 50 ml, 16.6 mmol) was collected at 0 °C and the 
crude acid chloride, dissolved in anhydrous DCM (15 ml), added dropwise to it. The 
mixture was stirred at room temperature for 2.5 hrs and excess diazomethane 
destroyed by a few drops of acetic acid. Saturated NaHCO 3 solution (25 ml) was 
added and the aqueous phase extracted with ether (2 x 15 ml). The total organic 
phase was washed with brine (25 ml), dried (MgSO 4) and rotary evaporated to give a 
orange oil (1.11 g). Flash column chromatography on silica gel using hexane/EtOAc 
(7:3) as eluent yielded a yellow oil (0.95 g, 86 %): [aD] —84 (c 0.5, CHC13) [lit. 149 
[CCD] —88.5 (c 0.5, EtOAc)]; Vmax (nujol) 2110.7 (NN), 1778.5 (lactam), 1723.1 
(ketone), 1644.0 (CN'); 6H  (250 MHz, CDC13) 1.65 (3H, d, J 7.3, Ca—CH3), 4.89 
(1H, q, J7.3, Ca-H), 5.41 (1H, s, CHN2), 7.69-7.77 (2H, m, Ar-I]), 7.81-7.86 (2H, m, 
Ar-H); öc (63 MHz, DEPT, CDC13) 14.5 (Ca-CH3), 52.2 (C-H), 53.8 (CH), [123.5 
(CH), 2C, Ar-H], 131.7 (ArCO), [134.3 (CH), 2C, Ar-H], 167.5 (CONCO), 190.1 
(COCHN2); MS FAB (+ve) found m/z 244 (MH, 47 %), 266 (MNa, 14), 216 
(IVIHtN2, 92), 174 (MtCOCHN2, 100); HRMS FAB (+ve) found m/z 244.07200 
(MH4), C 12H, 0N303 requires 244.07222. 
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5.2.9.3 2-((S)-3-Bromo-1-methyl-2-oxo-propyl)-isoindole-1 ,3-dione 72 
0 Me 
()4N_'YrBr 
To a solution of 2-((5)-3 -Diazo- 1 -methyl-2-oxo-propyl)-isoindole- 1,3 -dione 71 (1.62 
g, 6.66 minol) in DCM (80 ml) at 0 °C was added 48 % I{Br (1.50 ml, 13.32 mmol) 
dropwise. The reaction was stirred at room temperature overnight and saturated 
NaHCO3 solution (80 ml) added. The aqueous phase was extracted with DCM (2 x 
40 ml), and the total organic phase washed with brine (50 ml), dried (MgSO4) and 
rotary evaporated to give an off-white solid (1.68 g, 85 %): {a]D -41.5 (c 1.3, CHC13) 
[lit. 150 [a]D -36.61 (c 1.3, CHC13)]; mp 77-79 °C [lit. 150  70-71 'Cl; Vmax (nujol) 
1779.0 (lactam), 1713.4 (ketone); 6j  (250 MHz, CDC13) 1.64 (3H, d, J 7.2, CH3), 
3.96 (1H, d, J 12.8, CHAHBBr),  4.01 (1H, d, J 12.8, CHAHBBr),  5.18 (111, q, J 7.2, 
Ca-H), 7.71-7.79 (2H, m, Ar-H), 7.84-8.08 (2H, m, Ar-H); öc (63 MHz, DEPT, 
CDC13) 14.5 (Ca CH3), 30.8 (GH2Br), 51.6 (Ca-H), [123.7 (CH), 2C, Ar-H], 131.7 
(ArCO), [134.5 (CH), 2C, Ar-H], 167.4 (CONCO), 197.5 (COCH2Br); MS FAB 
(+ve) found m/z 296, 298 (MJ{4 , 97 %); FIRMS FAB (+ve) found m/z 295.99261 
(MH), 297.99099 (MH), C 12H,,BrNO3 requires 295.99223, 297.99031. 
5.2.10 Synthesis of Bromomethylketones - Method 3 




A solution of (R)-2-dibenzylamino-propionic acid methyl ester 67 (0.50 g, 1.76 
mmol) and dibromomethane (0.50 ml, 7.05 mmol) in anhydrous THF (20 ml) was 
cooled to —78 °C and n-butyllithiurn (1.6 M, 4.41 ml, 7.05 mmol) added dropwise. 
The solution was then stirred at —78 °C for 30 mins. Saturated ammonium chloride 
solution (10 ml) was added and the reaction allowed to warm to room temperature. 
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The mixture was then extracted with ether (3 x 7 ml) and the total organic phase 
dried (MgSO4) and rotary evaporated to give a gummy orange solid (0.719): 5 H (250 
MHz, CDC13) 1.22 (3H, d, J6.7, CaCH3), 3.44 (2H, d, J 13.5, CH2Ph), 3.64 (1H, q, 
J6.7, C(,,—H), 3.70, (2H, d, J 13.5, CH2Ph), 4.15 (1H, d, J 13.2 CH HBBr) ,  4.23 (1H, 
d, J 13.2 CH'H'Br), 7.30-7.37 (1 OH, m, Ar-I-i); MS FAB (+ve) found m/z 346, 348 
(TV1H, 23 %), 368 (MNa, 100). 
5.2.11 Synthesis of Enol Ether Derivatives from Dimedone Isomer 
4,4-Dimethylcyclohexane-1,3-dione 76 (5.00 g, 35.70 mmol) was dissolved in 
anhydrous methanol (45 ml) and chlorotrimethylsilane (4.75 ml, 37.40 mmol) added. 
DIPEA (13.05 ml, 74.90 mmol) was then added dropwise and the mixture stirred at 
room temperature overnight. The methanol was removed in vacuo and the residue 
dissolved in EtOAc (50 ml), washed with water (25 ml), saturated NaHCO 3 solution 
(25 ml), and then brine (25 ml). The organic phase was dried (MgSO 4) and rotary 
evaporated to give a pale yellow liquid (4.77 g). Flash column chromatography on 
silica gel using hexane/EtOAc (4:1) as eluent yielded two yellow liquids: 
5.2.11.1 3-Methoxy-4,4-dimethyl-cyclohex-2-enone 77 
J:];~ OMe 
(1.22 g, 22 %): bp 90 °C (0.4 mBar) [lit.  151  46.8-48.9 °C (0.08 Ton)]; v 	(neat) 
1662.3 (a,/3-unsaturated ketone), 1595.8 (C=C); 6,-, (250 MHz, CDC1 3) 1.19 (611, s, 
C(CH3)2), 1.81 (2H, t, J6.4, CH2C(CH3)2), 2.40 (2H, t, J6.4, CH2COMe), 3.66 (311, 
s, OCH3), 5.25 (111, s, CH=COMe); 6c  (63 MHz, DEPT, CDC13) 25.6 (C(CH 3)2), 
33.8 (CH2C(CH3)2), 35.7 (C(CH3)), 36.3 (CH2CO), 55.8 (OCH3), 100.8 
(CH=COMe), 183.9 (COMe), 199.6 (CO); MS ES (+ve) found m/z 177 (MNa, 100 
%). 
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5.2.11.2 3-Methoxy-6,6-dimethyl-cyclohex-2-enone 78 
MeOj:::to 
(3.21 g, 58 %): bp 85 °C (0.3 mBar) [lit. 151 45.1-46.1 °C (0.08 Torr)]; v 	(neat) 
1650.8 (a,/3-unsaturated ketone), 1613.2 (C=C); 8H  (250 MHz, CDC13) 1.09 (6H, s, 
C(CH3)2), 1.78 (211, t, J6.4, CH2C(CH3)2), 2.41 (2H, t, J6.4, CH2COMe), 3.66 (3H, 
s, OCH3), 5.25 (1H, s, CH=COMe); 8c  (63 M.IHz, DEPT, CDCI 3) 24.5 (C(CH3)2), 
26.0 (CH2C(CH3 )2), 35.0 (CH2COMe), 40.2 (C(CH3)2), 55.6 (OCH3), 100.6 
(CFI=COMe), 176.4 (COMe), 204.3 (CO); MS ES (+ve) found m/z 155 (MB, 80 
%), 177 (MNa, 100). 
5.2.12 Enaminone Synthesis 
5.2.12.1 5,5-Dimethyl-3-pyrrolidin-1 -yl-cyclohex-2-enone 80 
a 
NZ~O 
Dimedone 33 (5.00 g, 35.67 mmol) and pyrrolidine (2.98 ml, 35.67 mmol) were 
dissolved in toluene (150 ml) and the solution refluxed overnight using a Dean-Stark 
trap to remove the water. The toluene was removed in vacuo to give an orange solid 
(6.75 g, 98 %): mp 125-128 °C [lit. 152 129-132 °C]; Vmax (CHC13) 1599.7 (a,,8 
unsaturated ketone), 1557.2 (C=C); oH (250 MHz, CDC13) 1.04 (6H, s, C(CH3)2), 
1.92 (4H, m, NCR2 CH2CH2CH2), 2.17 (211, s, CH2CO), 2.25 (2H, s, CH2CN), 3.18 
(211, m, NCH2CH2CH2CR2), 3.37 (211, m, NCH2CH2CH2CH2), 4.99 (111, s, 
CH=CN); 0c  (63 MHz, DEPT, CDC13) 24.6 (NCH2CH2CH2CH2), 25.2 
(NCH2CH2CThCH2), 28.6 (C(CH3)2), 32.6 (C(CH3)2), 41.7 (CH2CN), 47.8 
(NCH2CH2CH2 CH2), 49.5 (CHCO), 97.0 (CH=CN), 161.8 (CH=CN), 195.5 (CO); 
MS ES (+ve) found m/z 194 (MH, 100 %). 
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5.2.12.2 1-(3-Methoxy-5,5-dimethylcyclohex-2-enylidene)-pyrrolidine 81 
O+j OMe 
5 ,5-Dimethyl-3 -pyrrolidin- 1 -yl-cyclohex-2-enone 80 (1.00 g, 5.17 ml) was dissolved 
in methyl iodide (10 ml) and the solution gently refluxed overnight. Methyl iodide 
was removed in vacuo to give a bright yellow solid (1.70 g, 98 %): mp 121-125 °C 
[lit. 108 146-149.5 °C]; Vm (CHC13) 2438.6 (CN), 1584.2 (C=C); oH (250 MHz, 
DMSO-d6) 1.25 (611, s, C(CH3)2), 2.21 (411, m, NCH 2CH2CH2CH2), 2.62 (2H, s, 
CH2), 2.92 (211, s, CH2), 4.06 (4H, m, NCH2CH2CH2CH2), 4.16 (311, s, OMe), 6.08 
(111, s, CH=COMe); Oc  (63 MHz, DEPT, DMSO-d6) 23.9 (NCH 2CH2CH2CH2), 24.1 
(NCH2CH2CH2CH2), 33.2 (C(CH3)2), 31.6 (C(CH3)2), 38.9 (CR2), 41.6 (CH2), 51.9 
(NCH2CH2CH2CH2), 58.0 (OCH3), 94.0 (CH=COMe), 172.3 (COMe), 181.5 (CN); 
MS ES (+ve) found m/z 208 (M+-I, 100 %). 
5.2.13 Alternative Synthetic Route: Enaminones to Diazoketones 





Dimedone 33 (4.56 g, 32.55 mmol) and L-alanine ethyl ester hydrochloride 40a (5.00 
g, 32.55 mmol) were dissolved in toluene (150 ml) and acetic acid (5.5 ml) added. 
The solution was then refluxed overnight using a Dean-Stark trap to remove the 
water. The toluene was removed in vacuo and the residue taken up in ether (50 ml) 
and washed with water (25 ml), then saturated NaHCO3 solution (2 x 25 ml). The 
aqueous phase was extracted with ether (2 x 25 ml) and the total organic phase 
washed with brine (25 ml), dried (MgSO4) and rotary evaporated to give a reddish oil 
(6.40 g, 82 %): [aID —35 (c 1.0, CHC13); Vm (CHC13) 3252.8 (N-H), 1739.0 (ester), 
150 
Chapter 5 	 Experimental 
1584.7 (a,#-unsaturated ketone), 1544.7 (C=C); 6H (250 MHz, CDC1 3) 1.01 (3H, s, 
C(CAH3CBH3)) ,  1.02 (311, s, C(CAH3CBH3)),  1.25 (3H, t, J7.2, OC112CH3), 1.40 (3H, 
d, J7.0, Ca CH3), 2.13 (211, s, CH2CNH), 2.18 (2H, s, CH2CO), 4.05 (1H, q, J7.0, 
Ca 11), 4.17 (2H, q, J 7.2, OCH2CH3), 4.99 (111, s, CH=CNH), 5.18 (1H, d, J 6.6, 
NH); 8c  (63 MHz, DEPT, CDC13) 14.0 (Ca-CR3), 17.8 (OCH2CH3), 28.1 
(C(CA1130H3), 28.2  (C(CAH3cH3)),  32.8 (C(CH3)2), 43.3 (CR2CNH), 50.2 
(GH2CO), 50.5 (Ca-H), 61.7 (OCH2CH3), 96.4 (GH=CN}T), 160.9 (CNH), 172.6 
(CO2Bt), 197.0 (CO); MS ES (+ve) found m/z 239 (Iv1H, 100 %). 
5.2.13.2 (S)-2-(5,5-Dimethyl-3-oxo-cyclohex-1 -enylamino)-propionic acid 42a 
M:X(LO 
(S)-2-(5 ,5-Dimethyl-3 -oxo-cyclohex- 1 -enylamino)-propionic acid ethyl ester 41a 
(6.20 g, 25.90 inmol) was suspended in saturated NaHCO 3 solution (80 ml) and the 
suspension refluxed for 2.5 hrs after which time a homogeneous solution had formed. 
After allowing to cool, the solution was concentrated in vacuo and the residue 
acidified to pH 4 with 2M HC1. This caused a solid to precipitate which was filtered 
and dried over P205 to give an off-white solid (3.70 g, 68 %): mp 197-199 °C [lit. 112 
214-215 °C]; [a]D —51.3 (c 1.5, 1120) [lit. 112 [aID —128 (c 1.5, EtOH)]; v., (CHC1 3) 
3341.1 (N-H), 1721.6 (acid), 1552.4 (a,fi-unsaturated ketone); 8H (250 MHz, 
CD3 0D) 1.10 (611, S, C(CH02), 1.52 (311, d, J 7. 1, C(,,CH3), 2.21 (211, 5, CH2CNH), 
2.40 (2H, s, CH2CO), 4.14 (1H, q, J7.1, Ca-H); 6c (63 MHz, DEPT, CD 30D) 17.7 
(Ca CR3), 28.3 (C(cH3)2), 33.7 (C(CH)2), 43.4 (CH 2CNH), 50.4 (CTT2CO), 52.3 
(Ca H), 95.2 (CH=CNR), 167.8 (CNN), 175.4 (COOH), 199.3 (CO); MS ES (+ve) 
found m/z 212 (ME, 100 %), 234 (MNa, 89). 
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5.2.13.3 ((S)-3-Diazo-1 -methyl-2-oxo-propyl)-(5,5-dimethyl-3-oxo-cyclohex-1-
enyl) carbamic acid isobutyl ester 85 
0 
, 2Z 
(S)-2-(5,5-Dimethyl-3-oxo-cyclohex-1-enylamino)-propionic acid 42a (1.00 g, 4.73 
mmol) was suspended in anhydrous THF (20 ml) under dry nitrogen and the mixture 
cooled to -10 °C (ice/salt bath). N-Methylmorpholine (1.04 ml, 9.46 mmol) was 
added, followed by iso-butyl chloroformate (1.23 ml, 9.46 mmol) dropwise. The 
mixture was then stirred at -10 °C for 30 mins. The mixture was quickly filtered and 
the filtrate cooled to 0 °C. A concentrated ethereal solution of diazomethane 
[prepared as described in 5.2.9.2 using same quantities of reagents] was then added 
dropwise. The resulting yellow solution was allowed to warm to room temperature 
and stirred for 3 hrs. Excess diazomethane was destroyed by addition of a few drops 
of acetic acid. Saturated NaHCO3 solution (25 ml) was then added and the aqueous 
phase extracted with ether (2 x 15 ml). The total organic phase was washed with 
brine (25 ml), dried (MgSO4) and rotary evaporated to give a yellow oil (1.43 g). 
Flash column chromatography on silica gel using hexane/EtOAc (7:3) as eluent 
yielded a yellow oil (0.42 g, 26 %): 6H  (250 MHz, CDC13) 0.86 (6H, d, J 6.7, 
(CH3)2CH), 1.02 (3H, s, C(CAH3CBH3)),  1.03 (311, s, C(CAH3CBH3)),  1.40 (3H, d, J 
7.1, Ca CH3), 1.86 (1H, m, (CH3)2CH), 2.20 (2H, s, CH2CO), 2.36 (1H, dd, J 17.7, 
0.8, CAHCBHCN),  2.60 (1H, dd, J 17.7, 1.0, CAHCBHCN),  3.87 (2H, d, J 6.6, 
CH2000N), 4.44 (1H, q, J7.1, C,,,-H), 5.42 (1H, s, CH=CN), 5.81 (1H, s, CHN2); 
8c (63 MHz, DEPT, CDC13) 14.7: (Ca CEI3), 18.9 ((CH3)2CH), 27.6 (CH3)2CH), 27.7 
(C(CH3CBH3), 27.9  (C(CH3CBH3)),  33.6 (C(CH3)2), 44.2 (CHCN), 50.7 
(CH2CO), 53.4 (CHN), 61.5 (Ccx H), 72.9 (CH2000), 121.8 (CHCN), 153.6 
(OCON), 159.0 (CN), 191.7 (COCHN2), 199.3 (CO); MS El (+ve) found m/z 336 
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(MH, 10 %), 266 (MtCOCHN2, 38), 206 (M-0O2Bu'-N 2, 38), 166 (MIHt 
COCHN2-CO2Bu', 100); HRMS El (+ve) found m/z 335.18451 (M), C17H25N304 
requires 335.18398. 
5.2.13.4 (S)-2- [(5,5-Dimethyl-3-oxo-cyclohex-1-enyl)-isobutoxycarbonyl-
amino]- propionic acid methyl ester 86 
0 0 
MeXN O 
By-product from reaction 5.2.13.3. Isolated as a colourless oil (0.06 g, 4 %) by flash 
chromatography on silica gel using hexane/EtOAc (7:3) as eluent: Vmax (CHC13) 
1747.2 (ester), 1712.5 (carbamate), 1666.2 (a,/3-unsaturated ketone), 1621.8 (C=C); 
H (250 MHz, CDC13) 0.88 (611, d, J 6.7, (CH3)2CH), 1.03 (3H, s, C(CAH3 CB113)) , 
1.05 (3H, 5, C(CAH3CBH3)), 1.50 (311, d, J 7.2, CaCH3), 1.89 (1H, m, (CH3) 2CH), 
2.22 (2H, s, CH2CO), 2.42 (1H, dd, J 17.6, 0.7, CAHCBHCN),  2.62 (1H, dd, J 17.6, 
1.0, CAHCBHCN), 3.69 (3H, s, OCH3), 3.89 (2H, d, J6.5, CH2000N), 4.42 (1H, q, 
J 7.2, C,,,-H), 5.82 (111, s, CH=CN); 6c  (63 N41z, DEPT, CDCI 3) 15.7 (Ca-Gil3), 
19.0 ((CH3)2CH), 27.7 (CH 3)2 cH), 28.0 (C(CH 3)2), 33.6 (C(CH3)2), 44.1 (GH2CN), 
50.8 (CH2CO), 52.5 (OCH3), 58.2 (Ca-H), 72.9 (GH2000), 120.9 (CHCN), 153.5 
(OCON), 160.2 (CN), 171.2 (CO2Me), 199.7 (CO); MS El (+ve) found m/z 325 (M, 
38 %), 266 (MtCO2Me, 38), 224 (M-0O2Bu', 38), 166 (M1HtCOCHN2CO2Bu', 
100); HRMS El (+ve) found m/z 325.18892 (M), C171127N0 5 requires 325.18945. 
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Thionyl chloride (0.26 ml, 3.62 mmol) was slowly added to methanol (2 ml) cooled 
to -10 °C (ice/salt bath). N-Methyl-L-alanine hydrochloride 87 (0.50 g, 3.58 mmol) 
was then added in portions and the resulting mixture heated under reflux for 1 hr. 
The volatiles were removed in vacuo to give an orange oil (0.60 g, overweight): oH 
(250 MHz, CIDC1 3) 1.69 (3H, d, .17.1, Ca CH3), 2.77 (3H, t, J4.9, NCH3), 3.81 (3H, 
s, OCH3), 3.96 (111, m, Q,-H); 8c  (63 MHz, DEPT, CDC1 3) 14.2 (Ca-CH3), 30.8 (N-
CH3), 53.2 (0GU3), 56.0 (Ca-H), 169.0 (CO2Me); MS ES (+ve) found m/z 118 
(IvJiH 100%). 
5.2.13.6 (S)-2- L(5,5-Dimethyl-3-oxo-cyclohex-1 -enyl)-methyl-aminol-propionic 
acid methyl ester 89 
0Ot MeXN LO 
Me 
Dimedone 33 (0.48 g, 3.42 mmol) and crude N-Methyl-L-alanine methyl ester 88 
(0.40 g, 3.41 mmol) were dissolved in toluene (20 ml) and acetic acid (0.5 ml) added. 
The solution was then refluxed for 3 hrs using a Dean-Stark trap to remove the water. 
The toluene was removed in vacuo and the residue taken up in DCM (30 ml) and 
washed with water (10 ml), then saturated NaHCO 3 solution (2 x 10 ml). The 
aqueous phase was extracted with DCM (2 x 10 ml) and the total organic phase 
washed with brine (20 ml), dried (MgSO 4), and rotary evaporated to give a reddish 
oil (0.35 g). Flash column chromatography on silica gel using EtOAc as eluent 
yielded an orange oil (0.12 g, 15 %): [aID —112 (c 1.0, CHC13); Vmax (CHC13), 1743.8 
(ester), 1612.2 (a,fJ-unsaturated ketone), 1557.7 (C=C); 8H  (250 MHz, CDC13) 1.00 
(3H, 5, C(CAH3CBH3)), 1.01 (3H, 5, C(C'H3C'H3)), 1.39 (3H, d, J7.1, Ca CH3), 2.09 
(2H, s, CH2CO), 2.22 (2H, d, .1 3.3 CH2CNMe), 2.73 (3H, s, N-CH3), 3.66 (3H, s, 0- 
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CH3), 4.47 (1H, q, J 7. 1, Ca-B), 5.12 (1H, s, CH=CNMe); öc (63 MHZ, DEPT, 
CDC13) 15.4 (C,,,-CH,), 28.4 (C(CH3CBH3),  28.6  (C(CAH3d3H3)),  327 (C(CH3)2), 
32.8 (N-CH3), 40.6 (CH2CNMe), 49.1 (cH2CO), 52.4 (OCH3), 55.5 (Ca-H), 98.8 
(CH=CNMe), 163.4 (CNMe), 171.3 (CO 2Me), 196.8 (CO); MS FAB (+ve) found 
m/z 240 (MB, 100 %), 180 (MtCO2Me, 39); HRMS FAB (+ve) found m/z 
240.15928 (MW), C 1 3H22NO3 requires 240.15997. 
5.2.14 General Methods for Carbenoid-Mediated Ring-Closure 	- 
Method A 
To a solution of Rh2(OAc) 4 93 (6.6 mg, 2.5 mol %) in anhydrous DCM (10 ml) was 
slowly added a solution of diazoketone 85 (0.20 g, 0.60 mmol) in anhydrous DCM 
(10 ml). The resulting mixture was stirred at room temperature overnight, then 
passed through a short silica pad. The filtrate was reduced in vacuo to give the crude 
product, which was purified by flash column chromatography on silica gel using 
hexarie/EtOAc gradient as eluent. 
Method B 
As for Method A but reaction mixture refluxed for 1.5 hrs. 
Method C 
Diazoketone 85 (0.040 g, 0.12 mmol) was dissolved in anhydrous DCM (4 ml) in a 
microwave test-tube and Rh2(OAc)4 93 (1.3 mg, 2.5 mol %) added. The test-tube 
was sealed and heated using microwave power (300 W) for 5 mins at 100 °C. The 
solvent was removed in vacuo to give the crude product which was purified as for 
Method A. 
Method D 
As for Method C but using anhydrous toluene as the solvent. 
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Method E 
As for Method A but using Rh2(cap)4 95 (l.'3 mol %) as catalyst. 
Method F 
As for Method A but using Rh2(pfb)4 94 (1 mol %) as catalyst. 
5.2.15 Summary of Results for Diazoketone 85 
Method A: Two main products isolated: 
Yellow oil (0.02 g): 'H NMR complex and unassignable; MS ES (+ve) found m/z 
308 (MIH, 73 %), 340 (100). 
Yellow solid (0.03 g): oH (250 MHz, CDC13) 1.00 (6H, d, J6.7), 1.09 (611, s), 2.00 
(111, m), 2.13 (31-1, s), 2.30 (2H, s), 2.57 (2H, s), 3.78 (2H, d, J6.7); 8c  (63 MHz, 
DEPT, CDC13) 19.3, 28.5, 35.5, 37.3, 52.7, 81.0, 111.9, 115.4, 138.1, 139.6, 192.3; 
MS ES (+ve) found m/z 250 (100 %). 
Method B: Three main products isolated: 
i) and ii) as above. 
Yellow oil (0.02 g) possibly resulting from Wolff rearrangement 102: 0H  (250 
MIHz, CDC13) 0.93 (6H, d, J6.7, (CH3)2CH), 1.10 (3H, s, C(CAH3CBH3)),  1.13 (311, 
S, C(CAH3CBH3)) ,  1.55 (3H, d, J7.0, Ca CH3), 1.92 (111, m, (CH3)2CH), 2.28 (2H, s, 
CH2CO), 2.40 (1H, d, J 17.5, CAHCBHCN),  2.75 (111, dd, J 17.5, 1.2, CAHCBHCN) , 
3.94 (211, d, J6.6, CH2000N), 4.31 (111, q, J7.0, Ca-H), 4.38 (2H, m COCH2), 5.83 
(1H, s, CH=CN); Oc  (63 MHz, DEPT, CDC1 3) 14.3 (Ca CH3), 19.0 ((CH3)2CH), 27.8 
(CH3)2 CH), 28.4 (C(cH3)2), 33.9 (C(CH 3)2), 44.3 (CHCN), 50.7 (CH2CO), 62.3 
(Ca H), 65.8, 73.4 (CH2000), 120.1 (CH=CN), 153.3 (OCON), 159.7 (CN), 199.3 
(CO), 206.0 (ketone); MS ES (+ve) found m/z 326 (MH, 100 %), 348 (MNa, 31). 
Methods C and D gave similar results to above. Methods E and F gave 
predominantly compound with m/z 326. 
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5.2.16 Synthesis of Diazoketone Isomer 
5.2.16.1 2-(4,4-Dimethyl-3-oxo-cyclohex-1-enylamino)-propionic acid ethyl 
ester 104 
MeN'° 
4,4 Dimethyl-1,3-cyclohexanedione 76 (4.56 g, 32.55 mmol) and D/L-alanine ethyl 
ester hydrochloride 103 (5.00 g, 32.55 mmol) were dissolved in toluene (150 ml) and 
acetic acid (5.5 ml) added. The solution was then refluxed for 2.5 hrs using a Dean-
Stark trap to remove the water. The toluene was removed in vacuo and the residue 
taken up in EtOAc (50 ml) and washed with water (25 ml), then saturated NaHCO 3 
solution (2 x 25 ml). The aqueous phase was extracted with EtOAc (2 x 25 ml) and 
the total organic phase washed with brine (25 ml), dried (MgSO4) and rotary 
evaporated to give a gummy yellow solid which was triturated with ether to produce 
a collectable pale yellow solid (5.74 g, 74 %): mp 107-108 °C; (CHC1 3) 3290.9 
(N-H), 1735.6 (ester), 1591.0 (ci,fi-unsaturated ketone), 1542.8 (C=C); 8 11 (250 MHz, 
CDC13) 1.05 (3H, s, C(CAH3CBH3)),  1.07 (3H, s, C(CAH3CBH3)),  1.25 (3H, t, J 7. 1, 
OCH2CH3), 1.39 (3H, d, J 7.0, C-CH3), 1.76 (2H, t, J 6.3 CH2CMe2), 2.36 (2H, t, J 
6.3 CH2CNH), 4.02 (1H, q, J7.0, Ca-H), 4.14 (2H, q, J7.1, OCH2CH3), 4.88 (1H, 5, 
CH=CNB), 5.04 (1H, d, J 6.7, NH); 6c  (63 MHz, DEPT, CDC1 3) 14.0 (Ca-CH3), 
17.9 (OCH2CH3), 24.9 (C(CH3)2, 26.4 (CH2CNH), 35.5 (CH2CMe2), 39.5 (C(CH3)), 
50.4 (Ca-H), 61.7 (OGII2CH3), 96.2 (CHCNH), 160.7 (CNH), 172.7 (CO 2Et), 202.5 
(CO); MS FAB (+ve) found m/z 240 (MH, 100 %), 166 (MtCO2Et, 34); HRMS 
FAB (+ve) found m/z 240.15993 (MH), C 131122NO3 requires 240.15997. 
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5.2.16.2 2-(4,4-Dimethyl-3-oxo-cyclohex-1 -enylamino)-propionic acid 105 
0 OH 
Me~:N~ 	0 
2-(4,4-Dimethyl-3-oxo-cyclohex-1-enylamino)-propionic acid 104 (5.50 g, 22.98 
mmol) was suspended in saturated NaHCO 3 solution (70 ml) and the suspension 
refluxed for 2.5 hrs, after which time a homogeneous solution had formed. After 
allowing to cool, the solution was concentrated in vacuo and the residue acidified to 
pH 1 with 2M HC1. This caused a solid to precipitate which was filtered and dried 
over P205 to give a white solid (2.86 g, 59 %): mp 199-200 °C; Vmax (nujol), 1745.3 
(acid), 1606.41 (a,fl-unsaturated ketone), 1556.3 (CC); 6H  (250 IVIHz, D20) 0.95 
(6H, s, C(CH3)2), 1.31 (3H, d, J 7.2, C-CH3), 1.63 (211, t, J 6.5 CH2CMe2), 2.51 
(2H, t, J 6.7 CH2CNH), 4.29 (1H, m, Q,,-H); 6c  (63 MHz, DEPT, D 20) 16.7 (Ca 
CH3), 24.6 (C(CH 3)2), 26.8 (CH2CNH), 34.7 (CH 2CMe2), 37.3 (C(CH)2), 52.7 (C,- 
H), 174.7 (CNH), 176.1 (COOH), 198.2 (CO); MS FAB (+ve) found m/z 212 (MH, 
100 %), 166 (MtCO2H, 49); FIRMS FAB (+ve) found m/z 212.12822 (MW) 
C 11 H18NO3 requires 212.12867. 
5.2.16.3 (3-Diazo-1 -methyl-2-oxo-propyl)-(4,4-dimethyl-3-oxo-cyclohex-1 - 
enyl) carbamic acid isobutyl ester 106 
N 
Me NJC~O 
2-(4,4-Dimethyl-3-oxo-cyclohex-1-enylamino)-propionic acid 105 (1.00 g, 4.73 
mmol) was suspended in anhydrous THF (20 ml) under dry nitrogen and the mixture 
cooled to -10 °C (ice/salt bath). N-Methylmorpholine (1.04 ml, 9.44 mmol) was 
158 
Chapter 5 	 Experimental 
added, followed by iso-butyl chloroformate (1.22 ml, 9.44 mmol) dropwise. The 
mixture was then stirred at -10 °C for 30 mins. The mixture was quickly filtered and 
the filtrate cooled to 0 °C. A concentrated ethereal solution of diazomethane 
[prepared as described in 5.2.9.2 using same quantities of reagents] was then added 
dropwise. The resulting yellow solution was allowed to warm to room temperature 
and stirred for 3 hrs. Excess diazomethane was destroyed by addition of a few drops 
of acetic acid. Saturated NaHCO 3 solution (25 ml) was then added and the aqueous 
phase extracted with ether (2 x 15 ml). The total organic phase was washed with 
brine (25 ml), dried (MgSO4) and rotary evaporated to give a yellow oil (1.40 g). 
Flash column chromatography on silica gel using hexane/EtOAc (7:3) as eluent 
yielded a yellow oil (0.23 g, 14 %): Vmax (CHC13), 2111.7 (N=N), 1706.7 
(carbamate), 1662.3 (a,#-unsaturated ketone); 6H  (250 MHz, CDC13) 0.88 (6H, d, J 
6.7, (CH3)2CH), 1.08 (3H, s, C(CAH3CH3)),  1.09 (311, s, C(C'H3 C'3H3)), 1.40 (3H, 
d, J7.2, Ca CH3), 1.81 (2H, t, J6.2 CH2CMe2), 1.83 (1H, m, (CH3)2CH), 2.51 (111, 
m, CHAHBCN),  2.73 (1H, m, CHAHBCN),  3.87 (211, d, J6.5, CH2000N), 4.51 (1H, 
q, J 7.2, Ca-H), 5.45 (IH, s, CH=CN), 5.76 (1H, s, CHN2); 8c  (63 MHz, DEPT, 
CDC13) 14.8 (CCH3), 19.0 ((C11 3)2CH), 23.7 (CH3)2 CH), 23.8 (C(cFT3)2), 27.8 
(CH2CNH), 35.7 (CH2CMe2), 40.4 (C(CH3)2), 53.6 (cHN2), 60.7 (Ca-H), 72.8 
(CH2000), 122.9 (CH=CN), 153.8 (OCON), 158.5 (CN), 192.0 (COCHN2), 204.0 
(CO); MS FAB (+ve) found m/z 336 (MH, 11 %), 266 (MtCOCHN2, 20), 166 
(MHtCOCHN2CO2Bu', 92); FIRMS FAB (+ve) found m/z 336.19224 (M1H), 
C 17H26N304 requires 336.19233. 
5.2.17 Synthesis of Acid Derivative 
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Method A 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid tert-butyl ester 53a 
(4.84 g, 18.03 mmol) was dissolved in anhydrous DCM (45 ml) and trifluoroacetic 
acid (15 ml) and triethylsilane (7.2 ml, 45.08 mmol) added. The mixture was then 
stirred at room temperature for 2 hrs. The volatiles were removed in vacuo to give a 
yellow oil (6.00 g), which was purified by flash column chromatography on silica gel 
using hexane/EtOAc (1:1) as eluent to give a white solid (2.95 g, 77 %): mp 120-122 
°C (Found C, 62.3; H, 7.6; N, 0.08 %. C11H160 4 requires C, 62.2; H, 7.6; N, 0.0 %); 
Vmax (CHC13) 1709.6 (acid), 1652.7 (a,/3-unsaturated ketone), 1615.1 (CC); 8H  (250 
MIHz, CDC13) 0.86 (3H, s, C(CAH3CBH3)),  1.11 (311, s, C(CAH3CBH3)),  2.07 (1H, d, 
J 17.4, CHAHBC(CH3)2),  2.30 (1H, dd, J 15.5, 3.0, CHAHBCO2H),  2.55 (111, dd, J 
17.4, 1. 1, CHAHBC(CH3)2),  2.73 (1H, dd, J 15.5, 8.8, CHAIII3CO2H),  2.80 (1 H, dd, J 
8.8, 3.0, CHCH2CO2H), 3.68 (311, s, OCH3), 5.40 (111, d, J 1.6, COCH=CO), 9.70 
(1H, br, OH); 6c  (63 MHz, DEPT, CDC13) 20.9 (C(CAH3CBHA, 28.8 
(C(CAH3d3H3)), 29.6 (CH2CO2H), 35.8 (C(CH 3)2), 44.3 (CH2C(CH3)2), 52.6 
(C}TCH2CO2H), 55.8 (OCH3), 100.6 (COCH=CO), 176.1 (COCH=COCH 3), 178.2 
(CO2H), 199.4 (COCH=COCH 3); MS FAB (+ve) found m/z 213 (MH, 100 %), 235 
(MNa, 89), 195 (Mt-OH, 95); HRMS FAB (+ve) found m/z 213.11288 (ME'), 
C 1 1 H1704 requires 213.11268. 
Method B 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid tert-butyl ester 53a 
(12.48 g, 46.51 mmol) was dissolved in anhydrous DCM (100 ml) and zinc bromide 
(52.37 g, 232.54 mmol) added. The mixture was stirred at room temperature 
overnight. Water (500 ml) was added and the mixture stirred for a further 3 hrs. The 
layers were separated and the aqueous phase extracted with DCM (3 x 250 ml). The 
total organic phase was washed with brine (200 ml), dried (MgSO 4), and rotary 
evaporated to give a sticky white solid, which was recrystallised from 
EtOAc/Hexane to give a white crystalline solid (5.74 g, 58 %). The filtrate was 
reduced in vacuo and the residue triturated to give a second crop of white solid (2.83 
ftII 
Chapter 5 	 Experimental 
g, 29 %). Both crops gave NMR spectra identical to those of the product from 
Method A. 
5.2.18 Synthesis of Cyclised Ligands Incorporating Amines 
General Coupling Method 
To a solution of (4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 
(10 mmol) and amine/amino acid (10 mmol) in anhydrous DCM (80 ml) was added 
HOBt (15 mmol), EDCI (13 mmol), and DIPEA (20 mmol). The mixture was then 
stirred at room temperature overnight. The reaction was quenched with brine (40 ml) 
and extracted with DCM (3 x 20 ml). The total organic phase was dried (MgSO 4) 






Using the general method, allylamine 110 was coupled to (4-methoxy-6,6.-dimethyl-
2-oxo-cyclohex-3-enyl)-acetic acid 109 (0.50 g, 2.36 mmol) to give the crude 
product as a dark brown oil (1.14 g) after work-up. This was purified by flash 
column chromatography on silica gel using hexane/EtOAc (1:4) as eluent to give an 
orange solid (0.42 g, 71 %): mp 64-66 °C; Vmax (CHC13) 3320.8 (NH), 1653.7 (a,/3 
unsaturated ketone), 1615.1 (CC); 6H  (360 MHz, CDC13) 0.83 (3H, s, C(CAH 
3CBH3)), 1.13 (3H, s, C(CAH3CBH3)),  2.12 (1H, d, J 17.4, CHAHBC(CH3)2),  2.18 (111, 
dd, J 14.2,2.6, CHAHBCONH),  2.52 (1H, dd, J 17.4, 1.4, CHHBC(CH3)2),  2.54 (1H, 
dd, J 14.2, 8.8, CHAHBCONH),  2.70 (1H, dd, J 8.8, 2.6, CHCH2CONH), 3.66 (3H, s, 
OCH3), 3.84 (2H, m, NIHCH2), 5.10 (2H, m, NIHCH2CHCH2), 5.34 (1H, d, J 1.6, 
COCH=CO), 5.81 (1H, m, NHCH2CHCH 2), 6.50 (1H, br, NH); 8 C (63 MHz, DEPT, 
CDC13) 21.0(C(CAH3CBH3)), 28.8  (C(CAH3d3H3)),  31.9 (CH2CONH), 36.1 
(C(CH3)2), 41.9 (NHCH2), 44.2 (CH2C(CH3)2), 53.5 (CHCH2CONH), 55.7 (OCH3), 
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100.7 (COCH=CO), 115.8 (NHCH2CHCH 2), 134.3 (NHCH2CHCH 2), 172.7 
(CONH), 175.9 (COCH=COCH 3), 200.4 (COCH=COCH3); MS FAB (+ve) found 
m/z 252 (MH, 25 %), 195 (M-NHallyl, 100); HRMS FAB (+ve) found m/z 
252.15921 (MH), C 14H22NO3 requires 252.15997. 




N-Allyl-2-(4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetamide 111(0.20 g, 
0.80 mmcl) was dissolved in anhydrous THF (7 ml) and 2M HC1 (7 ml) slowly 
added. The mixture was then stirred at room temperature overnight. EtOAc (30 ml) 
was added and the organic phase washed with water (10 ml) and saturated NaHCO3 
solution (10 ml). The aqueous phase was back-extracted with EtOAc (2 x 15 ml) and 
the total organic phase washed with brine (15 ml), dried (MgSO 4) and rotary 
evaporated to give a yellow oil (0.14 g). This was taken up in toluene (15 ml) and 
acetic acid (0.5 ml) added. The mixture was then heated under reflux for 2 hrs using 
a Dean-Stark trap to remove water. After allowing to cool, the toluene was removed 
in vacuo and the residue dissolved in DCM (20 ml) and washed with water (10 ml), 
then saturated NaHCO3 solution (10 ml). The aqueous phase was back-extracted 
with DCM (2 x 10 ml) and the total organic phase washed with brine (15 ml), dried 
(MgSO4) and rotary evaporated to give a yellow oil (0.10 g). This was purified by 
flash column chromatography on silica gel using hexane/EtOAc (4:1-3:2) as eluent to 
give an off-white solid (0.05 g, 29 %): mp 107-109 °C; 8H  (360 MHz, CDC13) 0.88 
(3H, s, C(C1H3CB113)),  1.08 (3H, s, C(CAH3CBH3)),  2.31 (211, s, CH2C(CH3)2), 2.37 
(1H, dd, J 17.6, 8.5, CHAHBCON),  2.60 (1H, dd, J 17.6, 9.2, CHAR13CON),  3.07 
(1H, m, CHCH2CON), 4.10 (2H, m, NCH2), 5.14 (2H, m, NCH 2CHCH2), 5.43 (1H, 
d, J 2.2, C=CHCO), 5.66 (1H, m, NCH2CHCH2); oc (63 MHz, DEPT, CDC1 3) 19.5 
(C(CAH3CBHA, 28.7  (C(CkH3cBH3)),  29.4 (CH2CON), 35.5 (C(CH3)), 42.7 
(NCH2), 44.6 (CHCH2CON), 52.9 (CH2C(CH 3 )2), 101.7 (C=CHCO), 118.4 
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(NCH2CHCH2), 129.7 (NCH2 CHCH2), 163.4 (C=CHCO), 174.6 (CON), 196.6 
(CCHCO); MS FAB (+ve) found m/z 220 (MH, 100 %), 242 (MNa, 52); HRMS 
FAB (+ve) found m/z 220.13321 (IvIH), C1 3H18NO2 requires 220.13375. 
5.2.19 Synthesis of Cyclised Ligands Incorporating Amino Acids 
5.2.19.1 (S)-2- [2-(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-
acetylamino]-3-phenyl-propionic acid methyl ester 115a and 115b 
MeO2C i' ~ 0 	OM 
Ph 
Using the general method, L-phenylalanine methyl ester hydrochloride 114 was 
coupled to (4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 (0.45 g, 
2.12 mmcl) to give a brown oil (1.60 g) after work-up. This was purified by flash 
column chromatography on silica gel using hexane/EtOAc (4:1-3:2) as eluent to give 
the diastereomers as (i) a colourless oil (0.24 g, 30 %) and (ii) a yellow solid (0.21 g, 
27 %) respectively: 
i) 8H  (360 MHz, CDC13) 0.83 (3H, s, C(CAH3CBH3)),  1.09 (3H, s, C(CAH 3 CI3H3)) , 
2.12 (1H, d, J 17.4, CH1HBC(CH3)2),  2.13 (1H, m, CHAHBCONH),  2.50 (1H, dd, J 
17.4, 1.4, CHAHI3C(CH3)2),  2.56 (2H, m, CHCHAHBCONH), 3.06 (1H, dd, J 13.8, 
6.2, PhCJtH'), 3.14 (1H, dd, J 13.8, 5.8, PhCHAHB),  3.70 (6H, s, OCH3 and 
CO2CH3), 4.91 (1H, m, C,,,-H), 5.38 (1H, d, J 1.6, COCH=COCH3), 6.63 (1H, br, 
NH), 7.20-7.47 (5H, m, Ar-H); 8c (63 MHz, DEPT, CDC13) 20.8 (C(CAH 3CBH3)) , 
28.8 (C(CAH3GBH3)),  31.4 (CH2CONH), 35.9 (C(CH)2), 37.9 (PhCH), 44.2 
(CH2C(CH3)2), 52.1 (CO2CH3), 53.0 (Ca H), 53.1 (CHCH2CONH), 55.6 (OCR3), 
100.7 (COcH=COCH3), [126.8 (CH), 128.4 (CH), 129.4 (CH), SC, Ar-H], 136.1 
(CH2Ph), 172.0 (CONH or CO2Me), 172.2 (CONH or CO 2Me), 175.6 
(COCH=COCH3), 199.9 (COCH=COCH3); MS FAB (+ve) found m/z 374 (ME, 87 
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%), 396 (M1Na, 80), 195 (M-PheOMe, 100); HRMS FAB (+ve) found m/z 
374.19650 (MH), C21 H28N05 requires 374.19675. 
ii) mp 131-134 °C; SH (360 MHz, CDC13) 0.81 (3H, s, C(CAH3CBH3)),  1.10 (3H, s, 
C(CAH 3CBH3)) ,  2.12 (1H, d, J 17.4, CHAHBC(CH3)2),  2.15 (1H, dd, J 14.0, 2.4, 
CHAHBCONH),  2.53 (1H, dd, J 17.4, 1.3, CHAHBC(CH3)2),  2.61 (1H, dd, J 14.0, 8.5, 
CHAHBCONH),  2.69 (1H, dd, J 8.5, 2.4, CHCH2CONH), 3.03 (1H, dd, J 13.8, 6.8, 
PhCHAHB), 3.15 (1H, dd, J 13.8, 5.7, PhCHAHI3),  3.67 (3H, s, CO2CH3 or OCH3), 
3.68 (3H, s, CO2CH3 or OCH3), 4.80 (1H, m, Ca-H), 5.36 (1H, d, J 1.6, 
COCH=COCH 3), 6.85 (1H, br, NH), 7.13-7.30 (5H, m, Ar-H); 8c (63 MHz, DEPT, 
CDC1 3) 20.9 (C(C&H3CBH3)),  29.0  (C(CAH3d3H3)),  31.5 (CH2CONH), 36.1 
(C(CH 3)2), 37.8 (PhCH2), 44.2 (CH2C(CH 3)2), 52.1 (CO2CH3), 53.1 (CHCH 2CONH 
or Ca-H), 53.4 (CHCH 2CON}1 or Ca-H), 55.6 (OcH3), 100.8 (COcF1=CO), [126.8 
(CH), 128.4 (CH), 129.2 (CH), 5C, Ar-H], 136.2 (CH2Ph), 172.0 (CONH or 
CO2Me), 172.6 (CONH or CO 2Me), 175.7 (COCH=COCH 3), 199.9 
(COCH=COCH3); MS FAB (+ve) found m/z 374 (MH, 94 %), 396 (MNa, 89),195 
(M-PheOMe, 100); HRIvIS FAB (+ve) found m/z 374.19635 (MH), C21 H28N05 . 
requires 374.19675. 
5.2.19.2 (S)-1-(1-Benzyl-2-oxo-butyl)-4,4-dimethyl-3,3a,4,5-tetrahydro-1 H-





propionic acid methyl ester diastereomers 115a and 115b (0.22 g, 0.59 mmol; 0.17 g, 
0.46 mmol) were dissolved separately in anhydrous THF (7 ml) and 2M HC1 (7 ml) 
slowly added to both. The mixtures were then stirred at room temperature overnight. 
EtOAc (30 ml) was added and the organic phases washed with water (10 ml) and 
saturated NaHCO3 solution (10 ml). The aqueous phases were back-extracted with 
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EtOAc (2 x 15 ml) and the total organic phases washed with brine (15 ml), dried 
(MgSO4) and rotary evaporated to give two yellow oils (0.18, 0.13 g). These were 
taken up separately in toluene (15 ml) and acetic acid (0.2 ml) added to both. The 
mixtures were then heated under reflux for 2 hrs using a Dean-Stark trap to remove 
water. After allowing to cool, the toluene was removed in vacuo and the residues 
dissolved in DCM (20 ml) and washed with water (10 ml) and saturated NaHCO 3 
solution (10 ml). The aqueous phases were back-extracted with DCM (2 x 10 ml) 
and the total organic phases washed with brine (15 ml), dried (MgSO4) and rotary 
evaporated to give two brown oils (0.081 g, 0.076 g). These were purified by flash 
column chromatography on silica gel using hexane/EtOAc (7:3) as eluent to give two 
yellow oils, (i) (0.0 18 g, 9 %) and (ii) (0.011 g, 7 %): 
6H  (250 MHz, CDC1 3) 0.70 (3H, s, C(CAH3CBH3)),  1.03 (3H, s, C(CAH 3 CBH3)) , 
2.27 (1H, dd, J 17.6, 8.8, CHAHBCON),  2.27 (2H, s, CH2C(CH3)2), 2.45 (1H, dd, J 
17.6, 9.2, CHAHBCON),  2.88 (1H, m, CHCH2CON), 3.29 (1H, dd, J 14.4, 11.6, 
PhCHAHB), 3.47 (1H, dd, J 14.4, 5.2, PhCHAHB),  3.77 (3H, s, CO2CH3), 4.94 (1H, 
dd, J 11.6, 5.2, C,,,-H), 5.25 (1H, d, J2.0, C=CHCO), 7.08-7.28 (5H, m, Ar-If); & 
(90 MHz, DEPT, CDC13) 19.3 (C(CAH3CI3H3)),  28.5 (C(C'H3 C'3H3)), 29.1 
(CH2CON), 32.8 (PhCH 2), 35.3 (C(CH3)2), 44.5 (CHICH2CO), 52.6 (GH 2C(CH3)2), 
52.9 (CO2CH3), 54.9 (Ce-H), 102.1 (C=CHCO), [127.1 (CH), 128.6 (CH), 128.7 
(CH), SC, Ar-H], 135.8 (CH2Ph), 162.2 (C=CHCO), 168.2 (CONH or CO2Me), 
174.4 (CONE or CO2Me), 196.5 (C=CHCO); MS FAB (+ve) found m/z 342 (MH, 
100 %), 364 (MNa, 54); HRMS FAB (+ve) found m/z 342.17040 (MIT4), 
C20H24N04 requires 342.17053. 
oH (250 MHz, CDC13) 0.80 (3H, s, C(CAH3CBH3)),  1.02 (3H, s, C(CAH3CBH3)) , 
2.05 (1H, dd, J 17.5, 8.9, CHAHBCON),  2.23 (1H, d, J 16.9 CHAHBC(CH3)2),  2.32 
(1H, d, J 16.9 CHAIJBC(CH3)2),  2.44 (1H, dd, J 17.5, 9. 1, CHARBCON),  2.93 (1H, 
m, CHCH2CON), 3.28 (1H, dd, J 14.3, 115 PhCHAHB),  3.48 (111, dd, J 14.3, 55 
PhCHAHB), 3.77 (3H, s, CO2CH3), 5.06 (1H, dd, J 11.3, 5.5, Ca-H), 5.40 (1H, d, J 
2.0, C=CHCO), 7.08-7.26 (5H, m, Ar-I); oc  (90 MHz, DEPT, CDC13) 19.5 
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(C(C'H3C8HA, 28.7 (C(C'H30H3)), 29.0 (CH2CON), 34.0 (Phd 2), 35.3 
(C(CH3)2), 44.3 (CHCH2CO), 52.6 (CH2C(CH3)2), 53.1 (CO2 CH3), 55.1 (Ca-H), 
102.1 (C=CHCO), [127.2 (CH), 128.5 (CH), 129.0 (CH), 5C, Ar-H], 135.6 (CH2Ph), 
162.5 (C=CHCO), 168.4 (CONH or CO2Me), 174.6 (CONH or CO 2Me), 196.6 
(C=CHCO); MS FAB (+ve) found m/z 342 (MIH, 100 %), 364 (MNa, 36); HRMS 
FAB (+ve) found m/z 342.17019 (IvllI), C20H24N04 requires 342.17053. 
5.2.19.3 (S)-6-Acetylamino-2- [2-(4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-




o 	H CO2Me 
Using the general method, N-a-acetyl-L-lysine methyl ester hydrochloride 120a was 
coupled to (4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 (0.89 g, 
4.20 mmol) to give an orange oil (7.00 g) after work-up. This was purified by flash 
column chromatography on silica gel using EtOAc/5 % MeOH as eluent to give a 
white foamy solid (1.29 g, 76 %) as a mixture of diastereomers: 8H  (250 MHz, 
CDC13) 0.81 (6H, s, C(C'H3C'3H3)), 1.09 (6H, s, C(CH3CBH3)),  1.41 (8H, m, CH2 
and C8H2), 1.71 (4H, m, CpH2), 1.97 (6H, s, CH3CONH) 2.11 (2H, d, J 17.5, 
CHAHBC(CH3)2), 2.15 (2H, dd, J 14.2, 2.6, CIIAHBCONH),  2.42 (2H, dd, 
CHAITII3CONH), 2.50 (2H, d, CH"H'3C(CH3)2), 2.71 (2H, m, CHCH2CONH), 3.17 
(4H, m, CH2), 3.64 (6H, s, OCH3), 3.66 (3H, s, OCH3), 3.67 (3H, s, OCH3), 4.46 
(2H, m, CaLl), 5.30 (2H, s, COCH=COCH3), 6.53 (2H, br, NB), 6.74 (111, d, J 7.6, 
NH), 6.89 (1H, d, J 7.4, NH); öc (63 MHz, DEPT, CDC13) 21.0 + 21.1 
(C(CAH3CBH3)), 22.0 + 22.1 (C1H2), 22.8 (NHCOCH3), 28.6 + 28.7 (C(CAH 3d3H3)) , 
28.8 (CH2), 31.1 + 31.2 (CH2CONH), 31.7 + 31.9 (CH2), 35.9 + 35.9 (C(CH3)), 
38.3 + 38.6 (CH2), 44.1 + 44.2 (CH2C(CH 3)2), 52.1 (CHCH2CONH), 52.1 
(CO2 CH3), 53.2 + 53.3 (CaH), 55.7 (OCH3), 100.6 (COCHCOCH 3), 170.2+ 170.4 
(NHCOCH 3), 172.9 (CONH or CO2Me), 173.1 (CONH or CO 2Me), 176.0 
(COCH=COCH3), 200.5 (COCH=COCH3); MS ES (+ve) found m/z 397 (MH, 100 
Irefel 
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%), 419 (MNa, 41); HRMS FAB (+ve) found m/z 397.23389 (MH4), C20H33N206 
requires 397.23386. 
5.2.19.4 (S)-6-Acetylamino-2-(4,4-dimethyl-2,6-dioxo-2,3,3a,4,5,6-hexahydro-
indol-1-yl).-hexanoic acid methyl ester 122a 
0 
H 	 N 0 
0 	 CO2Me 
(5)-6-Acetylamino-2-[2-(4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-
acetylamino]-hexanoic acid methyl ester 121a (1.00 g, 2.52 mmol) was dissolved in 
anhydrous THF (25 ml) and 2M HC1 (25 ml) slowly added. The mixture was then 
stirred at room temperature overnight. EtOAc (50 ml) was added and the organic 
phase washed with saturated NaHCO 3 solution (25 ml), then water (25 ml). The 
aqueous phase was back-extracted with EtOAc (2 x 25 ml) and the total organic 
phase washed with brine (30 ml), dried (MgSO 4) and rotary evaporated to give a 
yellow oil (0.20 g). This was taken up in toluene (20 ml) and acetic acid (0.5 ml) 
added. The mixture was then heated under reflux for 3 hrs using a Dean-Stark trap to 
remove water. After allowing to cool, the toluene was removed in vacuo and the 
residue dissolved in DCM (20 ml) and washed with water (10 ml) and saturated 
NaHCO3 solution (10 ml). The aqueous phase was back-extracted with DCM (2 x 10 
ml) and the total organic phase washed with brine (15 ml), dried (MgSO4) and rotary 
evaporated to give a brown oil (0.10 g). This was purified by flash column 
chromatography on silica gel using EtOAc/5 % MeOH as eluent to give a yellow oil 
(0.062 g, 7 %): oH (250 MHz, CDC13) 0.88 (3H, s, C(CAH3CH3)),  1.08 (3H, s, 
C(CAH3CBH3)) ,  1.30 (211, m, CH2), 1.54 (2H, m, CH2), 1.72 (2H, m, -Lys), 2.00 
(3H, s, CH3CONIH), 2.33 (211, s, CH2C(CH3)2), 2.34 (1H, dd, J 17.5, 8.4, 
CHAHBCON) ,  2.58 (1H, ddd, J 17.5, 9.1, 1.2, CHAIIBCON),  3.07 (1H, m, 
CHCH2CON), 3.46 (211, m, CH2), 3.71 (3H, s, OCH3), 4.53 (1H, m, CH), 5.45 (1H, 
d, J 2.1, C=CHCO), 6.26 (1H, d, J 7.5, NH); oc (63 MHz, DEPT, CDC13) 19.5 
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(C(C'H3C'3HA, 22.3 (CH2), 23.0 (NHCOCH3), 26.2 (C3H2), 28.7 (C(CAH3 CBH3)) , 
29.5 (G]2CON), 31.7 (CpH 2), 35.5 (C(CH3)2), 40.0 (CH2), 44.6 (CHCH2CON), 51.8 
(Ca-H), 52.4 (CO2CH3), 52.9 (CH2C(CH3)2), 101.0 (C=CHCO), 163.8 (CCHCO), 
169.8 (CO), 172.8 (CO), 175.2 (CO), 196.7 (CCHCO); MS ES (+ve) found m/z 365 
(1\'lli, 17 %), 387 (MNa, 100); HRMS FAB (+ve) found m/z 365.20766 (MIH), 
C19H29N205 requires 365.20765. 
5.2.19.5 (S)-2-[2-(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-
acetylamino] -5-(]V'-nitro-guanidino)-pentanoic acid methyl ester 121b 
Mi O r+ 
ON A 
2 N N)( 0 	OMe 
H H H CO2Me 
Using the general method, NGnitroLarginine methyl ester hydrochloride 120b was 
coupled to (4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 (2.00 g, 
9.42 mmol) to give an orange solid (7.05 g) after work-up. This was purified by 
flash column chromatography on silica gel using EtOAc/5 % MeOH as eluent to give 
an off-white solid (3.44 g, 85 %) as a mixture of diastereomers: 6H  (250 MHz, 
CDCI3) 0.83 (6H, s, C(CH3CBH3)),  1.09 (6H, s, C(CAH3CBH3)), 1.67 (4H, m, Arg- 
1.89 (4H, m, Arg-CH2), 2.12 (2H, m, CHAHBC(CH3)2),  2.25 (2H, m, 
CHAHBCONH), 2.49 (4H, m, CHAHBC(CH 3)2 + CHAHBCONH), 2.70 (1H, m, 
CHCH2CONH), 2.87 (1H, m, CHCH2CONH), 3.26 (2H, m, C8H2), 3.42 (2H, m, 
C&H2), 3.65 (3H, s, OCH3), 3.66 (3H, s, OCH3), 3.69 (3H, s, OCH3), 3.71 (3H, s, 
4.49 (1H, m, CH), 4.66 (1H, m, CA, 5.30 (1R, S, COCH=COCH3), 5.33 
(1H, s, COCH=COCH3), 6.81 (1H, br, NH), 7.38 (2H, m, NH), 7.75 (4H, m, NI]), 
8.65 (1H, br, NH); öc (63 MHz, DEPT, CDC1 3) 20.9 (CH3), 21.1 (CH3), 28.7 (CH 3), 
31.7 (CH2), 35.6 (quat), 35.9 (quat), 40.4 (CH 2), 40.6 (CH2), 43.9 (CH2), 44.3 (CH2), 
52.5 (CH3), 53.1 (CH), 55.8 (CH3), 55.9 (CH), 100.4 (CH), 100.5 (CH), 159.3 
(quat), 172.4 (quat), 176.4 (quat), 200.4 (quat); MS ES (+ve) found m/z 428 (MW, 
54 %), 450 (MNa, 60), 383 (MtNO2, 98); FIRMS FAB (+ve) found m/z 428.21447 









H H CO2Me 
(S)-2-[2-(4-Methoxy-6,6-dimethy1-2-oxo-cyclohex3enyI)..acety1amino]...5..(N.pjfro.. 
guanidino)-pentanoic acid methyl ester 121b (0.50 g, 1.17 mmol) was dissolved in 
acetone (10 ml) and 1M HC1 (10 ml) slowly added. The mixture was then stirred at 
room temperature overnight. The acetone was removed in vacuo and the residue 
diluted with brine (10 ml) and extracted with EtOAc (3 x 20 ml). The total organic 
phase was dried (MgSO4), and rotary evaporated to give a yellow oil (0.40 g). This 
was taken up in toluene (25 ml) and acetic acid (1.0 ml) added. The mixture was 
then heated under reflux for 3 hrs using a Dean-Stark trap to remove water. After 
allowing to cool, the toluene was removed in vacuo and the residue dissolved in 
EtOAc (25 ml) and washed with water (10 ml) and saturated NaHCO 3 solution (10 
ml). The aqueous phase was back-extracted with EtOAc (2 x 10 ml) and the total 
organic phase washed with brine (15 ml), dried (MgSO4) and rotary evaporated to 
give a gummy solid. This was purified by flash column chromatography (dry-
loading) on silica gel using EtOAcI5 % MeOH as eluent to give an off-white solid 
(0.040 g, 9 %) as a mixture of diastereomers: 8H  (360 MHz, CDC13) 0.90 (3H, s, 
C(CAH3CBH3)), 0.91 (3H, s, C(CAH30H3)),  1.09 (6H, s, C(CH3CBH3)),  1.58 (411, 
m, Arg-CH2), 2.08 (4H, m, Arg-CH2), 2.32 (2H, s, CHAHI3C(CH3)2), 2.34 (211, s, 
CH'II'3C(CH3 )2), 2.43 (211, m, CHAHBCON),  2.69 (211, m, CHAHBCON),  3.21 (211, 
m, CHCH2CON), 3.30 (4H, m, C8H2), 3.68 (3H, s, OCH3), 3.69 (3H, s, OCH3), 4.71 
(1H, m, CH), 4.92 (1H, m, Call), 5.30 (111, 5, CCHCO), 5.45 (1H, 5, CCHCO), 
7.59 (1H, br, NH), 8.60 (111, m, Nil); öc (90 MHz, DEPT, CDC13); 19.5 
(C(,CAH3CBHA, 23.8 (Arg-CH2), 25.3 (Arg-CH2), 28.6 (C(CAH3H3)),  29.3 + 29.4 
(CH2CON), 35.6 (C(CH3) 2), 40.5 (CH2), 44.3 + 44.5 (CHCH2CON), 52.6 
(CH2C(CH3)2), 52.8 + 53.8 (Ca H), 52.9 + 53.0 (CO2 CH3), 101.7 + 102.4 
(C=CHCO), 159.2 (C=NH), 162.5 (C=CHCO), 168.7 (CO), 175.6 + 175.7 (CO), 
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197.3 (C=CHCO); MS ES (+ve) found m/z 396 (MH, 84 %), 418 (MNa, 100); 
HIRMS FAR (+ve) found m/z 396.18833 (Iv1IH), C17H26N 506 requires 396.18831. 
5.2.19.7 (S)-6-Benzyloxycarbonylamino-2-[2-(4-methoxy-6,6-dimethyl-2-oxo- 
cyclohex-3-enyl)-acetylaminol -hexanoic acid methyl ester 121c 
H 
PhOyN y 0 
	OMe 
o 	H CO2Me 
Using the general method, N-e-CBz-L-lysine methyl ester hydrochloride 120c was 
coupled to (4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 (2.00 g, 
9.42 mmcl) to give an orange oil (7.67 g) after work-up. This was purified by flash 
column chromatography on silica gel using hexane/EtOAc (1: I)-EtOAc as a gradient 
eluent to give an orange oil (4.47 g, 97 %) as a mixture of diastereomers: 6H  (250 
MIHz, CDC1 3) 0.77 (6H, s, C(CAH3CBH3)),  1.04 (3H, s, C(CAH3CI3H3)),  1.05 (3H, s, 
C(CAH 3CBH3)) ,  1.40 (8H, m, C1H2 and C8H2), 1.71 (4H, m, CH2), 2.09 (4H, m, 
CHAHBC(CH 3)2 + CHAHBCONH), 2.43 (4H, m, CHAHBC(CH3)2 + CHAHBCONH) , 
2.62 (1H, m, CHCH2CONH), 2.78 (1H, m, CHCH2CONH), 3.11 (4H, m, CH2), 3.36 
(311, s, OCH3), 3.57 (311, s, OCH3), 3.63 (3H, s, CO2CH3), 3.65 (3H, s, CO2CH3), 
4.45 (1H, m, CH), 4.58 (1H, m, CH), 5.01 (4H, m, CH2Ph), 5.13 (ill, br, NH), 
5.22 (1H, s, COCH=COCH3), 5.30 (ill, s, COCH=COCH3), 5.95 (1H, br, NH), 6.52 
(1H, d, J 8.2, NH), 7.05 (1H, d, J 7.5, NH), 7.25 (1011, m, Ar-H); 8c  (63 MHz, 
DEPT, CDC13) 21.0 + 21.1 (C(CAH3CBH3)),  21.7 + 22.2 (CH2), 28.7 
(C(CAH3d3H3)), 29.1 (C8112), 31.6 (CH2CONH or CH2), 31.7 (CH2CONH or 
35.7 + 36.0 (C(CH 3)2), 40.1 + 40.5 (CH2), 44.0 + 44.2 (CH2C(CH3)2), 51.6 + 51.9 
(Call), 52.2 (CO2CH3), 53.2 + 53.3 (CHCH2CONH), 55.4 + 55.6 (0CJ43), 66.1 + 
66.4 (PhCH2), 100.6 (COCH=COCH3), [127.6 + 127.7 (Cl), 127.9 (CH), 128.3 + 
128.3 (CH), IOC, Ar-H], 136.5 1- 136.9 (Ph), 156.4 + 156.7 (NHCOO), 172.4 + 
172.7 (CON}1 or CO2Me), 172.9 + 173.0 (CONH or CO2Me), 176.0 
(COCH=COCH3), 200.4 (COCH=COCH3); MS ES (+ve) found m/z 489 (ME, 100 
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%), 511 (MNa, 55); FIRMS FAB (+ve) found m/z 489.26072 (M} +), C26H37N207 
requires 489.26008. 
5.2.19.8 (S)-6-Benzyloxycarbonylamino-2-(4,4-dimethyl-2,6-dioxo-2,3,3a,4,5,6-
hexahydro-indol-1-yl)-hexanoic acid methyl ester 122c 
Ph O N (NO 
0 	 CO2Me 
(S)-6-Benzyloxycarbonylamino-2-[2-(4-methoxy-6,6-dimethyl-2-oxo-cyclohex...3... 
enyl)-acetylamino]-hexanoic acid methyl ester 121c (2.26 g, 4.62 mmol) was 
dissolved in acetone (40 ml) and 2M HC1 (20 ml) slowly added. The mixture was 
then stirred at room temperature overnight. The acetone was removed in vacuo and 
the residue diluted with brine (10 ml) and extracted with EtOAc (3 x 20 ml). The 
total organic phase was dried (MgSO 4), and rotary evaporated to give an orange oil 
(2.25 g). This was taken up in toluene (50 ml) and acetic acid (1.00 ml) added. The 
mixture was then heated under reflux for 3 hrs using a Dean-Stark trap to remove 
water. After allowing to cool, the toluene was removed in vacuo and the residue 
dissolved in EtOAc (50 ml) and washed with water (20 ml) and saturated NaHCO 3 
solution (20 ml). The aqueous phase was back-extracted with EtOAc (2 x 20 ml) and 
the total organic phase washed with brine (30 ml), dried (MgSO 4) and rotary 
evaporated to give an orange oil (1.20 g). This was purified by flash column 
chromatography on silica gel using hexane/EtOAc (2:3) as eluent to give a yellow oil 
(0.58 g, 27 %) as a mixture of diastereomers: 6H (360 MIHz, CDC1 3) 0.83 (3H, s, 
C(CH3 CB}{ 3)) ,  0.84 (3H, s, C(CAH3CBH3)),  1.00 (3H, s, C(C'H3C 11H3)), 1.01 (311, s, 
C(CkH3CBH3)), 1.17 (411, m, CH2 or CH2), 1.42 (411, m, C7H2 or C8H2), 1.96 (4H, 
m, CH2), 2.26 (411, s, CH2C(CH3)2), 2.33 (2H, m, CHAHBCON),  2.56 (2H, m, 
CHAIIBCON), 3.04 (611, m, CH2 + CHCH2CON), 3.62 (311, s, OCH3), 3.64 (3H, s, 
OCH3), 4.64 (1H, m, Ccjl), 4.79 (1H, m, CUR), 4.99 (4H, m, CH2Ph), 5.24 (1H, d, J 
1.9, C=CHCO), 5.31 (1H, d, J 1.9, C=CHCO), 7.25 (10H, m, Ar-H); 5 C (63 MHz, 
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DEPT, CDC13) 19.3 (C(CAH3CBH3)),  23.0 + 23.2 (CH2 or C,H2), 26.2 + 27.5 (CH2 
or CoH2), 28.5 (C(CAH3CHH3)),  29.0 (CH2 or CH2CON), 29.2 (CH2 or CH2CON), 
35.3 + 35.4 (C(CH3)), 40.4 (CH2), 44.2 (CHCH2CON), 52.5 (CH2C(CH3) 2), 52.6 + 
52.7 (CO2Cfl3), 53.1 (CH), 66.3 (PhCH 2), 101.8 + 102.5 (C=CHCO), [127.9 (CH), 
128.3 (CH), bC, Ar-H], 136.4 (Ph), 156.2 (NHCOO), 161.7 + 162.6 (CCHCO) 
168.6 (CON or CO2Me), 174.8 + 174.9 (CON or CO2Me), 196.4 (CCHCO); MS ES 
(+ve) found m/z 457 (MW, 100 %), 479 (MNa, 45); HIRMS FAB (+ve) found m/z 
457.23332 (MH), C25113 3N206 requires 457.23386. 
5.2.19.9 (S)-6-Amino-2-(4,4-dimethyl-2,6-dioxo-2,3,3a,4,5,6-hexahydro-indol-






indol-1-yl)-hexanoic acid methyl ester 122c (0.052 g, 0.11 mmol) was dissolved in 
anhydrous DCM (3 ml) and iodotrimethylsilane (77.5 .il, 0.57 mmol) slowly added. 
The mixture was then stirred at room temperature overnight. The mixture was 
quenched with MeOH (100 p.1) and stirred for 5 mins. The solvent was removed in 
vacuo and the residue taken up in ether/30 % acetic acid (15 ml). The aqueous layer 
was separated and extracted a further time with ether (7 ml) and then freeze-dried 
overnight to give an orange foam (0.030 g, 83%): v, (CHC1 3) 3257.2 (NIH2), 
1744.3 (ester), 1652.7 (a,/IJ-unsaturated ketone), 1615.1 (CC), 1558.2 (NH 2); 5H 
(250 MHz, DMSO) 0.83 (3H, s, C(CAH3CBH3)),  0.84 (3H, s, C(CAH3CI3H3)),  1.03 
(6H, s, C(CAH3CBH3)),  1.22 (4H, m, C.H2 or C8H2), 1.51 (4H, m, CH2 or C6H2), 
1.94 (4H, m, CH2), 2.12 (2H, d, CItHBC(CH3)2),  2.39 (2H, d, CHAII13C(CH3)2) , 
2.46-2.66 (4H, m, CH2CON), 2.76 (4H, m, CH2), 3.35 (2H, m, CHCH2CON), 3.63 
(6H, S, CO2CH3), 4.80 (1H, t,J7.5, CH), 4.92 (IH, dd,J 10.3, 5.1, CH), 5.29 (1H, 
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s, CCHCO), 5.51 (1H, s, CCHCO); Sc  (63 MHz, DEPT, DMSO) 20.2 
(C(CAH3 CBH3)) ,  23.2 (CH2 or C6H2), 27.0. (C1H2 or CH2), 29.9 (CH2), 28.9 
(C(CAH 3 d3H3)) ,  29.9 (CH2CON), 36.3 (C(CH3)2), 39.6 (CH 2), 44.6 (CHCR2CON), 
53.3 (C0CH3), 53.5 (CH2C(CH3)2), 53.8 + 54.7 (CaR), 101.3 + 101.8 (C=CHCO), 
164.3 + 165.4 (C=CHCO), 170.1 (CON or CO2Me), 176.3 + 176.5 (CON or 
CO2Me), 196.9 + 197.0 (CCHCO); MS FAB (+ve) found m/z 323 (MH, 32 %), 




indol-1-yl)-hexanoic acid methyl ester 122c (0.25 g, 0.55 mmol) was dissolved in 
DCM (5 ml) and HBr in acetic acid (0.50 ml, 2.76 mmol) slowly added. The mixture 
as then stirred at room temperature for 2.5 hrs. The volatiles were removed in vacuo 
and the residue taken up in water (10 ml) and freeze-dried overnight to give a 
gummy bright orange solid. This was dissolved in acetone and a few drops of 
concentrated HC1 added. The volatiles were removed in vacuo to give a foamy. 
orange solid (0.15 g, 77 %): MS ES (+ve) found m/z 323 (Mil{1 , 100 %), and 1 H 
NMR spectrum was representative of correct product but was not as clean as that 
obtained from Method A. 
5.2.20 Synthesis of Aldehyde Derivative 





3-Methoxy-5 ,5-dimethyl-6-(3-methyl-but-2-enyl)-cyclohex-2-enone 53b (5.00 g, 
22.49 mmol) was dissolved in anhydrous DCM (180 ml) and pyridine (2.9 ml) and 
Sudan Red 7B (2.5 mg) added. The pink solution was cooled to —78 °C and ozone 
bubbled through for 8 hrs. Dry nitrogen was bubbled through the pale pink solution 
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for 15 mins to remove unreacted ozone and the solution then poured onto zinc dust 
(15 g). Acetic acid (20 ml) was added and the mixture allowed to warm to room 
temperature overnight. The mixture was passed through Celite and the filtrate 
washed with water (3 x 80 ml), 5 % NaOH solution (50 ml), and water (50 ml). The 
aqueous phase was back-extracted with DCM (100 ml) and the total organic phase 
washed with brine (50 ml), dried (MgSO4) and rotary evaporated to give a brown 
liquid (2.50 g). This was purified by flash column chromatography on silica gel 
using hexane/EtOAc (7:3) as eluent to give a yellow oil (0.48 g, 11 o/o): Vmax (neat) 
1722.1 (aldehyde), 1648.8 (a,#-unsaturated ketone), 1614.1 (C=C); 8H  (250 MHz, 
CDC13) 0.86 (3H, s, C(CAH3CBH3)),  1.07 (3H, s, C(CAH3CBH3)),  2.15 (1H, d, J 17.4, 
CHAHBC(CH3)2) ,  2.23 (1H, dd, J 16.2, 3.2, CHAHBCOH),  2.54 (111, dd, J 17.4, 1.2, 
CHAII13C(CH3)2), 2.81 (lH, dd, J 16.1, 9.2, CHAHBCOH),  2.93 (1H, dd, J 9.2, 3.2, 
CHCH2COH), 3.66 (3H, s, OCH3), 5.35 (1H, d, J 1.7, COCH=COCH3), 9.88 (1H, d, 
J 1.9, COB); 8c (63 MHz, DEPT, CDC1 3) 21.1 (C(CH3CBH3)),  29.0 
(C(CAH3 d3H3)) ,  35.4 (C(CH3)), 38.1 (CH 2COH), 44.2 (CH2C(CH3 )2), 51.9 
(CHCH2COH), 55.7 (OCH3), 100.4 (COCH=CO), 175.9 (COCH=COCH3), 198.5 
(COCH=COCH3), 201.2 (COH); MS FAB (+ve) found m/z 197 (MH, 100 %), 195 
(MtCOH, 46); HRMS FAB (+ve) found m/z 197.11760 (MH), C 11 H 1703 requires 
197.11777. 
Method B 
3-Methoxy-5,5-dimethyl-6-(3-methyl-but-2-enyl)-cyclohex-2-enone 53b (5.44 g, 
24.46 mmol) was dissolved in acetone/water (4:1) (125 ml) and the solution cooled 
to 0 °C. N-methylmorpholine (5.73 g, 48.93 mmol), and osmium tetroxide (2.5 % in 
tert-butanol, 3.07 ml, 1 mol %) were then added and the mixture stirred at room 
temperature for 3.5 hrs. The mixture was partitioned between saturated sodium 
thiosulfate solution (50 ml) and EtOAc (50 ml) and the layers were separated. The 
aqueous phase was extracted with EtOAc (2 x 25 ml) and the total organic phase was 
washed with brine (50 ml), dried (MgSO4) and rotary evaporated to give a dark 
brown oil (7.00 g): MS ES (+ve) found m/z 257 (IV1B (diol), 100 %). This was 
carried through to the next step without purification. 
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To a vigorously stirred slurry of silica gel (48 g) and DCM (300 ml) was added a 
solution of sodium periodate (7.85 g, 36.68 mmol) in water (48 ml) dropwise. A 
solution of the diol (7.00 g) in DCM (50 ml) was then added dropwise. The mixture 
was stirred at room temperature for 1 hr, then filtered through a glass-sintered funnel. 
The silica was washed with DCM (2 x 100 ml) and the filtrate reduced in vacuo to 
give a brown liquid (5.12 g). This was purified by Kugelrohr distillation to give a 
yellow oil (4.61 g, 96 %): bp 195 °C (0.5 mBar); NIN4R spectra consistent with those 
from Method A. 
5.2.21 Reductive Amination Reactions 
Method A 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3 -enyl)-acetaldehyde 126 (0.25 g, 1.27 
mmol) and allylamine 110 (0.48 ml, 6.37 mmol) were dissolved in anhydrous MeOH 
(15 ml) and sodium cyanoborohydride (0.048 g, 0.77 mmol) added. The solution 
was reduced to pH 5-6 with acetic acid and the mixture stirred in the presence of 4 A 
molecular sieves at room temperature overnight. The mixture was quenched with 
saturated NaHCO 3 solution (20 ml) and extracted with EtOAc (3 x 25 ml). The 
aqueous phase was back-extracted with EtOAc (2 x 15 ml) and the total organic 
phase washed with brine (25 ml), dried (MgSO4) and rotary evaporated to give a dark 
brown oil: MS ES (+ve) found m/z 275 (56 %), 300 (100); 1 H NMR spectrum 
complex and unassignable with no indication of presence of required product. 
Method B 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3 -enyl)-acetaldehyde 126 (0.50 g, 2.55 
mmol) was dissolved in anhydrous MeOH (8 ml) and allylamine 110 (0.76 ml, 10.19 
mmol) added. A solution of sodium cyanoborohydride (0.16 g, 2.55 mmol) and zinc 
chloride (0.17 g, 1.27 mmol) in anhydrous MeOH- (4 ml) was then added, and the 
mixture stirred at room temperature overnight. The mixture was quenched with 5 % 
NaOH solution and the volatiles removed in vacuo. EtOAc (50 ml) was added and 
the layers separated. The organic phase was washed with water (15 ml), brine (15 
ml), then dried (MgSO4) and rotary evaporated to give a bright orange oil (0.63 g): 
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MS ES (+ve) found m/z 275 (100 %), 300 (36); Flash column chromatography on 
silica gel using EtOAcI5 % MeOH isolated a colourless oil (0.25 g): MS ES (+ve) 
found m/z 300 (100 %); 1 H NIvIR spectrum broad and unassignable 
Method C 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetaldehyde 126 (0.30 g 1.52 
mmol) and allylamine 110 (0.11 ml, 1.52 mmol) were dissolved in anhydrous MeOH 
(15 ml) and anhydrous sodium acetate (0.25 g, 3.06 mmol), followed by sodium 
cyanoborohydride (0.16 g, 2.55 mmol) were added. The mixture was then stirred in 
the presence of 4 A molecular sieves at room temperature overnight. 1M HC1 was 
used to bring the pH to pH 2, then saturated aqueous sodium carbonate was added to 
adjust to pH 10. The mixture was extracted with EtOAc (3 x 15 ml) and the total 
organic phase washed with brine (15 ml), dried (MgSO 4) and rotary evaporated to 
give a brown oil (0.26 g): MS ES (+ve) found m/z 261 (13 %), 275 (100), 300 (8); 
Purification by Kugelrohr distillation did not give rise to any discernible product. 
Method D 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetaldehyde 126 (0.25 g 1.27 
mmol) and benzylamine 128 (0.21 ml, 1.91 mmol) were dissolved in anhydrous 
MeOH (15 ml) and acetic acid (4 drops) added. The mixture was stirred at room 
temperature for 2 hrs and sodium cyanoborohydride (0.16 g, 2.55 mmol) added. 
Stirring was then continued overnight. The mixture was quenched with saturated 
NaHCO3 solution (10 ml) and extracted with EtOAc (3 x 15 ml). The total organic 
phase washed with brine (15 ml), dried (MgSO4) and rotary evaporated to give an 
orange oil (0.38 g): Flash column chromatography on silica gel using EtOAc as 
eluent failed to isolate any discernible product. 
Method E 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3 -enyl)-acetaldehyde 126 (0.25 g 1.27 
mmol) and allylamine 110 (0.14 ml, 1.91 mmol) were dissolved in anhydrous DCM 
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(15 ml) and acetic acid (4 drops) added. The mixture was heated under reflux for 3 
hrs, allowed to cool, and sodium cyanoborohydride (0.16 g, 2.55 mmol)added. The 
mixture was then stirred at room temperature overnight. The mixture was quenched 
with saturated NaHCO 3 solution (10 ml) and extracted with EtOAc (3 x 15 ml). The 
total organic phase was washed with brine (15 ml), dried (MgSO 4) and rotary 
evaporated to give a yellow oil (0.28 g): Flash column chromatography on silica gel 
using hexane/EtOAc (1:1) as eluent isolated a yellow oil (0.032g. 13 %): 
5.2.21.1 6-(2-Hydroxy-ethyl)-3-methoxy-5,5-dimethyl-cyclohex-2-enone 124 
HO 
0 	OMe 
Vmax (neat) 3408.6 (OH), 1649.8 (a,f3-unsaturated ketone), 1613.2 (C=C); 6H  (250 
MHz, CDCI3) 0.95 (3H, s, C(CAH3CBH3)),  1.24 (3H, s, C(CAH3CBH3)),  1.62 (2H, m, 
CH2CH20H), 2.20 (1H, dd, J 9.4, 3.6, CHCH2CH20H), 2.25 (1H, d, J 17.8, 
CHAHBC(CH3)2) ,  2.34 (1H, d, J 17.8, CHAH13C(CH3)2),  3.31 (1H, m, 011), 3.65 (2H, 
m, CH2CH20H), 3.70 (3H, s, OCH3), 5.37 (1H, s, COCH=COCH3), 9.88 (1H, d, J 
1.9, COIl); 8C (63 MHz, DEPT, CDC13) 23.3 (C(CkH3CBH3)),  28.2 (CH2CH20H), 
28.6 (C(CAH3d3H3)),  35.4 (C(CH3)), 42.2 (CH 2C(CH3)2), 54.8 (CHCH2CH20H), 
55.7 (OCH3), 62.1 (CH2 CH20H), 100.5 (COCH=C0), 176.5 (COCH=COCH3), 
203.3 (COCH=COCH3); MS FAB (+ve) found m/z 199 (MH, 100 %), 221 (MNa, 
40) 181 (M+-OH, 80); HRMS FAB (+ve) found m/z 199.13344 (MH), C 11 H 1903 
requires 197.13342. 
Method F 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetaldehyde 126 (0.25 g 1.27 
mmol) and benzylamine 128 (0.126 ml, 1.16 mmol). were dissolved in anhydrous 
THF (10 ml) and titanium isopropoxide (0.68 ml, 2.54 mmol)) added. The mixture 
was then stirred overnight at room temperature [MS ES (+ve) found m/z 286 
(imineH, 100 %)]. EtOH (3 ml) was added, followed by sodium borohydride (0.13 
g, 3.47 mmol) and the mixture stirred for a further 8 hrs. The mixture was poured 
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into 2M aqueous ammonia solution (12 ml), filtered and washed with EtOAc (30 ml). 
The filtrate layers were separated and the aqueous extracted with EtOAc (20 ml). 
The total organic phase was washed with brine (20 ml), dried (Na2SO 4) and rotary 
evaporated to give an orange oil (0.30 g): MS ES (+ve) found m/z 272 (100 %); very 
little trace by TLC. 






Repeat of procedure 5.2.4.4 using 5-bromo-2-methyl-2-pentene 134 (5.00 ml, 37.59 
mmol) as the elecrophile. A yellow liquid (8.50 g) was obtained after work-up. This 
was purified by flash column chromatography on silica gel using hexanefEtOAc 
(4:1-1:1) gradient eluent to give a yellow oil (0.97 g, 13 %): 	(neat) 1656.6 
unsaturated ketone), 1616.1 (ring C=C); 8 H (250 MHz, CDC13) 0.95 (3H, s, 
C(CH3CBH3)) ,  1.04 (3H, s, C(CH3CBH3)),  1.48 (214, m, CH2CH2CHMe2), 1.58 
(311, s, CH=C(CH3CBH3),  1.66 (3H, s, CH=C(CAH3CBH3),  1.92 (1H, dd, J 8.4, 4.7, 
COCHC(CH3)2), 2.03 (2H, m, CH2CH=CMe2), 2.14 (1H, d, J 17.7, CHHBC(CH3)2), 
2.31 (1H, d, J17.7, CHAHJ3C(CH3)2),  3.65 (3H, s, OCH3), 5.08 (1H, m, CH=CMe2), 
5.25 (1H, s, COCH=COCH3); 8C  (63 MHz, DEPT, CDC13) 17.7 
(CH=C(CkH 3CBH3)) , 24.5  (C(CAH3CBH3)),  25.6 (CH=C(C"H3d3H3)), 26.3 (CH2), 
27.1 (CH2), 28.5 (C(CAH3d3H3)),  35.0 (C(CH3)2), 41.3 (cH2C(CH3)2), 55.4 (OCH3), 
56.5 (COCHC(CH3)2), 100.1 (COCH=COCH3), 124.2 (CH2CH2CH=CMe2), 131.9 
(CH=CMe2), 174.9 (COCH=COCH3), 202.4 (COCH=COCH3); MS FAB (+ve) 
found m/z 237 (MH, 100 %); FIRMS FAB (+ve) found m/z 237.18548 (MEt), 








Repeat of Method B (section 5.2.20.1) on 3-methoxy-5,5-dimethyl-6-(4-methyl-pent-
3-enyl)-cyclohex-2-enone 135 (0.95 g, 4.02 mmol). A brown liquid (0.69 g) was 
obtained after work-up, which was purified by Kugelrohr distillation to give a yellow 
oil (0.60 g, 70 %): bp 150 °C (0.1 mBar); Vmax (neat) 1721.2 (aldehyde), 1651.7 (a,fl-
unsaturated ketone), 1614.1 (C=C); 6H  (250 MHz, CDC13) 0.95 (3H, s, C(CAH 
3C'3H3)), 1.06 (3H, s, C(CAH3CBH3)),  1.65 (1H, m, CHAHBCH2COH),  1.85 (1H, m, 
CHAHBCH2COH), 1.91 (1H, dd, J 10.9, 2.8, COCHC(CH3)2), 2.19 (1H, d, J 17.7, 
CHAHBC(CH3)2), 2.29 (1H, d, J 17.7, CHAHBC(CH3)2),  2.58 (2H, m, CH2CH2COH), 
3.63 (3H, s, OCH3), 5.22 (1H, d, J 1.7, COCH=COCH 3), 9.74 (1H, t, J 1.0, COR); 8c  
(63 MHz, DEPT, CDC13) 18.1 (CH2CH2COH), 23.8 (C(C&H3CH3)),  28.5 
(C(CAH3d3H3)), 35.2 (C(CH3)2), 41.6 (CH2), 42.9 (CH2), 55.5 (OCH3), 55.7 
(COCHC(CH 3)2), 100.1 (COCH=CO), 175.3 (COCH=COCH 3), 201.7 (CO), 202.2 
(CO); MS FAB (+ve) found m/z 211 (MH, 100 %), 233 (MNa, 27); HRMS FAB 
(+ve) found 211.13346 (MH), C 12H 1903 requires 211.13342. 
5.2.23 Reductive Amination on Extended Aldehyde 
Repeat of Method A (section 5.2.21) using 3-(4-methoxy-6,6-dimethyl-2-oxo-
cyclohex-3-enyl)-propionaldehyde 136 (0.20 g, 0.951 mmol). An orange oil was 
obtained (0.19 g) after work-up: MS ES (+ve) found m/z 252 (MH, 5 %), 259 (100); 
Flash column chromatography on silica gel using EtOAc/5 % MeOH as eluent 
isolated an off-white oil whose 1 H N1\41R spectrum contained peaks representative of 
the desired product. However, spectrum was not clean and appeared to indicate the 
presence of a mixture of compounds. 
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5.2.24 Alternative Methods to Form Secondary Amines 
5.2.24.1 6-(2-Hydroxy-ethyl)-3-methoxy-5,5-dimethyl-cyclohex-2-enone 124 
HO 
0 	OMe 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetaldehyde 126 (0.25 g, 1.26 
mmol) was dissolved in anhydrous MeOH (5 ml) and solid-supported borohydride 
(0.37 g, 1.40 mmol) added. The mixture was then shaken at room temperature 
overnight. The MeOH layer was filtered and the resin washed with MeOH (5 x 5m!). 
The filtrate and washings were reduced in vacuo to give a brown oil (0.23 g, 91 
MS ES (+ve) found m/z 199 (MH, 100 %); 'H NIvIR was consistent with that found 
for 5.2.21.1. 
Nucleophilic Substitution Reaction with Benzylamine 
6-(2-Hydroxy-ethyl)-3 -methoxy-5 ,5-dimethyl-cyclohex-2-enone 124 (0.22 g, 1.11 
mmol) was dissolved in anhydrous DCM (10 ml) and cooled to 0 °C. Anhydrous 
triethylamine (0.187 ml, 1.33 mmol), followed by methanesulfonyl chloride (0.103 
ml, 1.33 mmol) were then added dropwise. The mixture was then allowed to warm 
to room temperature and stirred for 4 hrs. The solvent was removed in vacuo and the 
residue taken up in anhydrous DMF (10 ml). Benzylamine (0.139 ml, 1.11 mmol), 
followed by catalytic cesium carbonate (35 mg, 10 mol %) were then added, and the 
mixture stirred at room temperature overnight. Water (10 ml) was added and the 
reaction extracted with EtOAc (4 x 20 ml). The total organic phase was washed with 
brine (20 ml), dried (Na 2 SO4) and rotary evaporated to give an orange liquid (0.60 g). 
MS ES (+ve) and NIMR failed to provide evidence of desired secondary amine 
product. Flash column chromatography on silica gel using hexane/EtOAc (7:3) as 
eluent isolated a yellow oil (0.062 g, 34 %): 
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5.2.24.2 4,4-Dimethyl-3,3a,4,5-tetrahydro-2H-benzofuran-6-one 138 
CO 
6H (250 MHz, CDC1 3) 0.84 (3H, s, C(CAH3CH3)),  1.05 (3H, s, C(CAH3CBH3)),  1.80 
(1H, dq, J 12.4, 8.6, CHAHBCH2O),  2.06 (1H, m, CHAHBCH20),  2.09 (1H, d, J 16.3, 
CHAHBC(CH3)2) ,  2.19 (1H, d, J 16.3, CHAHBC(CH3)2),  2.83 (111, ddd, J 12.6, 7.8, 
2.1, CHCH2CR20), 4.15 (111, ddd, J 11.8, 8.9, 5.5, CH2CIfH BO)  , 4.46 (1H, t, J8.7, 
CH2CHAIIBO) ,  5.32 (111, d, J 1.8, C=CHCO), 9.88 (1H, d, J 1.9, COH); 6c  (63 MHz, 
DEPT, CDC13) 19.7 (C(CAH3CBH3)),  24.1 (CH2CH20), 29.2 (C(CAH3d3H3)),  34.9 
(C(CH3)2), 50.2 (CHCH2CH20), 52.0, (CH2C(CH3)2), 72.7 (CH2GH20), 99.4 
(C=GHCO), 180.8 (C=CHCO), 198.6 (C=CHCO); MS ES (+ve) found m/z 167 
(MJ{, 100%). 
Conversion to Alkyl Bromide 
6-(2-Hydroxy-ethyl)-3 -methoxy-5 ,5 -dimethyl-cyclohex-2-enone 124 (0.25 g, 1.26 
mmol) was dissolved in anhydrous DCM (10 ml) and cooled to 0 °C. Phosphorus 
tribromide (75 p1, 0.798 mrnol) was slowly added and the mixture stirred at 0 °C for 
15 mins, then at room temperature for 5 hrs. The mixture was poured onto ice and 
diluted with brine (20 ml). The aqueous phase was extracted with DCM (3 x 15 ml) 
and the total organic phase washed with brine (15 ml), dried (MgSO4) and rotary 
evaporated to give an orange liquid (0.17 g). This was purified by flash column 
chromatography on silica gel using hexane/EtOAc (7:3) as eluent to give an off-
white solid (0.14 g, 67 %): MS ES (+ve) found m/z 167 (100 %); NIVIIR spectra was 
consistent with that found for the furan derivative 138 (5 .2.24.2). 
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(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetaldehyde 126 (2.00 g, 10.19 
mmol) was dissolved in acetone (80 ml) and 2M HC1 (40 ml) slowly added. The 
mixture was then stirred at room temperature overnight. The acetone was removed 
in vacua and the mixture diluted with brine (30 ml) and extracted with EtOAc (3 x 
50 ml). The total organic phase was dried (Na2SO 4) and rotary evaporated to give an 
off-white solid (1.66 g). This was recrystallised from hexane/EtOAc to give a white 
solid (0.70 g, 38 %). The filtrate was reduced in vacua and the residue triturated 
with ether to afford a second crop of white solid (0.51 g, 27 %): mp 111-113 °C; 
(CHC13) 3234.0 (OH), 1619.9 (C=C); 6H  (360 MHz, CDC13) 0.90 (3H, s, C(CAH 
3CBH3)) ,  1.10 (3H, s, C(CAH3CBH3)),  1.86 (1H, br, CHAHBCHOH),  2.11 (111, br, 
CHAIIBCHOH) ,  2.22 (1H, d, J 16.3, CHAHBC(CH3)2),  2.31 (111, d, J 16.5, 
CHAHBC(CH3)2) ,  3.29 (1H, br, CHCH2CHOH), 5.48 (1H, s, CCHCO), 6.02 (1H, s, 
C112CHOH); 8C (90 MHz, DEPT, CDC1 3) 19.9 (C(CAH3CBH3)),  29.3 
(C(CAH3 CBH3)) ,  31.1 (CH2CHOH), 35.4 (C(CH), 48.3 (CHCH2CHOH), 51.9, 
(CH2C(CH3)2), 99.6 (CCHCO), 103.1 (CH2CHOH), 181.9 (C=CHCO), 200.8 
(C=CHCO); MS FAB (+ve) found m/z 183 (MIH, 100 %); HRMS FAB (+ve) found 
m/z 183.10214 (MH), C 1 0H1503 requires 183.10212. 
5.2.25.2 1 -Benzyl-4,4-dimethyl-1 ,2,3,3a,4,5-hexahydro-indol-6-one 141 
c'L 
Ph-' 
2-Hydroxy-4,4-dimethyl-3 ,3a,4,5-tetrahydro-2H-benzofuran-6-one 140 (0.20 g, 1.10 
mmol) was dissolved in anhydrous DCM (10 ml) and benzylamine 128 (0.24 ml, 
2.19 ml) added. The mixture was stirred in the presence of 4 A molecular sieves at 
room temperature for 2 hrs. NaCNBH3 (0.14 g, 2.19 mmol) was added and the 
solution adjusted to pH 6 with acetic acid. The mixture was then stirred at room 
temperature for a further 3 hrs. The solvent was removed in vacuo and the residue 
taken up in water (10 ml), basified with 5 % NaOH solution to pH 10, and extracted 
with EtOAc (3 x 20 ml). The total organic phase was washed with brine (15 ml), 
dried (MgSO4) and rotary evaporated to give a gummy colourless oil (0.26 g). This 
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was purified by flash column chromatography on silica gel using EtOAc/5 % MeOH 
as eluent to give a yellow oil (0.047 g, 17 %): 8H  (360 MHz, CDC13) 0.90 (3H, s, 
C(CAH3CBH3)) ,  1.01 (3H, s, C(CAH3CBH3)),  1.71 (1H, m, CIIAHBCH2N),  1.95 (1H, 
m, CH"R'3CH2N), 2.12 (1H, d, J 16.4, CHAHBC(CH3)2),  2.24 (1H, d, J 16.4, 
CHAIIBC(CH3)2) ,  2.83 (1H, ddd, J 12.1, 7.8, 1.2, CHCH2CH2N), 3.51 (2H, m, 
CH2CH2N), 4.32 (2H, s, PhCH2), 5.13 (1H, s, CCHCO), 7.12 (2H, m, Ar-H), 7.26 
(3H, m, Ar-H); 8c (90 MHz, DEPT, CDC13) 19.8 (C(CAH3CI3HA,  22.1 (CH2CH2N), 
28.9 (C(CAH3d3H3)),  34.6 (C(CH3)2), 49.8 (PhCH2), 51.9 (CH2C(CH3)2 or 
CH2 CH2N), 52.0 (CH2C(CH3)2 or CH2 CH2N), 52.1 CHCH2CH2N), 91.4 (C=CHCO), 
[127.4 (CH), 127.9 (CH), 128.8 (CH) 5C, Ar-H], 135.3 (Ph), 168.5 (C=CHCO), 
196.2 (C=CHCO); MS ES (+ve) found m/z 256 (MH, 100 %); HRMS FAB (+ve) 
found m/z 256.16965 (MH), C 17H22N0 requires 256.170 14. 
5.2.25.3 1 -AllyI-4,4-dimethyl-1,4,5,7-tetrahydro-indol-6-one 143 
'—I 
	LO  
2-Hydroxy-4,4-dimethyl-3 ,3a,4,5-tetrahydro-2H-benzofuran-6-one 140 (0.54 g, 2.96 
mmol) was dissolved in anhydrous DCM (25 ml) and allylamine 110 (0.24 ml, 3.26 
mmol) added. The mixture was stirred in the presence of 4 A molecular sieves at 
room temperature overnight. NaCNBH3 (0.14 g, 2.19 mmol) was added and the 
solution adjusted to pH 6 with acetic acid. The mixture was then stirred at room 
temperature for a further 24 hrs. The reaction was worked-up as described for 
5.2.25.2 to give an off-white oil (0.43 g). This was purified by Kugelrohr distillation 
to give a dark brown oil (0.30 g, 50 %); bp 250 °C (0.5 mBar); 8H  (250 MIHz, CDC13) 
1.25 (6H, s, C(CH3)2), 2.51 (CH2C(CH3)2), 3.37 (2H, s, NCCH2CO), 4.33 (2H, m, 
NCH2CHCH2), 4.97 (1H, m,NCH2CHCHAHI3),  5.18 (1H, m,NCH2CHCHAJIB),  5.91 
(1H, m, NCH2CHCH2), 6.09 (1H, d, J 2.8, NCHCII), 6.60 (1H, d, J 2.8, 
NCH=CH); 6c  (63 MHz, DEPT, CDC13) 30.5 (C(CH 3)2), 33.8 (C(CH3)2), 37.4 
(NCCH2CO), 49.3 (NCH2CHCH2), 55.1 (cH2C(CH3)2), 103.3 (NCH=CH), 117.1 
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(NCH2CRCH2), 120.7 (NCH=CH), 122.1 (CCH=CHN), 127.4 (NCCH2CO), 133.9 
(NCH2CHCH2), 208.9 (NCCH2CO); MS ES (+ve) found m/z 204 (ME, 65 %), 226 
(MNa, 15); HRMS FAB (+ve) found m/z 204.13897 (MH 4), C 1 3H18N0 requires 
204.13884. 
5.2.25.4 (S).6-Benzyloxycarbonylamino-2-(4,4-dimethyl-6-oxo-2,3,3a,4,5,6-




0 	 CO2Me 
2-Hydroxy-4,4-dimethyl-3 ,3a,4,5-tetrahydro-2H-benzofuran-6-one 140 (0.80 g, 4.39 
mmol) was dissolved in anhydrous DCM (40 ml) and N-s-CBz-L-lysine methyl ester 
hydrochloride 120c (1.60 g, 4.83 mmol), foliwed by DIPEA (0.84 ml, 4.83 mmol) 
were added. The mixture was stirred at room temperature overnight. NaCNBH3 
(0.55 g, 8.79 mmol) was added and the solution adjusted to pH 6 with acetic acid. 
The mixture was then stirred at room temperature for a further 24 hrs. The reaction 
was worked-up as described for 5.2.25.2 to give a yellow oil (2.34 g). This was 
purified by flash column chromatography on silica gel using EtOAc/5 % MeOH as 
eluent to give a colourless oil (1.08 g, 56 %) as a mixture of diastereomers: Vmax 
1738.5 (ester), 1713.4 (carbamate), 1578.4 (cr,fi-unsaturated ketone); 6H  (360 MHz, 
CDC13) 0.81 (3H, s, C(CAH3CBH3)),  0.83 (3H, s, C(CAH3CBH3)),  0.97 (6H, s, 
C(CH3CBH3)) ,  1.24 (4H, m, Lys-CH2), 1.46 (4H, m, Lys-CH2), 1.84 (8H, m, CH2 + 
CH2CH2N), 2.06 (111, d, J 16.4, CHAHBC(CH3)2),  2.11 (1H, d, J 16.5, 
CHAHBC(CH 3)2) ,  2.18 (1H, d, J 16.4, CHHBC(CH3)2),  2.23 (1H, d, J 16.5, 
CHI1BC(CH3)2) ,  2.79 (2H, m, CHCH2CH2N), 3.11 (4H, m, CH2), 3.43 (4H, m, 
CH2CH2N), 3.63 (6H, s, OCH3), 4.07 (211, m, Calf), 4.93 (1H, 5, CCHCO), 4.97 
(1H, s, C=CHCO), 5.00 (4H, m, CH2Ph), 5.13 (2H, br, NH), 7.25 (10H, m, Ar-H); 6c 
(63 MHz, DEPT, CDC13) 19.6 + 19.7 (C(CAH3CI3H3)),  22.0 (GH2CH2N), 22.9 + 23.3 
(Lys-CH2), 28.3 (Lys-CH2), 28.8 + 28.9 (C(C'H3d 3H3)), 29.2 (Lys-CH2), 34.4 + 
34.6 (C(CH3)2), 40.4 (CH2), 47.8 + 48.5 (CH2C(CH3)2), 51.5 + 52.0 (CHCH2CH2N), 
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52.1 (CH2CH2N), 52.3 + 52.4 (CO2CH3), 56.8 + 57.0 (CH), 66.4 (PhCH 2), 92.0 + 
92.4 (C=CHCO), [127.9 (CH), 128.4 (CH), bC, Ar-HI, 136.4 (Ph), 156.4 
(NHCOO), 169.2 (C=CHCO or CO2Me), 170,6 + 170.7 (C=CHCO or CO 2Me), 
196.6 (C=CHCO); MS FAB (+ve) found m/z 443 (MH, 4 %), 465 (MNa, 100); 
HRMS FAB (+ve) found m/z 443.25401 (MT{'), C25H35N205 requires 443.25460. 
5.2.25.5 (S)-6-Amino-2-(4,4-dimethyl-6-oxo-2,3,3a,4,5,6-hexahydro-indol-1-




indol-1-yl)-hexanoic acid methyl ester 144 (0.20 g, 0.45 mmol) was dissolved in 
anhydrous DCM (12 ml) and iodotrimethylsilane (0.31 ml, 2.26 mmol) slowly added. 
The mixture was then stirred at room temperature overnight. The mixture was 
quenched with MeOH (0.4 ml) and stirred for 5 mins. The solvent was removed in 
vacuo and the residue taken up in ether/30 % acetic acid (25 ml). The aqueous layer 
was separated and extracted a further time with ether (10 ml) and then freeze-dried 
overnight to give an orange oil (0.11 g, 79 %): Vmax 3415.3 (NH2), 1742.4 (ester), 
1586.2 (a,8-unsaturated ketone), 1550.5 (NH2); 8H  (360 MHz, DMSO) 0.85 + 0.86 
(6H, s, C(CAH3CBH3)),  1.07 + 1.08 (6H, s, C(CAH3CI3H3)),  1.27 (4H, m, Lys-CH2), 
1.56 (4H, m, Lys-CH2), 1.77 (2H, m, CHAHBCH2N),  1.91 (4H, m, CH2), 2.12 (2H, 
m, CHABBCH2N),  2.23 (2H, m, CHAIIBC(CH3)2),  2.62 (2H, br-d, CHARBC(CH3)2), 
2.81 (4H, m, CH2), 3.19 (1H, m, CHCH2CH2N), 3.30 (1H, m, CHCH2CH2N), 3.68 
(4H, m, CH2CH2N), 3.71 (611, s, OCH3), 4.82 (2H, m, Call), 5.56 (1H, br-s, 
C=CHCO), 5.62 (1H, br-s, CCHCO); öc  (63 MHz, DEPT, DMSO) 19.4 + 19.5 
(C(CAH3CBHA, 20.5 (CH2CH2N), 22.8 + 22.1 (Lys-CH 2), 26.1 + 26.2 (Lys-CH2), 
26.9 (CH2), 27.3 + 27.4 (C(C'H3d3H3)), 34.4 + 34.7 (C(CH3)), 38.3 (CH 2), 46.1 + 
46.4 (CH2C(CH3)2), 50.8 + 51.6 (CH2CH2N), 52.1 + 52.4 (CHCH2CH2N), 52.7 + 
52.8 (CO2CH3), 57.9 + 58.3 (CH), 90.9 + 91.1 (CCHCO), 168.4 + 171.8 
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(C=CHCO), 177.0 + 177.7 (CO2Me), 189.3 + 190.0 (C=CHCO); MS FAB (+ve) 
found m/z 309 (MH, 100 %); HRMS FAB (+ve) found m/z 309.21759 (Mff4 ), 
C 17H29N203 requires 309.2 1782. 
5.2.26 Synthesis of Hydrazide Derivative 
5.2.26.1 (4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 
hydrazide 146 
0! H2NOMe 
(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 (0.50 g, 2.36 
mmol) was dissolved in anhydrous DCM (10 ml) and HOBt (0.38 g, 2.82 mmol) and 
EDCI (0.54 g, 2.82 mmol) added. The mixture was stirred at room temperature for 2 
hrs then added dropwise to a solution of hydrazine hydrate (0.27 ml, 4.71 mmol) and 
cyclohexene (0.06 ml) in anhydrous DCM (5 ml) at -20 °C. After addition was 
complete, the reaction was quenched with water (5 ml) and extracted with EtOAc (2 
x 10 ml). The organic phase was washed with saturated NaHCO3 solution (10 ml) 
and brine (10 ml), then dried (MgSO4) and rotary evaporated to give a gummy 
yellow solid (0.31 g, 58 %): Vmax (CHC13) 3329.5 (NH), 1652.7 (a,#-unsaturated 
ketone), 1615.1 (C=C); 8H (250 MHz, CDC1 3) 0.82 (3H, s, C(CAH3CBH3)) ,  1.11 (3H, 
S, C(CH3CBH3)), 2.11 (1H, d, J 17.4, CHAHBC(CH 3)2), 2.14 (1H, dd, J 14.4, 2.9, 
CIfkHBCONH),  2.45 (1H, dd, J 14.4, 9.0, CHARBCONH) ,  2.53 (1H, dd, .117.4, 1.1, 
CHAHI3C(CH3)2), 2.75 (1H, dd, J9.0, 2.9, CHCH2CONH), 3.65 (3H, s, OCH3), 5.31 
(1H, d, J 1.6, COCH=COCH3), 7.78 (1H, br, Nil); 8c  (63 Iv1}Iz, DEPT, CDC13) 21.0 
(C(CH3CBHA, 28.8 (C(CH3 CBH3)), 29.6 (CH2CONH), 35.9 (C(CH), 44.2 
(CH2C(CH3)2), 52.9 (CHCH2CONIH), 55.7 (OCH3), 100.7 (COCH=CO), 173.8 
(CONH or COCH=COCH3), 175.8 (CONH or COCHCOCH3), 200.0 
(COCH=COCH3); MS FAB (+ve) found m/z 227 (MIH, 80 %), 249 (MNa, 43),195 











(4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid hydrazide 146 (0.20 g, 
0.88 mmol) was dissolved in TRIP (7 ml) and 2M HC1 (7 ml) slowly added. The 
mixture was then stirred at room temperature overnight. EtOAc (30 ml) was added 
and the organic phase washed with water (10 ml) and saturated NaHCO 3 solution (10 
ml). The aqueous phase was back-extracted with EtOAc (2 x 15 ml) and the total 
organic phase washed with brine (15 ml), dried (MgSO 4) and rotary evaporated to 
give a brown oil (0.09 g). This was purified by flash chromatography on silica gel 
using hexane/EtOAc (3:2) as eluent to give a gummy white solid (0.01 g, 5 %): oH 
(250 MHz, CDC13) 0.94 (3H, s, C(CAH3CBH3)),  1.08 (3H, s, C(CAH3CBH3)),  2.03 
(1H, d, J 16.5, CItHBC(CH3)2),  2.25 (1H, t, J 15.3, CFfHBCONH),  2.32 (1H, dd, J 
16.5, 1.3, CHAHBC(CH3)2),  2.45 (1H, dd, J 15.4, 6.3, CHCH2CONH), 2.55 (1H, dd, 
J 15.3, 6.3, CHAHI3CONH),  3.67 (3H, s, OCH3), 5.44 (1H, d, J 1.8, CH=COCH3), 
8.36 (1H, br, NI]); 0c  (63 MHz, DEPT, CDC1 3) 21.1 (C(CAH3CH3)),  27.9 
(C(CAH3 CBH3)),  28.0 (CH2CONIH), 34.9 (C(CH), 41.7 (CHCH 2CONH), 43.9 
(CH2C(CH3)2), 55.5 (OC}13), 95.7 (CH=COCH3), 153.2 (N=CCH), 164.8 
(CH=COMe), 168.0 (CONH); MS FAB (+ve) found m/z 209 (MH, 100 %), 231 
(MNa, 21); HRMS FAB (+ve) found m/z 209.12896 (MH), C11H17N202 requires 
209.12900. 
5.2.27 Synthesis of Enantiomerically Pure Ligands 
5.2.27.1 (R)-4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 150a 
o4 
OHk 2L 0 	OMe 
Racemic 4-methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 (8.36 g, 
39.38 mmol) was dissolved in a minimum volume of IPA and (R)-(+)-a-methyl 
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benzylamine 148a (5.58 ml, 43.32 mmol) added. The resulting precipitate was 
filtered and recrystallised twice from IPA. The salt was dissolved in EtOAc (25 ml) 
and washed with 1M HC1 (5 x 10 ml). The total acidic phase was extracted with 
EtOAc (2 x 10 ml) and the total organic phase washed with brine (15 ml), dried 
(MgSO4) and rotary evaporated to give a white crystalline solid (1.68 g): 73 % ee by 
chiral HPLC (tR = 23 mins). The solid was purified by repeating the above 
procedure to afford a white crystalline solid (0.51 g, 12 %): 93 % ee by chiral HPLC 
(tR = 24 mins): [c] D —36 (c 1.0, CHC13). 




Racemic 4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 (5.77 g, 
27.18 nimol) was obtained from the mother liquors of the above reaction (5.2.27.1) 
and resolved using (S)-(-)-a-methyl benzylamine 149b (3.85 ml, 29.90 mmol) to 
give a white crystalline solid (0.50 g, 17 %): 98 % ee by chiral HPLC (tR = 10 mins): 
[aID +37 (c 1.0, CHC13). 
5.2.27.3 (S)-6-Benzyloxycarbonylamino-2- [2-((R)-4-methoxy-6,6-dimethyl-2-





0 	 H CO2Me 
(R)-4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 150a (0.50 g, 2.36 
mmol) was coupled to N-c-CBz-L-lysine methyl ester hydrochloride 120c (0.78 g, 
2.36 nimol) using the general method (5.2.18) to give an orange oil (1.45 g) after 
work-up. This was purified by flash column chromatography on silica gel using 
hexane/EtOAc (1:1)-EtOAc as gradient eluent to give a yellow oil (0.80 g, 69 %): 
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v 	(CHC13) 3319.9 (NH), 1740.4 (ester), 1713.4 (carbamate), 1651.7 (a,f3- 
unsaturated ketone), 1614.1 (C=C); 6H  (360 MHz, CDC13) 0.83 (3H, s, C(CAH 
3CBH3)), 1.11 (3H, s, C(CAH3CI3H3)),  1.34 (211, m, C7H2 or CH2), 1.49 (2H, m, C.H2 
or C6H2), 1.75 (2H, m, C13H2), 2.12 (1H, d, J 17.4, CHAHBC(CH3)2),  2.19 (1H, d, 
11.9, CHAHBCONH),  2.49 (111, d, J 17.4, CHAHBC(CH3)2),  2.65 (2H, m, 
CHAII!3CONH + CHCH2CONH'), 3.16 (2H, m, C6H2), 3.62 (311, s, OCH3), 3.69 (3H, 
S, CO2CH3), 4.50 (1H, m, C ( H), 5.03 (2H, s, CH2Ph), 5.16 (1H, br, NH), 5.36 (1H, s, 
COCH=COCH 3), 7.08 (1H, d, J7.7, NH), 7.30 (SH, m, Ar-H); 8C (90 MHz, DEPT, 
CDC13) 20.9 (C(CAH3CI3H3)),  22.2 (CH2 or C&H2), 28.7 (C(CAH3d3H3)),  29.1 (C1H2 
or C8H2), 31.6 (CH2CONH or CH2), 31.7 (CH2CONH or CH2), 36.1 (C(CH3)2), 
40.5 (CH2), 44.1 (cH2C(CH3) 2), 51.9 (C11), 52.2 (CO 2 C113), 53.2 (CHCH 2CONH), 
55.6 (OCH3), 66.4 (PhCH2), 100.7 (COCH=COCH 3), [127.6 (CH), 127.9 (CH), 
128.4 (CH), SC, Ar-H], 136.5 (Ph), 156.4 (NHCOO), 172.7 (CONH or CO2Me), 
172.9 (CONH or CO2Me), 175.9 (COCH=COCH 3), 200.3 (COCH=COCH 3); MS 
FAB (+ve) found m/z 489 (MH, 58 %), 511 (MNa, 11); HRMS FAB (+ve) found 
m/z 489.26009 (MW), C 26H37N207 requires 489.26008. 
5.2.27.4 (S)-6-Benzyloxycarbonylamino-2-((R)-4,4-dimethyl-2,6-dioxo-





3-enyl)-acetylamino]-hexarioic acid methyl ester 151b (0.32 g, 0.78 mmol) was 
dissolved in acetone (8 ml) and 2M HC1 (8 ml) slowly added. The mixture was then 
stirred at room temperature overnight. The solvent was removed in vacuo and brine 
(5 ml) added. The mixture was extracted with EtOAc (3 x 10 ml), and the total 
organic phase washed with brine (8 ml), dried (MgSO 4) and rotary evaporated to an 
orange oil (0.38 g). This was purified by flash column chromatography on silica gel 
IM 
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using hexane/lEtOAc (2:3) as eluent to give a colourless oil (0.026 g, 9  
1743.3 (ester), 1720.2 (carbamate), 1619.0 (C=C); 8H  (360 MHz, CDC13) 0.90 (311, s, 
C(CAH3CBH3)) ,  1.08 (3H, s, C(CAH3CBH3)),  1.23 (211, m, CH2 or C8H2), 1.49 (2H, 
m, C7H2 or C8H2), 2.10 (2H, m, CH2), 2.34 (211, s, CH2C(CH3)2), 2.39 (111, dd, J 
17.8, 8.6, CHAHBCON),  2.62 (1H, dd, J 17.8, 9.2, CHARBCON),  3.12 (3H, m, CH2 
+ CHCH2CON), 3.71 (3H, s, OCH3), 4.71 (111, dd, J 10. 1, 5.6, Cj1), 4.77 (111, br, 
NH), 5.07 (211, s, CH2Ph), 5.38 (1H, d, J2.0, CCHCO), 7.34 (5H, m, Ar-H); 8c (90 
MHz, DEPT, CDC13) 19.5 (C(CAH3CBH3)),  23.2 (CH2 or C8112), 27.6 (C112 or 
C,H2), 28.7 (C(CAH3d3H3)),  29.1 (CH2 or CIT2CON), 29.2 (CpH 2 or C112CON), 35.5 
(C(CH3)2), 40.5 (CEH2), 44.4 (CHCH2CON), 52.7 (CH2C(CH3)2), 52.9 (CO2 CH3), 
54.0 (CaH), 66.6 (PhCH2), 102.0 (C=CHCO), [128.1 (CH), 128.5 (CH), 5C, Ar-H], 
136.5 (Ph), 156.3 (NIHCOO), 162.7 (C=CHCO) 168.7 (CON or CO2Me), 174.9 
(CON or CO2Me), 196.6 (CCHCO); MS ES (+ve) found m/z 457 (MM, 81 %),479 
(MNa, 10); HRMS FAB (+ve) found m/z 457.23382 (MiH), C 25H33N206 requires 
457.23386. 
5.2.27.5 (5)-6-Benzyloxycarbonylamino-2- [2-((S)-4-methoxy-6,6-dimethyl-2-




0 	 H CO2Me 
(S)-4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 150b (0.50 g, 2.36 
mmol) was coupled to N-E-CBz-L-lysine methyl ester hydrochloride 120c (0.78 g, 
2.36 mmol) using the general method (5.2.18) to give an orange oil (1.84 g) after 
work-up. This was purified by flash column chromatography on silica gel using 
hexane/EtOAc (1:1) as eluent to give a yellow oil (0.90 g, 78 %) Vmax (CHC13) 
3328.5 (NH), 1735.6 (ester), 1711.5 (carbamate), 1655.6 (a,/J-unsaturated ketone), 
1614.1 (C=C); 8H  (250 MHz, CDC13) 0.82 (3H, s, C(CAH3CH3)),  1.09 (3H, s, 
C(CAH 3CBH3)) ,  1.44 (411, m, CH2 + C8H2), 1.77 (211, m, CpH2), 2.07 (1H, d, J 17.4, 
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CHIkHBC(CH 3)2) ,  2.22 (1H, dd, J 14.2, 2.8, CHAHBCONH),  2.39 (1H, dd, J 14.2, 9.7, 
CHAI]BCON}{) ,  2.48 (1H, d, J 17.4, CHAHBC(CH3)2),  2.83 (1H, dd, J 9.7, 2.8, 
CHCH2CONH), 3.18 (2H, m, CH2), 3.41 (3H, s, OCH3), 3.71 (3H, s, CO2CH3), 4.63 
(1H, m, CaH), 5.02 (1H, d, J 12.5, CHAHBPh),  5.12 (1H, d, J 12.5, CHAIIBPh),  5.27 
(1H, s, COCH=COCH3), 5.98 (1H, br, NH), 6.53 (1H, d, J 8.3, NH), 7.28 (5H, m, 
Ar-B); 8c (63 MHz, DEPT, CDC1 3) 21.1 (C(CAH3CI3H3)),  21.7 (CH2 or CH2), 28.7 
(C(CAH3BH3) + C1H2 or C8H2), 31.7 (CH2CONH or CpH2), 31.8 (CH2CONH or 
CH2), 35.7 (C(CH3)2), 40.1 (CH2), 44.3 (CH2C(CH3)2), 51.6 (CaH), 52.2 
(CO2CH3), 53.2 (CHCH2C.ONH), 55.4 (OCH), 66.1 (PhCH2), 100.6 
(COCHCOCH3), [127.6 (CH), 127.7 (CH), 128.3 (CH), 5C, Ar-H], 136.9 (Ph), 
156.7 (NHCOO), 172.4 (CONH or CO 2Me), 172.9 (CONH or CO 2Me), 175.9 
(COCH=COCH3), 200.4 (COCH=COCH3); MS FAB (+ve) found m/z 489 (MM, 73 
%), 511 (MNa, 8); HRMS FAB (+ve) found m/z 489.26014 (MH), C261H3 7N207 
requires 489.26008. 
5.2.27.6 (S)-6-Benzyloxycarbonylamino-2-((S)-4,4-dimethyl-2,6-dioxo-
2,3,3a,4,5,6-hexahydro-indol-1-yl)-hexanoic acid methyl ester 153b 
0 
H 	 N 	o PhO N 
CO2Me 
(S)-6-Benzyloxycarbonylamino-2-[2-((S)-4-methoxy-6,6-dimethyl-2-oxo-cyclohex-
3-enyl)-acetylamino]-hexanoic acid methyl ester 151b (0.38 g, 0.78 mmol) was 
dissolved in acetone (8 ml) and 2M HC1 (8 ml) slowly added. The mixture was then 
stirred at room temperature overnight. The solvent was removed in vacuo and brine 
(5 ml) added. The mixture was extracted with EtOAc (3 x 10 ml), and the total 
organic phase washed with brine (8 ml), dried (MgSO4) and rotary evaporated to an 
orange oil (0.38 g). This was purified by flash column chromatography on silica gel 
using hexane/EtOAc (2:3) as eluent to give a colourless oil (0.036 g, 10 %): v,, ( 
1743.3 (ester), 1719.2 (carbamate), 1619.0 (C=C); 614 (360 MHz, CDC13) 0.91 (3H, s, 
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C(CAH3CBH3)) ,  1.09 (3H, s, C(CAH3CBH3)),  1.22 (2H, m, C.H2 or CöH2),  1.51 (211, 
m, CH2 or C&112),  1.95 (1H, m, CHAHB),  2.11 (1H, m, CHAHB),  2.34 (2H, s, 
CH2C(CH3)2), 2.44 (1H, dd, J 17.8, 8.6, CHAHBCON),  2.65 (1H, dd, J 17.8, 9.3, 
CHAHJ3CON) ,  3.12 (3H, m, CH2 + CHCH2CON), 3.69 (3H, s, OCH3), 4.86 (2H, m, 
CaH+ NH), 5.07 (2H, s, CH2Ph), 5.31 (1H, d, J2.0, C=CHCO), 7.33 (5H, m, Ar-H); 
6c (90 MHz, DEPT, CDC13) 19.5 (C(CkH3CBH3)),  23.3 (CH2 or C,H2), 26.3 (CH2 
or C8112), 28.7 (C(CAH3d3H3)),  29.2 (CH2 or C112CON), 29.3 (CH2 or CH2CON), 
35.6 (C(CH3)2), 40.5 (CH2), 44.3 (CHCH2CON), 52.6 (CH2C(CH3)2), 52.8 
(CO2CH3), 53.2 (CH), 66.6 (PhCH 2), 102.6 (C=GHCO), [128.1 (CH), 128.5 (CH), 
SC, Ar-H], 136.4 (Ph), 156.4 (NHCOO), 162.0 (CCHCO) 168.7 (CON or CO 2Me), 
175.0 (CON or CO2Me), 196.8 (C=CHCO); MS ES (+ve) found m/z 457 (MT{, 100 
%), 479 (MINa, 12); HRMS FAB (+ve) found m/z 457.23388 (MH), C25H33N206 
requires 457.23386. 
5.2.28 Synthesis of Fluorescently-Tagged Ligands 
5.2.28.1 (S)-2-Amino-6-(5-dimethylamino-naphthalene-1 -sulfonylamino)-
hexanoic acid methyl ester 166 
Me2N —ff\ 	NIT 
0 	 2 
' —S —N "COMe 
\=! H 
2 11 H
Commercially 	available 	(S)-2-amino-6-(5-dimethylamino-naphthalene- 1- 
sulfonylamino)-hexanoic acid 165 (1.00 g, 2.64 mmol) was suspended in anhydrous 
MeOH (15 ml) and the mixture cooled to 0 °C. Thionyl chloride (1.63 ml, 22.4 
mmol) was then slowly added and the mixture stirred at room temperature overnight. 
The solvent was removed in vacuo to give a foamy brown solid (1.20 g): v (KBr) 
3433.6 (NH2), 1746.2 (ester), 1320.0 (SO2), 1141.7 (SO2); oH (360 MHz, CD30D) 
1.49 (4H, m, C1H2 + CH2), 1.87 (2H, m, CjH2), 2.93 (2H, m, CH2), 3.53 (6H, s, 
N(CH3)2), 3.87 (3H, s, OCH3), 4.03 (1H, m, Cal]), 7.93 (2H, m, Ar-H), 8.15 (1H, d, 
J 7.6, Ar-H), 8.42 (1H, d, J 7.2, Ar-H), 8.66 (1H, d, J 8.6, Ar-H), 8.96 (1H, d, J 8.7, 
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Ar-M; 8c  (90 MHz, DEPT, CD30D) 21.0 (CH2), 28.3 (CR 2), 29.0 (CR2), 41.5 
(CR2), 46.1 (N(CH3)2), 51.9 (CH + OCH3), [118.9 (CH), 125.1 (CH), 2C Ar-H], 
125.3 (quat), [126.1 (CH), 126.6 (CH), 126.9 (CH), 3C Ar-H], 128.7 (quat), [129.2 
(CH), 1C Ar-H], 136.8 (quat), 138.7 (quat), 168.9 (CO 2CH3); MS FAB (+ve) found 




acid methyl ester 167 






4-Methoxy-6,6-dimethyl-2-oxo-cyclohex-3-enyl)-acetic acid 109 (0.54 g, 2.54 
mmol) was coupled to (S)-2-amino-6-(5-dimethylamino-naphthalene- 1-
sulfonylamino)-hexanoic acid methyl ester 166 (1.00 g, 2.54 mmol) using the general 
method (5.2.18) to give a brown oil (2.00 g) after work-up. This was purified by 
flash column chromatography on silica gel using hexane/EtOAc gradient eluent to 
give the individual diastereomers as two fluorescent foams: (i) (0.51 g, 34 %) and (ii) 
(0.52 g, 35 %). 
i) vma,, (CHC13) 1738.5 (ester), 1639.2 (a,fi-unsaturated ketone), 1612.2 (C=C), 
1319.1 (SO2), 1143.6 (SO2); 8H  (250 MHz, CDC13) 0.89 (311, s, C(CAH3CHH3)),  1.13 
(311, s, C(CAH3CBH3)),  1.33 (4H, m, CH2 + C6H2), 1.60 (2H, m, CH2), 2.13 (1H,d, 
J 17.4, CHHBC(CH3)2),  2.33 (211, m, CH2CONH), 2.55 (1H, d, J 17.4, 
CHAIIBC(CH3)2) ,  2.85 (6H, s, N(CH3) 2), 2.90 (111, m, CHCH2CONH), 2.93 (211, m, 
CEH2), 3.59 (3H, s, OCH3), 3.67 (3H, s, CO2CH3), 4.60 (1H, m, Call), 5.67 (1H, d, J 
1.3, COCHCOCH3), 6.45 (1H, d, J8.5, NH), 6.82 (1H, t, J5.8, NH), 7.14(111, d, J 
7.0, Ar-H), 7.44 (1H, t, J 7.3, Ar-H), 7.48 (1H, t, J 7.3, Ar-H), 8.16 (1H, dd, J 7.3, 
1.2, Ar-R), 8.33 (111, d, J 8.7, Ar-H), 8.48 (1H, d, J 8.5, Ar-H); öc (63 MHz, DEPT, 
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CDC13) 21.1 (C(CAH3CBH3)),  21.3 (CH2 or C5H2), 28.3 (CH2 or C,H2), 28.8 
(C(CAH3 d3H3),  31.4 (CH2), 32.1 (CH2CONH), 35.8 (C(CH3)2), 42.1 (C€H2), 44.2 
(CH2C(CH3)2), 45.3 (N(cH3)), 51.5 (Call), 52.2 (CO2CH3), 53.3 (CHCH2CONH), 
55.9 (OCH3), 100.8 (COCH=COCH3), [115.0 (CH), 119.3 (CH), 123.1 (CH), 127.7 
(CH), 128.9 (CH), 5C Ar-HI, 129.6 (quat x 2), [129.7 (CH), 1C Ar-H], 135.6 (quat), 
151.5 (quat), 172.6 (CONH or CO2Me), 172.8 (CONH or CO2Me), 176.7 
(COCHCOCH3), 201.2 (COCH=COCH3); MS FAB (+ve) found m/z 588 (MJI, 26 
%), 610 (MNa, 4); HRMS FAB (+ve) found m/z 588.27412 (MIH4 ), C30H42N307S 
requires 588.27435. 
ii) v,( (CHC13) 3298.6 (NH), 1741.4 (ester), 1655.6 (a,#-unsaturated ketone), 
1613.2 (C=C), 1317.1 (SO2), 1144.6 (SO2); 8H  (250 MHz, CDC13) 0.84 (3H, s, 
C(CkH3 CBH3)) ,  1.11 (3H, s, C(CAH3CBH3)),  1.36 (4H, m, CH2 + C5H2), 1.60 (2H, 
m, CH2), 2.13 (1H, d, J 17.5, CH1HBC(CH3)2),  2.24 (1H, dd, J 14.0, 2.3, 
CF/kHBCONH) ,  2.50 (1H, d, J 17.5, CHAHBC(CH3)2),  2.61 (1H, dd, J 14.0, 8.9, 
CHAHBCONH) ,  2.70 (1H, dd, J 8.9, 2.3, CHCH2CONH), 2.85 (8H, brs, N(CH3)2 + 
CH2), 3.64 (6H, s, OCH3 + CO2CH3), 4.39 (1H, m, Cçjl), 5.45 (1H, d, J 1.3, 
COCH=COCH3), 5.73 (1H, t, J6.0, NH), 7.05 (1H, d, J7.7, NH), 7.14 (1H, d, J7.1, 
Ar-H), 7.48 (2H, m, Ar-H), 8.19 (1H, dd,J7.3, 1.2, Ar-H), 8.30 (1H, d,J8.7, Ar-H), 
8.49 (1H, d, J 8.5, Ar-H); 8c (63 MBz, DEPT, CDC13) 21.2 (C(CAH3CBH3)),  21.9 
(CH2 or C8H2), 28.7 (C(CAH3CI3H3 + CH2 or C6H2), 31.2 (CH2), 32.8 (CH2CONH), 
36.0 (C(CH3)2), 42.5 (CH2), 43.9 (GH2C(CH3)2), 45.3 NCH), 51.8 (CH), 52.2 
(CO2cH3), 53.1 (CHCH 2CONH), 55.8 (OCJI3), 100.6 (COCH=COCH3), [115.0 
(CH), 118.9 (CH), 123.0 (Cl), 128.0 (CH), 129.2 (CH), 5C Ar-H], 129.5 (quat), 
129.7 (quat), [130.0 (CH), 1C Ar-H], 134.9 (quat), 151.7 (quat), 172.6 (CONH or 
CO2Me), 173.0 (CONH or CO2Me), 176.3 (COCH=COCH3), 200.7 
(COCH=COCH3); MS FAB (+ve) found m/z 588 (MH, 18 %), 610 (MNa, 4); 
HRMS FAB (+ve) found m/z 588.27438 (MIll4), C30H42N307S requires 588.27435. 
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5.2.28.3 (S)-6-(5-Dimethylamino-naphthalene-1-sulfonylamino)-2-((S/R)-4,4-
dimethyl-2,6-dioxo-2,3,3 a,4,5,6-hexahydro-indol-1-yl)-4-methyl-







dimethyl-2-oxo-cyclohex-3-enyl)-acetylamino]-hexanoic acid methyl ester 167a 
(0.40 g, 0.68 mmol) was dissolved in acetone (15 ml) and 2M HC1 (15 ml) slowly 
added. The mixture was then stirred at room temperature overnight. The acetone 
was removed in vacuo and the residue diluted with brine (10 ml) and extracted with 
EtOAc (3 x 20 ml). The total organic phase was dried (MgSO 4) and rotary 
evaporated to give an orange oil (0.13 g). This was purified by flash column 
chromatography on silica gel using hexane/EtOAc (1:1) as eluent to give a bright 
yellow foam (0.015 g, 4 %): 8H  (360 MHz, CDCI3) 0.92 (3H, s, C(CAH3C113)),  1.11 
(3H, s, C(CAH3CBH3)),  1.22 (2H, m, CH2 or C8H2),  1.42 (2H, m, C7H2  or CE,H2), 
1.92 (2H, m, CH2), 2.36 (2H, s, CH2C(CH3)2), 2.46 (1H, dd, J 17.7, 8.5, 
CHAHBCON) ,  2.71 (1H, dd, J 17.7, 9.2, CHAHBCON),  2.84 (1H, m, C€H2), 2.91 (611, 
s, N(CH3)2), 3.15 (1H, ddd, J9.2, 8.5, 2.2, CHCH2CON), 3.69 (311, s, CO2CH3), 4.79 
(1H, m, Cj1), 4.88 (1H, t, J 6.2, NE), 5.30 (1H, d, J 2.2, CCHCO), 7.21 (1H, d, J 
7.5, Ar-H), 7.55 (2H, m, Ar-H), 8.22 (1H, dd, J7.3, 1.3, Ar-H), 8.27 (1H, d, J8.6, 
Ar-H), 8.56 (1H, d, J 8.6, Ar-H);, öc (90 MHz, DEPT, CDC1 3) 19.6 (C(CAH3CI3H3)), 
22.8 (C112), 25.9 (CH2), 28.5 (CH2), 28.7 (C(CAH3d3H3),  29.4 (cFI2), 35.6 
(C(CH3)2), 42.7 (CH2), 44.3 (CHCH2CON), 45.4 (N(CH3)), 52.6 (CH2C(CH3)2), 
52.8 (CO2CH3), 53.0 (CaR), 102.6 (CCHCO), [115.3 (CH), 118.7 (CH), 123.3 
(CH), 128.4 (CH), 4C Ar-H], 129.5 (quat x 2), [129.7 (CH), 130.4 (CH), 2C Ar-HI, 
134.5 (quat), 151.7 (quat), 162.2 (C=CHCO), 168.7 (CON or CO2Me), 175.2 (CON 
or CO2Me), 197.1 (C=CHCO); MS FAB (+ve) found m/z 556 (MH, 100 %), 578 
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(MNa, 26); FIRMS FAB (+ve) found m/z 556.24859 (Mff'T), C29H38N306S requires 
556.24813. 
(S)-6-(5-Dimethylamino-naphthalene- 1 -sulfonylamino)-2-[2-(4-methoxy-6,6-
dimethyl-2-oxo-cyclohex-3-enyl)-acetylamino] -hexanoic acid methyl ester 167b 
(0.40 g, 0.68 mmol) was dissolved in THF (15 ml) and 2M HC1 (15 ml) slowly 
added. The mixture was then stirred at room temperature overnight. The TFIF was 
removed in vacuo and the residue diluted with brine (10 ml) and extracted with 
EtOAc (3 x 25 ml). The total organic phase was washed with saturated NaHCO3 
solution (10 ml), brine (10 ml), dried (MgSO 4) and rotary evaporated to give a 
yellow foamy solid (0.093 g). This was purified by flash column chromatography on 
silica gel using hexane/EtOAc (1:1) as eluent to give a bright yellow oil (0.033 g, 9 
%): oH (360 MHz, CDC1 3) 0.93 (3H, s, C(CAII3CI3H3)),  1.10 (3H, s, C(CAH 3CBH3)) , 
1.19 (2H, m, CH2 or C8H2), 1.41 (2R, m, C1H2 or CH2), 1.95 (2H, m, CH2), 2.35 
(211, s, CH2C(CH3)2), 2.44 (111, dd, J 17.7, 8.6, CHAHBCON),  2.64 (1H, dd, J 17.7, 
9.2, CHAIIBCON),  2.83 (111, m, CH2), 2.89 (611, s, N(CH3)2), 3.16 (111, ddd, J9.2, 
8.6, 2. 1, CHCH2CON), 3.70 (3H, s, CO 2CH3), 4.58 (111, m, CjI), 4.91 (111, t, J6.2,. 
NH), 5.35 (1H, d, J2.1, CCHCO), 7.19 (1H, d, J7.1, Ar-H), 7.54 (2H, m, Ar-H), 
8.21 (1H, dd, J7.3, 1.3, Ar-H), 8.26 (1H, d, J8.6, Ar-H), 8.54 (1H, d, J8.6, Ar-H); 
oc (90 MHz, DEPT, CDC13) 19.6 (C(CAH3CBH3)),  22.7 (CH2), 27.2 (CH2), 28.6 
(CH2), 28.7 (C(CAH3d3H3),  29.2 (CH2), 35.5 (C(CH3)2), 42.7 (C EH2), 44.4 
(CHCH2CON), 45.4 (N(CH3)), 52.7 (CH 2C(CH3)2), 52.9 (CO2 CH3), 53.8 (C H), 
101.9 (C=CHCO), [115.2 (CH), 118.6 (CH), 123.2 (CH), 128.4 (CH), 4C Ar-H], 
129.5 (quat), 129.6 (quat), [129.8 (CH), 130.4 (CH), 2C Ar-H], 134.5 (quat), 151.9 
(quat), 162.9 (C=CHCO), 168.7 (CON or CO 2Me), 175.3 (CON or CO 2Me), 196.8 
(C=CHCO); MS FAB (+ve) found m/z 556 (MH, 45 %), 578 (MNa, 23); RRMS 
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Appendix A 
Bond lengths [A] and angles [deg] for 149a. 
Me  
)+ 
Ph N}{3 0 
OOMe 
149a 
C(1)-C(2) 1.520(4) C(16)-C(22) 1.527(4) 
C(1)-C(6) 1.450(4) C(17)-C(18) 1.391(5) 
C(l)-0(7) 1.237(3) C(17)-H(17) 1.000 
C(2)-C(3) 1.544(4) C(1 8)-C( 19) 1.386(7) 
C(2)-C(8) 1.527(4) C( 1 8)-H( 18) 1.000 
C(2)-H(2) 1.000 C(19)-C(20) 1.367(7) 
C(3)-C(4) 1.541(5) C(1 9)-H(1 9) 1.000 
C(3)-C( 12) 1.536(5) C(20)-C(2 1) 1.398(5) 
C(3)-C( 13) 1.524(6) C(20)-H(20) 1.000 
C(4)-C(5) 1.479(5) C(21)-H(21) 1.000 
C(4)-H(41) 1.000 C(22)-N(23) 1.487(4) 
C(4)-H(42) 1.000 C(22)-C(24) 1.521(6) 
C(5)-C(6) 1.348(4) C(22)-H(22) 1.000 
C(5)-0(14) 1.348(3) N(23)-H(231) 0.900 
C(6)-H(61) 1.000 N(23)-H(232) 0.900 
C(8)-C(9) 1.525(4) N(23)-H(233) 0.900 
C(8)-H(81) 1.000 C(24)-H(241) 1.000 
C(8)-H(82) 1.000 C(24)-H(242) 1.000 
C(9)-O(10) 1.275(4) C(24)-H(243) 1.000 
C(9)-O(1 1) 1.241(4) C(2)-C(1)-C(6) 119.5(2) 
C(12)-H(121) 1.000 C(2)-C(1 )-0(7) 120.1(3) 
C(12)-H(122) 1.000 C(6)-C(1 )-0(7) 120.4(3) 
C(12)-H(123) 1.000 C(1)-C(2)-C(3) 112.1(3) 
C(1 3)-H( 131) 1.000 C(1 )-C(2)-C(8) 109.8(2) 
C(13)-H(132) 1.000 C(3)-C(2)-C(8) 114.8(3) 
C(13)-H(133) 1.000 C(1)-C(2)-H(2) 106.486 
0(14)-C(15) 1.439(4) C(3)-C(2)-H(2) 106.489 
C(15)-H(151) 1.000 C(8)-C(2)-H(2) 106.490 
C(15)-H(152) 1.000 C(2)-C(3)-C(4) 107.4(3) 
C(15)-H(153) 1.000 C(2)-C(3)-C(12) 110.2(3) 
C(16)-C(17) 1.390(5) C(4)-C(3)-C(12) 107.9(3) 




























































































C(2 1 )-C(1 6)-C(22) 
C(1 6)-C(1 7)-C(1 8) 
C(1 6)-C(1 7)-H(1 7) 
C(1 8)-C(1 7)-H(1 7) 
C( 1 7)-C( 1 8)-C( 19) 
C(1 7)-C(1 8)-H(1 8) 
C(19)-C(18)-H(1 8) 
C(1 8)-C(1 9)-C(20) 
C(1 8)-C(1 9)-H( 19) 
C(20)-C(1 9)-H(1 9) 
C( 1 9)-C(20)-C(2 1) 
C(19)-C(20)-H(20) 
C(2 1 )-C(20)-H(20) 
C(20)-C(2 1 )-C( 16) 
C(20)-C(2 1 )-H(2 1) 






























































C( 1 )-C(2) 1.526(3) C(l 4)-H(1 4A) 0.9500 
C(1)-C(4) 1.537(3) C(14)-H(1 4B) 0.9500 
C(1)-C(8) 1.542(3) C(2)-C(1)-C(4) 110.10(19) 
C( 1 )-C(3) 1.544(3) C(2)-C( 1 )-C(8) 109.6(2) 
C(2)-H(2A) 0.9800 C(4)-C( 1 )-C(8) 105.88(18) 
C(2)-H(2B) 0.9800 C(2)-C(1 )-C(3) 109.4(2) 
C(2)-H(2C) 0.9800 C(4)-C( 1 )-C(3) 112.13(19) 
C(3)-H(3A) 0.9800 C(8)-C( 1 )-C(3) 109.62(19) 
C(3)-H(3B) 0.9800 C(1 )-C(2)-H(2A) 109.5 
C(3)-H(3C) 0.9800 C(1 )-C(2)-H(2B) 109.5 
C(4)-C(5) 1.502(3) H(2A)-C(2)-H(2B) 109.5 
C(4)-C(9) 1.532(3) C(1 )-C(2)-H(2C) 109.5 
C(4)-H(4) 1.0000 H(2A)-C(2)-H(2C) 109.5 
C(5)-C(6) 1.352(3) H(2B)-C(2)-H(2C) 109.5 
C(5)-N(1 1) 1.380(3) C(1)-C(3)-H(3A) 109.5 
C(6)-C(7) 1.456(3) C(1 )-C(3)-H(3B) 109.5 
C(6)-H(6) 0.9500 H(3A)-C(3)-H(3B) 109.5 
C(7)-0(7) 1.232(3) C(1)-C(3)-H(3C) 109.5 
C(7)-C(8) 1.512(4) H(3A)-C(3)-H(3C) 109.5 
C(8)-H(8A) 0.9900 H(3 B)-C(3)-H(3 C) 109.5 
C(8)-H(8B) 0.9900 C(5)-C(4)-C(9) 103.74(18) 
C(9)-C(1 0) 1.510(3) C(5)-C(4)-C(1) 110.94(18) 
C(9)-H(9A) 0.9900 C(9)-C(4)-C(1) 118.90(19) 
C(9)-H(9B) 0.9900 C(5)-C(4)-H(4) 107.6 
C(10)-0(10) 1.211(3) C(9)-C(4)-H(4) 107.6 
C(10)-N(1 1) 1.388(3) C(1)-C(4)-H(4) 107.6 
N(1 1)-C(12) 1.465(3) C(6)-C(5)-N(1 1) 126.7(2) 
C(12)-C(13) 1.488(4) C(6)-C(5)-C(4) 124.7(2) 
C(12)-H(12A) 0.9900 N( 11 )-C(5)-C(4) 108.62(19) 
C(12)-H(12B) 0.9900 C(5)-C(6)-C(7) 118.5(2) 
C(13)-C(14) 1.311(4) C(5)-C(6)-H(6) 120.7 




















O(10)-C(10)-N(1 1) 123.9(2) 
0(10)-C(10)-C(9) 128.0(2) 
N(1 1)-C(1 O)-C(9) 108.06(19) 
C(5)-N(11)-C(10) 112.36(19) 
C(5)-N(1 1)-C(12) 125.2(2) 
C(10)-N(11)-C(12) 122.1(2) 

















Bond lengths [A] and angles [deg] for 53a. 
0 
BY) 0 	OMe 
53a 
C(1)-C(2) 1.531(3) C(16)-H(161) 1.000 
C(1)-C(3) 1.536(2) C(1 6)-H(1 62) 1.000 
C( 1 )-C(4) 1.548(2) C(1 6)-H( 163) 1.000 
C(1)-C(9) 1.541(2) C(17)-H(171) 1.000 
C(2)-H(2 1) 1.000 C(1 7)-H( 172) 1.000 
C(2)-H(22) 1.000 C(17)-H(173) 1.000 
C(2)-H(23) 1.000 0(1 8)-C( 19) 1.441(2) 
C(3)-H(3 1) 1.000 C(1 9)-H(191) 1.000 
C(3)-H(32) 1.000 C(19)-H(192) 1.000 
C(3)-H(33) 1.000 C(1 9)-H(1 93) 1.000 
C(4)-C(5) 1.520(2) C(2)-C(1 )-C(3) 109.21(15) 
C(4)-C( 10) 1.526(2) C(2)-C(1 )-C(4) 111.92(15) 
C(4)-H(41) 1.000 C(3)-C(1 )-C(4) 110.99(14) 
C(5)-0(6) 1.228(2) C(2)-C(1 )-C(9) 110.47(14) 
C(5)-C(7) 1.453(2) C(3)-C(1 )-C(9) 108.13(15) 
C(7)-C(8) 1.346(2) C(4)-C(1 )-C(9) 106.02(13) 
C(7)-H(7 1) 1.000 C(1 )-C(2)-H(2 1) 109.447 
C(8)-C(9) 1.495(2) C(1)-C(2)-H(22) 109.478 
C(8)-0( 18) 1.348(2) H(2 1 )-C(2)-H(22) 109.491 
C(9)-H(9 1) 1.000 C(1 )-C(2)-H(23) 109.457 
C(9)-H(92) 1.000 H(21)-C(2)-H(23) 109.463 
C(10)-C(1 1) 1.5 12(2) H(22)-C(2)-H(23) 109.492 
C(1 0)-H(1 01) 1.000 C(1)-C(3)-H(3 1) 109.464 
C(10)-H(102) 1.000 C(1 )-C(3)-H(32) 109.465 
C(1 1)-0(12) 1.200(2) F1(31)-C(3)-H(32) 109.464 
C( 11 )-0(1 3) 1.342(2) C(1 )-C(3)-H(33) 109.478 
0(1 3)-C(1 4) 1.477(2) H(3 1 )-C(3)-H(33) 109.483 
Q1 4)-C( 15) 1.520(3) H(32)-C(3)-H(33) 109.474 
C(14)-C(16) 1.511(3) C(1)-C(4)-C(5) 110.80(13) 
C(14)-C(17) 1.518(3) C(1)-C(4)-C(1 0) 115.26(14) 
C(1 5)-H(151) 1.000 C(5)-C(4)-C(10) 110.28(15) 
C( 1 5)-H( 152) 1.000 C(1 )-C(4)-H(4 1) 104.672 





C(10)-C(4)-H(41) 105.242 C(14)-C(17)-H(171) 
C(4)-C(5)-0(6) 120.53(15) C(14)-C(17)-H(172) 
C(4)-C(5)-C(7) 117.31(15) H(171)-C(17)-H(172) 
0(6)-C(5)-C(7) 122.14(16) C(14)-C(17)-H(173) 
C(5)-C(7)-C(8) 119.62(16) H(171)-C(17)-H(173) 
C(5)-C(7)-H(71) 120.179 H(172)-C(17)-H(173) 
C(8)-C(7)-H(71) 120.198 C(8)-0(18)-C(19) 
C(7)-C(8)-C(9) 124.05(15) 0(18)-C(19)-H(191) 
C(7)-C(8)-0(18) 125.24(16) 0(18)-C(19)-H(192) 
C(9)-C(8)-0(18) 110.71(15) H(191)-C(19)-H(192) 
C(1)-C(9)-C(8) 113.39(15) 0(1 8)-C(19)-H(193) 
C(1)-C(9)-H(9 1) 108.470 H(191)-C(19)-H(193) 











C(10)-C(1 1)-0(13) 109.66(15) 
0(12)-C(1 1)-0(13) 125 .28(17) 
C(11)-0(13)-C(14) 120.61(14) 
0(13)-C(14)-C(15) 102.25(15) 
0(13)-C(14)-C(16) 110.33(15) 
C(15)-C(14)-C(16) 111.01(17) 
0(13)-C(14)-C(17) 109.32(14) 
C(15)-C(14)-C(17) 110.11(18) 
C(16)-C(14)-C(17) 113.26(19) 
C(14)-C(15)-H(151) 109.446 
C(14)-C(15)-H(152) 109.440 
H(151)-C(15)-H(152) 109.488 
C(14)-C(15)-H(153) 109.448 
H(151)-C(15)-H(153) 109.502 
H(152)-C(15)-H(153) 109.503 
C(14)-C(16)-H(161) 109.460 
C(14)-C(16)-H(162) 109.431 
H(161)-C(16)-H(162) 109.457 
C(14)-C(16)-H(163) 109.475 
H(161)-C(16)-H(163) 109.517 
H(162)-C(16)-H(163) 109.486 
109.473 
109.470 
109.501 
109.445 
109.466 
109.473 
117.08(14) 
109.479 
109.466 
109.477 
109.469 
109.476 
109.461 
